Investigating the biosynthesis of the fungal metabolites Squalestatin S1, Strobilurin A and SCH–642305 by Lebe, Karen Elisabeth
Investigating the Biosynthesis of the Fungal
Metabolites Squalestatin S1, Strobilurin A and
SCH–642305
Von der Naturwissenschaftlichen Fakultät der
Gottfried Wilhelm Leibniz Universität Hannover
zur Erlangung des Grades
Doktorin der Naturwissenschaften (Dr. rer. nat.)
genehmigte Dissertation
von
Karen Elisabeth Lebe, M. Sc.
2020
Referent: Prof. Dr. Russell Cox
Korreferent: Prof. Dr. Andreas Kirschning
Tag der Promotion: 29. November 2019
Abstract
The main focus of the presented work concentrated on understanding and engineering the biosyn-
thesis of three polyketides produced by filamentous fungi: squalestatin S1 1, strobilurin A 2 and
SCH–642305 3. In a combined genetic and chemical approach, the order and functions of genes and
proteins involved in the three biosynthetic pathways were elucidated.
Using a combination of targeted gene knockout in the native organism and heterologous expression
in Aspergillus oryzae (A. oryzae) three previously unknown oxygenases were identified from 1 biosyn-
thetic gene cluster (BGC) and their role in the biosynthesis of 1 were determined. Two non–heme
iron–dependent oxygenases were shown to catalyse a series of six consecutive oxidations to form the
highly oxidised, bioactive core of squalestatins and an unusual copper–dependent oxygenase was
found to introduce a hydroxyl required for later acetylation.
During strobilurin biosynthesis, an FAD dependent monooxygenase was identified and shown in vitro
to catalyse an unusual oxidative rearrangement to form the core β–methoxyacrylate toxophore of this
valuable class of agricultural fungicides. In vivo fungal expression studies revealed the biosynthetic
pathway to bolineol 4 from the same BGC and uncovered the role of two O–methyltransferases.
In attempts to reveal each biosynthetic step in SCH biosynthesis, with special regard to formation
of the 6–membered ring, the full BGC was coexpressed and re-established in A. oryzae. Only minor
amounts of the final product were found due to a shunt pathway in A. oryzae. An early pathway
intermediate was hydrolysed and oxidised and thus stopped the biosynthesis to 3.
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Zusammenfassung
Der Fokus der Doktorarbeit lag auf dem Verständnis und dem Engineering der Biosynthesewege
von drei Polyketiden, die von filamentösen Pilzen produziert werden: Squlaestatin S1 (SQS1) 1,
strobilurin A 2 and SCH–642305 3. In einer Kombination aus chemischer und genetischer Analyse
wurde die Funktion und Reihenfolge der an der Biosynthese beteiligten Proteine entschlüsselt.
Durch gezielte Gen–Knockouts und Heterologe Expression in Aspergillus oryzae (A. oryzae) wurden
drei bisher unbekannten Oxygenasen aus dem SQS1 Gencluster identifiziert und ihre Rolle in der
Biosynthese bestimmt. Es wurde gezeigt, dass zwei Nicht–Häm–Eisen–abhängige Oxygenasen
eine Serie von sechs aufeinanderfolgenden Oxidationen katalysieren, die zu dem hochoxidierten,
bioaktiven Zentrum von den Squalestatinen führen. Eine ungewöhnliche Kupfer–abhängige Oxyge-
nase ist verantwortlich für die Einführung einer Hydroxylgruppe, welche im weiteren Verlauf der
Biosynthese acetyliert wird.
In der Strobilurin–Biosynthese wurde eine FAD–abhängige Monooxygenase identifiziert. In vitro
Studien mit der Monooxygenase zeigten, dass sie eine ungewöhnliche oxidative Umlagerung zum β–
Methoxyacrylat–Toxophor katalysiert, die dieser wertvollen Klasse von landwirtschaftlich genutzten
Fungiziden ihre Wirkung verleiht. Durch In–vivo–Expressionsstudien in Pilzen konnte der weitere
Biosyntheseweg zu Bolineol 4 aufgeklärt werden. Für die Biosynthese von Bolineol und 2 ist dasselbe
Gencluster verantwortlich. Im Zuge dieser Arbeit konnte die Rolle von zwei O–Methyltransferasen
in beiden Biosynthesewegen enthüllt werden.
In dem Versuch, jeden Biosyntheseschritt in der SCH–Biosynthese unter besonderer Berücksichti-
gung der Bildung des 6–gliedrigen Rings aufzudecken, wurden alle Gene des Biosyntheseclusters
vollständig in A. oryzae coexprimiert und die Biosynthese rekonstruiert. Das Endprodukt konnte nur
in geringen Mengen detektiert werden, da durch endogene Enzyme in A. oryzae ein frühes Biosyn-
theseintermediat hydrolysiert und oxidiert wurde, womit die Biosynthese zu 3 früh unterbrochen
wurde.
Schlagwörter: Naturstoffe, Biosynthese, Pilze, Polyketide
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1 Introduction
In history, nature has always been the biggest source for medicine. Thousands of years ago our
ancestors used plants and herbs to relieve pain or wrapped them around wounds for a better healing
process. During history natural products from plants, bacteria, and fungi build an important basis for
the development of new pharmaceuticals. The term "natural products" can be defined as compounds
naturally produced by living organisms. A more narrow perspective defines them as small molecules
relevant for primary and secondary metabolism. In contrast to primary metabolites, such as fatty
acids or amino acids, secondary metabolites are not essential for survival of the organism but
generally provide a benefit in competition with other organisms.1,2 Due to their wide range of
complex structures and their high selectivity, natural products cover a broad spectrum of bioactivity
and are widely used in the food, pharmaceutical and agricultural industries.3
Secondary metabolites are produced by most living organisms including animals, plants, bacteria
and fungi among others. As the research project described in this thesis is about the biosynthesis
of three secondary metabolites produced by fungi, the next section will focus on fungal natural
products.
1.1 Fungal natural products
Fungi are key components of life on the earth. For humans they are often unimposing and it is easy
to lose sight of their importance. That is why they are often referred to as the “Forgotten Kingdom”.4
The basidiomycetes, together with the ascomycetes, make up the sub–kingdom Dikarya – often
referred to as the “higher fungi”.5 Strobilurin A 2, one of the secondary metabolites discussed in this
thesis, is produced by a basidomycete: Strobilurus tenacellus.6 The two other compounds described
in this work, squalestatin S1 (SQS1) 1 produced by Phoma sp.7 and SCH–642305 3 produced by
Phomopsis sp. CMU–LMA8, belong to the phylum of ascomycetes.
1
1.1 Fungal natural products
Figure 1.1 Examples of fungal natural products of different classes (polyketides, nonribosomal peptides, terpenes and
alkaloids).
Throughout history, fungi have been used for preparation of alcoholic beverages, medication in
traditional medicine and for cultural purposes, as drugs or food.9 In 1922 more than 200 fungal
secondary metabolites were characterised under the leadership of Harold Raistrick.10 The most
famous example of a fungal metabolite is penicillin G 5 (Fig. 1.1), which was discovered in 1929 by
Alexander Fleming. The treatment with 5 saved many lives in Word War II because of its antibiotic
activity.2
The search for natural products has continued unabated and thousands of compounds have been
subsequently isolated and characterised. Some of the most important natural products for the
pharmaceutical industry derived from fungal sources.9 Most of them show antibacterial, antifungal
or antitumour activity which makes them attractive for human interest as plant and animal toxins,
growth hormones and pharmaceuticals. Besides, the enormous chemical complexity and diversity of
these compounds, which arise from a limited number of precursors from primary metabolism, make
this an important field of current research.11
2
1.1 Fungal natural products
Fungal secondary metabolites are classified according to the biosynthetic pathway they derive from.
Most secondary metabolites belong to the diverse class of polyketides which are made by polyketide
synthases (PKS). Examples include squalestatin S1 112, inhibitor of squalene synthase, lovastatin
613, an inhibitor of 3–hydroxy–3–methyl–glutaryl (HMG) CoA reductase (both cholesterol level–
lowering agents)14, strobilurin A 215, an agricultural fungicide, SCH–642305 316, a bacterial DNA
primase inhibitor, aflatoxin B1 717, a carcinogenic agent, and 6–methylsalicylic acid (6–MSA) 8.18
Other natural products, like 5, are made by nonribosomal peptide synthetases (NRPSs) and therefore
belong to the class of nonribosomal peptides. Terpenes, like aristocholene 919 and alkaloids, such as
ergotamine 1020, also belong to the group of secondary metabolites.
1.1.1 Polyketide biosynthesis
Polyketides show an extremely large structural diversity and build up one of the major classes
of fungal metabolites. The scaffold can vary from small compounds, such as 6–MSA 8, to large
molecules such as squalestatin S1 1. Nevertheless, they share a common pattern of biosynthesis which
is similar to the biosynthesis of fatty acids. In 1955, Birch and coworkers realised that polyketides and
fatty acids share similarities in de novo biosynthesis by discovering that polyketides are generated
from the same simple building blocks (acetate units) by repeated condensation reactions, as fatty
acids.21 Publications addressing the origin of fatty acids and polyketides have been published much
earlier in the Journal of the Chemical Society in 1907.22,23
Fatty acid biosynthesis is a primary metabolic pathway. The chemical logic, the enzymatic machinery
and the building blocks appear to have been recruited by the secondary pathways of polyketide
assembly in living organisms.24
Logic of fatty acid biosynthetic machinery
Fatty acids are primary metabolites that are synthesised by complex biosynthetic machinery, called
fatty acid synthases (FAS). Polyketides are secondary metabolites which are built by polyketide
synthases (PKS). The general logic for the biosynthetic process is the same for both and can be
divided in three phases: loading; chain extension and β–processing (Scheme 1.2).
The starter unit for fatty acid and polyketide biosynthesis is usually acetyl–CoA 11 and in most cases
malonyl–CoA 12 is used as elongation unit. Acetate 13 is activated as coenzyme A (CoA) thiolester
by the acetyl–CoA synthetase enzyme with consumption of adenosine triphosphate (ATP, Scheme 1.2,
step I).25
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The first step in the biosynthesis of fatty acids and polyketides is the loading process, where ac-
tivated acetyl–CoA 11 is transferred onto the acyl carrier protein (ACP) of the FAS/PKS by the
acyl transferase (AT) (Scheme 1.2, step II). The apo–ACP must be activated via post–translational
modification by a phosphopantetheinyl transferase (PPTase). The PPTase installs the CoA derived 4’–
phosphopantetheine arm (PPant), forming holo–ACP, which enables the bound β–ketoester to access
all active sites of the FAS protein (Scheme 1.1).25 In biochemical studies, ACP–bound substrates can
sometimes be mimicked by synthesised N–acetylcysteamine thiolesters (SNAC) 15, as those possess
the same structural feature compared to the terminal part of 14 (Scheme 1.1).26,27
Scheme 1.1 Conversion of apo–ACP to holo–ACP with consumption of CoA 14 and ATP by a phosphopantetheinyl transferase
(PPTase).
The acetate is further transferred to the thiol of the β–ketosynthase (KS), leaving space at the AT
for loading extender unit malonyl–CoA 12 to the ACP (Scheme 1.2, steps III, IV). The malonyl
thiolester can undergo facile enzyme–mediated decarboxylation to lose CO2 and furnish the acetyl–
CoA carbanion in the biosynthetic direction (Scheme 1.2, step V). This decarboxylated thiolclaisen
condensation is the key reaction type for fatty acid and all subclasses of polyketide chain elongations
and is catalysed by the KS.28
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Scheme 1.2 Biosynthetic steps in fatty acid and polyketide biosynthesis, including loading of the starter and extender units,
chain elongation and β–processing.
Further modifications of the β–carbonyl (β–processing) are catalysed by β–ketoreductase (KR), which
reduce the β–group with cosubstrate NAD(P)H to the β–OH–acyl–S–ACP 16. Subsequent dehydra-
tion by dehydratase (DH), which abstracts one of the acidic α–hydrogens, results in an unsaturated
thiolester 17. Because of the resulting conjugation, the terminus of the olefin is electrophilic and
can accept a hydride from NADPH in the active site of the enoylreductase (ER) yielding a fully
saturated thiolester 18 (Scheme 1.2, steps VI, VII, VIII). After further elongation rounds by C2 units
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the furnished chain is released by the thiolesterase (TE) domain. In the case of fatty acid biosynthesis
the product is a carboxylic acid (hydrolytic release).24,25,28 In polyketide biosynthesis the release can
either be hydrolytic or reductive, resulting in aldehydes or alcohols (Scheme 1.2, steps IX, X).
PKS use the same set and logic of chemical reactions as FAS (Scheme 1.2), but the key difference
is that of programming.29 Both biosynthetic pathways control the chain length by the number of
extensions, but PKS can additionally control starter and extender unit selection and the extent of
reduction and elimination during each β–processing cycle.2,30,31 In addition fungal PKS often have
a functional C–MeT domain which can methylate the β–carbon at the start of the β–processing
cycle.29
Multidomain protein architecture
According to differences in structure, FAS proteins are divided into type I and II systems. Type I FAS
are large multifunctional proteins found in animals and fungi, containing all domain activities for
fatty acid biosynthesis in one megasynthase protein.32 On the contrary, type II FAS is characterised by
a set of dissociated monofunctional proteins, which putatively assemble to non–covalent complexes
(found in bacteria and plants). FAS consist of a single module that is used iteratively.33
PKS are classified in three types according to enzyme organisation.34 Type I PKS are multifunctional
enzymes that can be divided in modular type I PKS, which occur mostly in bacteria and iterative
type I PKS, which are predominantly found in fungi.29,35 Each single module of a modular type I
PKS catalyses one cycle of polyketide chain elongation, such as the 6–deoxyerythromycin B synthase
(DEBS) in the biosynthesis of erythromycin A 19 (Scheme 1.3).36 DEBS compromises three proteins
(DEBS 1–3), which contain seven modules with 28 domains working in line. Each module is
constituted of ACP and KS domains for loading and chain extension. Further a combination of
β–processing domains is included in a module: KR; DH and ER. Propionyl–CoA 20 is the starter
unit for module 1. The chain is further elongated with 6 x S–methylmalonyl–CoA 21 yielding a
C15–chain.37 The polyketide chain is released by macrolactonisation catalysed by the cis–acting TE
domain to furnish 6–desoxyerythronolide B (6–dEB) 22 and subsequent post–elongation tailoring
events (oxidations by P450 cytochromes and glycosyltransferases) give 19 (Scheme 1.3).37
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Scheme 1.3 Modular organisation of DEBS megasynthase and biosynthetic steps to erythromycin 19.
Type II PKS systems are characterised by sets of monofunctional proteins and work in an iterative
fashion to build up aromatic polyketides. Furthermore, ACP–independent type III PKS are reported.
Type III systems are also known as chalcone synthase–like PKS. These homodimeric enzymes act
directly on acyl–CoA substrate.34 All three types of PKS systems are found in bacteria. Type I PKS
are also known from fungi and type III PKS are also found in plants and fungi.29
Fungal PKS
In fungi, the predominant type of PKS are iterative type I megasynthases, which synthesise complex
natural products using a single set of domains (one module) in a highly programmed, iterative
fashion.38 They can be functionally and phylogenetically organised into three main classes: nonre-
ducing (NR), highly reducing (HR), and partial–reducing (PR) PKS.29,38,39 In addition to the catalytic
domains described for fatty acid biosynthesis (Scheme 1.2), an iterative fungal PKS can also include
further domains, e.g. for methylation of the α–carbon by a C–methyl transferase (C–MeT) using a
methyl group from S–adenosylmethionine (SAM).38 Polyketide synthases discussed in this thesis
all belong to the class of iterative fungal type I hrPKS, including squalestatin hexaketide synthase
(SQHKS), StPKS (strobilurin pathway) and SchPKS (SCH–642305 pathway). A prominent example of
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iterative fungal hrPKSs is the well studied LovB (lovastatin nonaketide synthase, LNKS) of lovastatin
6 biosynthesis40 or the SQS tetraketide synthase (SQTKS) of 1 biosynthesis (Scheme 1.4).41
LNKS (encoded by lovB) was shown to possess a disfunctional ER domain within the enzyme, but
coexpression experiments with an enoyl reductase encoding gene (lovC), located downstream of
lovB yielded the expected PKS product dihydromonacolin L 23 (Scheme 1.4 A).42 Thus LovC is a
trans–acting ER. Expression of the gene encoding SQTKS in A. oryzae yielded the tetraketide 24
showing it has a functional ER (Scheme 1.4 B).41
Scheme 1.4 Two examples of prominent iterative fungal hrPKS. A, coexpression of lovB and lovC in A. nidulans; B, domain
organisation of SQTKS and expression product 24.
The structural diversity of polyketides and accompanying diverse biological activities are the result of
programmed tailoring steps catalysed by the single domains of iterative hrPKS, which are selectively
used during different iterations of chain elongation, e.g. in lovastatin biosynthesis.40 Furthermore,
the choice of a different starter unit, such as benzoyl–CoA 25, yields more diversity.
The use of benzoate starter unit by fungal PKS is relatively uncommon in polyketide biosynthesis.
However, 25 serves as a metabolite in the biosynthesis of important plant metabolites including
cocaine 2643 and taxol 2744. There are also bacterial metabolites, such as enterocin 28 (Strepto-
mycetes maritimus)45 and soraphen A 29 (Sorangium cellulosum)46, which use benzoyl CoA in their
biosynthesis. In addition, two of the three fungal polyketides (squalestatin S1 1 and strobilurin A 2)
discussed in this thesis use a benzoate starter unit (Scheme 1.5).7,47,48
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Scheme 1.5 Examples of natural products consisting of benzoyl–CoA building blocks.
The diversity of fungal polyketides derive not only from the programmed iterative cycles of the PKS,
but most importantly by post–polyketide–synthesis steps, which are discussed in section 1.1.2.2
1.1.2 Post–assembly line tailoring
Tailoring steps occur after release of the polyketide chain. The released products often do not possess
the biological activities of the matured end products and need to undergo further decoration steps
carried out by dedicated post–assembly line tailoring enzymes.49
The most commonly found post–PKS modifications are catalysed by oxidoreductases. This very
broad group of enzymes covers oxygenases, peroxidases, reductases, and dehydrogenases.50 They
can for example catalyse the insertion of one or two oxygen atoms from atmospheric O2, or the
hydride transfer resulting in reduction or oxidation of alcohols to aldehydes and ketones.28
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Also methylations at oxygen, nitrogen or carbon centres by S–adenosyl methionine (SAM, 30) depen-
dent methyltransferases are common features of tailoring.50 An example is the O–methyltransferase
(O–MeT) LtLasM from the biosynthetic gene cluster producing the phytotoxic fungal polyketide
lasiodiplodin 31, which was shown to be responsible for the methylation of the C-3 phenolic alcohol
of desmethyl–lasiodiplodin 32 to lasiodiplodin 31 by coexpression of LtLasM with two hrPKS from
the BGC: LtLasS1 and LtLasS2, in yeast (Scheme 1.6).51
Scheme 1.6 Biosynthetic steps to lasiodiplodin 31 with a final O–methylation step catalysed by O–MeT LtLasM.
Often acyltransferases play a role in tailoring of the polyketide chain, such as during the biosynthesis
of lovastatin 6, where an acyltransferase LovD catalyses the transfer of a diketide to monacolin J
33 in the final step of the biosynthesis (Scheme 1.7).52 A similar transfer was also reported from
squalestatin 1 biosynthesis, where a tetraketide chain was loaded to the core of 1 as the last step of
the biosynthesis (Section 2).53
Scheme 1.7 Final step in lovastatin 6 biosynthesis catalysed by acyltransferase LovD.
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Activation of atmospheric oxygen and oxygenases
As atmospheric oxygen is a diradical it is inert towards spin paired organic compounds and therefore
not accessible by biological systems. Enzymes which are able to activate atmospheric O2 are divided
into oxidases and oxygenases, which incorporate oxygen atoms from dioxygen into the product(s).54
The latter are again divided into monooxygenases that catalyse the incorporation of one atom of
oxygen into the product and one atom to H2O, while dioxygenases incorporate both atoms of oxygen
into the product(s). Nature has evolved two strategies to reduce oxygen by one or two–electrons
transfer. The first strategy requires active transition metal ions such as iron or copper and the
second option involves the organic cofactor flavin adenine dinucleotide (FAD/FADH2).54 Enzyme
classes catalysing these reactions are iron dependent oxygenases: heme–dependent cytochrome P450
enzymes/ non–heme iron–dependent oxygenases; and FAD dependent monooxygenases.
FAD dependent monooxygenases
FAD dependent enzymes, also called flavoenzymes, are redox enzymes, which utilize the cova-
lently enzyme–bound cofactor FAD/FADH2. Often nicotinamide adenine dinucleotide (phosphate)
(NAD(P)+ 34(35)/NAD(P)H 36(37)) is also bound to the enzyme in order to reduce FAD 38 to
FADH2 39. NAD(P)H is in this case the reducing agent via two electrons transfer by hydride (H−)
(Scheme 1.8).55
Scheme 1.8 Reduction of NADPH/NADH.
Upon binding of O2 the reduced form 39 forms the reactive hydroperoxyflavin 40 species, which is
able to transfer oxygen either by nucleophilic attack of the substrate (Scheme 1.9), or by a nuclephilic
attack to the substrate. In the next step a water molecule is eliminated from 41 and the resulting 38 is
further reduced to FADH2 39 by consuming reduced NAD(P)H (Scheme 1.9).56
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Scheme 1.9 Oxygen activation by FADH2 and regeneration and epoxidation of an olefin 42 to the epoxide 43.
A well known example for an FAD dependent monooxygenase (FMO) occurs in fungal tropolone
biosynthesis. TropB is an enzyme shown to catalyse the step from 3–methylorcinaldehyde 44 to the
hydroxylated dearomatized product 45 by in vivo and in vitro studies (Scheme 1.10).57
Scheme 1.10 Biosynthetic step in tropolone biosynthesis to stipitaldehyde 46 catalysed by FAD dependent monooxygenase
TropB.
Cytochrome P450 monooxygenases
Cytochrome P450 monooxygenases (P450s) are heme–dependent enzymes that catalyse a diverse
array of reactions and play key roles in the biosynthesis of natural products.58 The heme (iron
protoporphyrin IX) prosthetic group, which is coordinated by a thiolate ion is important for the
reductive activation of molecular oxygen (Scheme 1.11 B).59
The complex multistep mechanism starts with the heme in the resting form 47 (Scheme 1.11). Upon
binding of the substrate (RH) the distal water ligand dissociates to yield 48. A single electron
reduction leads to the ferrous state 49 by a redox partner. Subsequently, the iron (II) binds dioxygen
at the top axial plane of the heme ring to form a ferric peroxo state 50 (Scheme 1.11 A). The Fe(II)–O2
complex 50 is in resonance with the Fe(III)–superoxide 51. A second single–electron reduction
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(electron comes e.g. from FADH2) to 52 and further protonation furnishes the transient compound
0 (ferric hydroperoxo) species 53. Additional protonation of this intermediate leads to cleavage of
the weak O-O single bond with loss of water resulting in the highly valent oxo–iron cation radical
(compound 1) 54, which is in resonance with Fe(V)=O oxo species (Scheme 1.11 A). The ferryl oxo
compound 1 is a strong oxidising agent. It can abstract a hydrogen atom from the substrate to form
compound 2 55 and a carbon radical, prior to rebound of the hydroxyl to the substrate radical to
form the hydroxylated product (Scheme 1.11 C).60
Scheme 1.11 Catalytic mechanism of P450s adapted from Munro et al.60 A, cytochrome P450 reaction cycle; B, iron atom in
the equatorial plane of the heme; C, homolytic mechanism and hydroxyl radical rebound in heme–dependent oxygenases.
Cytochrome P450 GsfF was shown to catalyse the oxidation of griseophenone B 56 to yield desmethyl–
dehydro griseofulvin A 57 during the biosynthesis of griseofulvin 58.61 Computational analysis
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suggests that GsfF preferentially performs phenolic O–H abstraction over benzene epoxidation
during the oxidation to form the grisan structure (Scheme 1.12).62
Scheme 1.12 Role of P450 GsfF during griseofulvin 58 biosynthesis.
Non–heme iron–dependent oxidative enzymes
A class of enzymes called non-heme iron-dependent oxygenases are versatile enzymes which can
catalyse a variety of reactions.63 Non–heme iron and α–ketoglutarate dependent oxygenases (αKG–
NHFe) are the largest known subclasses of mononuclear non-heme iron enzymes and they are widely
distributed in bacteria, fungi, plants and vertebrates, where they play a role in e.g. DNA/ RNA
repair but also in biosynthesis of natural products.64 They catalyse hydroxylation, dealkylation,
desaturation, epoxidation, epimerisation, halogenation, cyclisation, peroxide formation, and ring
expansion/contration reactions by generating an FeIV–oxoiron intermediate for C–H bond activa-
tion.65,66 The family of αKG–NHFe possess two conserved structural features. On the one hand Fe(II)
is ligated by two His residues and a carboxylate from either Glu or Asp. This metal motif is termed:
2–His–1–carboxylate motif. On the other hand it is located within a double–stranded β–helix fold
(Fig. 1.2).67
Figure 1.2 Structural information of αKG–NHFe TauD from taurine biosynthesis. Overall fold and the His–Asp–His “facial
triad”, PDB ID: 1OS7, iron centre is illustrated as filled black circle, taken from Wu et al.63
The catalytic cycle was clarified using structural and mechanistic studies. In an example for hydrox-
ylation reaction, the cofactor FeI I is coordinated in the 2–His–1–carboxylate facial triad 59. Upon
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binding of α–ketoglutarate (αKG) 60 the iron center displaces two of the three water molecules to
yield 61 (Scheme 1.13). The remaining water molecule is released as soon as the substrate (R–H)
binds to the active site of the enzyme (62) vacating space for binding the triplet oxygen molecule
generating the FeI I I–superoxo intermediate 63. The peroxide radical can then attack C-2 of αKG to
give a peroxohemiketal bicyclic intermediate 64, which collapses via oxidative decarboxylation to
release CO2 and yielding the high valence FeIV=O (ferryl) intermediate 65. This species can abstract
a hydrogen atom from the substrate to reduce the iron to the FeI I I–OH state 66 forming the substrate
radical. In the end of the catalytic cycle the hydroxyl radical rebounds onto the substrate radical
yielding the hydroxylated product (R–OH) and returning the iron back to the FeI I state 67, releasing
the product and succinate 68 to give 59 (Scheme 1.13).65,66
Scheme 1.13 Catalytic cycle of non–heme iron αKG–dependent oxygenase adopted from Tang et al.66
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Halogenases are a subset of αKG–NHFe enzyme superfamily, which can install a halogen (Cl· or
Br·) at an inactivated carbon center. The first discovered enzyme of that class was SyrB2 in 2005.
It is involved in the biosynthesis of the non–ribosomal peptide syringomycin E 69, catalysing the
chlorination of the methyl group of threonine (Scheme 1.14).68,69
Scheme 1.14 Chlorination in biosynthesis of non–ribosomal peptide syringomycin E 69 catalysed by SyrB2.68,69
1.2 Investigation of natural product biosynthesis in fungi
There are numerous approaches known to investigate the biosynthesis of natural products. Two
prominent methods are isotopic labelling and targeted gene knockouts in the native producer. A
very powerful method to understand and also engineer secondary metabolite biosynthetic pathways
is heterologous expression.
1.2.1 Isotopic labelling
Isotopic labelling studies have been used for many years to investigate biosynthetic pathways of
polyketides. The method can reveal information about the polyketide backbone, the starter unit and
also about later stages of the biosynthesis, such as oxidative or reductive modifications. The usage
of isotopes is not "out of fashion", but still continues to give important insights into biosynthetic
pathways of secondary metabolites.70 In 2017, the structure of the fungal phytotoxins known as the
phyllostictines has been revised using stable isotopes.71
Early labelling studies were conducted using radioactive labels, such as 14C and 3H. These are
β–emitters which can be detected by a scintillation counter to a low level of incorporation due to a
low background. The disadvantage of this technique is not only the radioactivity but that the exact
position of incorporation in the molecule can only be determined by degradation studies.
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Figure 1.3 Illustration of feeding labelled precursors and subsequent signal enhancement of incorporated atoms in 13 NMR
spectra, adapted from Simpson.72
However, pioneering work in the field of polyketide biosynthesis was done by Birch and coworkers
using 14C labelled acetate units to study the biosynthetic origin of 6–MSA 8 among others.21
More recent labelling techniques use stable isotopes such as 13C, 2H, 15N and 19F. 13C labelling
techniques reveal information about complete labelling patterns by determining the enhancement
of individual 13C resonances. Examples for incorporation of 13C–enriched precursors ([1–13C]–,
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[2–13C]–, or [1,2–13C2]–acetate) into contiguous carbons of a polyketide–derived metabolite are
illustrated in figure 1.3. Incorporation of a singly 13C–labelled precursor enhances the content of
13C at a particular carbon which results in an increase in intensity of the signal for that carbon
compared to natural abundance of 13C (1.1%) (Fig. 1.3 A–C). If a doubly labelled precursor like
[1,2–13C2]–acetate is incorporated in a metabolite (bond stays intact), it will lead to the observation
of a 13C–13C spin coupling in the corresponding 13C NMR spectrum (Fig. 1.3, D).72
Feeding labelled 13C precursors allows the origin of the carbon skeleton of a compound to be
determined. However, it is also important to investigate the biosynthetic origin of the oxygen
atoms to understand the mechanism of the conversion during biosynthesis. The isotope 18O2 can be
introduced as doubly labelled acetate ([1–13C,18O2]–acetate) or by growth in an 18O2 environment.
The isotope itself is not NMR active, but it is possible to use 13C as a "reporter" nucleus for oxygen
to detect it indirectly by changes induced in the 13C NMR chemical shifts of directly–attached
carbon atoms.73 Substitution of a proton alpha or beta to the 13C by deuterium or oxygen causes an
upfield shift (∆δ) in the 13C chemical shift (Fig 1.3, E+F). The shift (∆δ) depends on the atom and the
hybridisation of the 13C atom to which it is attached.72,74
1.2.2 Gene knockout
Targeted gene knockouts or gene silencing experiments are a useful tool to elucidate natural product
biosynthesis. These experiments are widely used to investigate the function of encoded proteins
and link pathway steps to their genes/cluster by disrupting the gene of interest (GOI) from the
biosynthetic gene cluster (BGC) and analysing the changes in secondary metabolite production. A
popular strategy to disrupt GOI is based on stable integration of exogenous DNA into the fungal
genome by homologous recombination (HR) using a polyethylene gylcol (PEG)/ CaCl2 based
transformation protocol.75 Other transformation techniques have been shown to be successful for
filamentous fungi, such as electroporation of protoplasts,76 or Agrobacterium tumefaciens mediated
transformation.77 When the exogenous DNA is inside the fungal cell it is integrated into the genome
by replacing the targeted gene by a marker gene (e.g. an antibiotic resistance gene). Thus the GOI
is inactivated and not further expressed. For this purpose the transformed DNA is constructed
to occupy two sequences homologous to the GOI which flank a selection marker on either side
(Scheme 1.15, left and right).
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Scheme 1.15 Integration of a knockout cassette by homologous recombination [a] and ectopic integration of a knockout
cassette resulting in false positive transformants [b].
In this study transformants are selected by using the E. coli gene hph, encoding a hygromycin
B (hygB) phosphatase as selection marker for the antibiotic hygromycin B.75,78 However, DNA–
mediated transformation experiments are a challenging task because the transferred DNA can be also
integrated ectopically into the genomic DNA. In some cases ectopic integration can be predominant
(Scheme 1.15 b).79 The reason is that DNA integration in filamentous fungi is mainly driven by
non–homologous end joining (NHEJ). The NHEJ–mechanism is based on random ectopic integration
of DNA into the genome and site–specific recombination occurs at less than 1%.79
In order to reduce the number of false positive transformants a split–marker technology can be
used. The split–marker method was initially established for S. cerevisiae80 before it has been also
applied to a number of filamentous fungi. The modified gene disruption method is known as
bipartite marker strategy and was developed in A. nidulans.81 The bipartite method ensures that
substitution of a wild–type targeted gene is only possible when three cross–over events occur
between two individually cotransformed DNA fragments to generate an intact resistance gene
(Scheme 1.16).81 The resistance gene used for MF5453 is hph which is flanked by homologous gene
sequences of the targeted gene that allow homologous recombination between fungal genomic
DNA and the two parts of the knockout cassettes to substitute the targeted gene by the selectable
marker (Scheme 1.16). A successful application of the split–marker system was shown in 2001 for
Acremonium chrysogenum in which the mecB gene was inactivated. The gene mecB encodes for a
cystathionine–gamma–lyase, which is required for cephalosporin C biosynthesis. Targeted gene
disruption frequency was increased to 5%.82 Catlett et al. utilized the hygromycin B resistance marker
for selection and they could increase integration efficiencies to up to 100% by using flanking regions
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of only 285–761 bp in size.83 Also in our group it was shown that the bipartite strategy was applied
successfully to a variety of other fungi, resulting in frequent disruption of the GOI.53,84,85
Scheme 1.16 Bipartite marker strategy: Reduction of ectopic integration by cotransformation of two DNA fragments with
three homologous recombination events.
There are also other approaches for investigation of gene functions. One of them is post–transcriptional
gene silencing, which is based on mRNA degradation. In comparison to gene disruption methods,
silencing causes only decreased yields, but not complete vacancy of the explored secondary metabo-
lite. Gene silencing relies on introduction of antisense RNA to the mRNA of the targeted gene. An
RNA dependent RNA polymerase promotes the formation of a deviant double stranded RNA, which
initiates the endogenous silencing pathway in fungi.86
Scheme 1.17 Biosynthesis of tenellin 70. A, knockout of tenS; B, biosynthetic steps catalysed by P450s TenA and TenB.
Both methods, gene disruption and silencing were reported to be successful during the investigation
of tenellin 70 biosynthesis. The core gene, tenS (PKS–NRPS), was knocked out and showed abolition
of 70 production and a silencing method targeting the two P450 encoding genes (tenA and tenB) was
reported to result in accumulation of pathway intermediates pretenellin–A 71 and pretenellin–B 72
(Scheme 1.17).87,88
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1.2.3 Fungal heterologous expression
Heterologous expression of single genes, partial or entire gene clusters is a powerful tool to elucidate
the biosynthetic steps of secondary metabolites in bacteria or fungi. In addition to the analysis poten-
tial, heterologous expression also bears numerous engineering possibilities and promises progress in
the discovery of novel compounds or optimisation of product yields.89 For some fungi targeted gene
knockout or transformation methods are ineffective, since the GOI is mainly incorporated ectopically.
One example is Sarocladium schorii, the producer of the fungal meroterpenoid xenovulene A 73. Here,
heterologous expression was the preferred method to study the pathway.90
In order to uncover the steps of a biosynthetic pathway, several genes have to be expressed simulta-
neously. This involves the transfer of all relevant genes from a donor strain to a suitable, foreign host
to reconstitute the biosynthetic pathway in vivo. In general, many polyketide–synthesising strains
show poor laboratory growth or possess inefficient transformation and homologous recombination
abilities. It is therefore desirable to transplant entire BGC into model strains which are more tractable
to genetic manipulation.91
For bacterial BGC this has been achieved via bifunctional phage P1–derived artificial chromosomes
(PAC) vectors.92 More recently it was shown that large gene clusters can be directly cloned into E. coli
expression vectors. Using this approach, ten PKS and NRPS pathways from Photorhabdus luminescens
were directly transferred into E. coli.93 Expression of fungal genes in bacteria such as E. coli or
actinomyces is difficult as it bears several problems. Bacterial hosts cannot process eukaryotic
introns and often possesses a significant codon bias. Furthermore, bacteria show difficulty in
correctly folding fungal polypeptides.94 However, E. coli is often a suitable platform for recombinant
purification of single proteins which enables analysis of individual enzymes in vitro such as TropB, a
FAD–dependent monooxygenase during stipitaldehyde 46 biosynthesis (Scheme 1.10).57
Another host used for heterologous expression of fungal BGC is the yeast strain S. cerevisiae. Ad-
vantages of this host are that homologous recombination is highly efficient and that yeast itself
has an insignificant endogenous secondary metabolism, minimising the risk of side reactions and
cross chemistry between the expressed pathway and endogenous biosynthesis. Nevertheless, the
latter advantage can sometimes be a limiting factor, e.g. lacking relevant building blocks.95 Last year,
HEx (Heterologous EXpression) synthetic biology platform was developed for rapid expression of
fungal biosynthetic gene clusters in S. cerevisiae to overcome the problem of accessing metabolites
of uncultivable organisms or silent gene clusters. Harvey and coworkers showed that 22 out of 41
fungal BGC produced detectable compounds (by liquid chromatography–mass spectrometry, LCMS
analysis) while expressed in yeast.96
21
1.2 Investigation of natural product biosynthesis in fungi
In addition to E. coli and S. cerevisiae, A. oryzae spp. are often chosen as heterologous host for
studying fungal biosynthetic pathways. This was shown to be successful in many examples and was
summarised in multiple reviews.89,97,98,99,100 There are a number of advantages of filamentous fungi
as heterologous hosts in contrast to E. coli and yeast: strains are usually stable and easily cultured in
the lab, they can be modified genetically and it is not essential to coexpress a foreign PPTase gene
to provide the prosthetic group for the ACP domains of PKS. Furthermore the genetic systems of
the producing fungi and the host are in some cases compatible and therefore cDNA preparation or
engineering intron removal is not always required.98 Most commonly, A. oryzae is selected as host,
as it has been used for a long time for fermentation to get food products like sake, miso and soy
sauce.100 Moreover, this species has been given the status of "Generally Regarded As Safe" (GRAS)
organism, accordingly safe to be used for food and pharmaceuticals.101
In 2010, heterologous expression was first used to reconstitute a complete fungal biosynthetic
multigene cluster. The biosynthesis of tenellin 70 was reconstituted by expressing four genes (tenS,
tenC, tenA, tenB) of the pathway from Beauveria bassiana in arginine auxotrophic A. oryzae M–2–3
strain with each gene under the control of the starch–inducible amyB promotor (Scheme 1.17).94
The biosynthesis of more complex fungal metabolites containing a higher number of genes, such as
byssochlamic acid, agnestadride A84 and xenovulene A 73 have also been successfully investigated
through heterologous expression experiments.90 The entire biosynthetic pathway of the complex fun-
gal meroterpenoid 73 was reconstituted in heterologous host A. oryzae. This allowed the elucidation
of each chemical step and enzyme involved in the biosynthesis, including the initial formation of
tropolone intermediates, a putative hetero Diels—Alder enzyme, a new class of terpene cyclases and
two enzymes involved in oxidative ring contractions (Scheme 1.18).90
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Scheme 1.18 Basic steps in the biosynthesis of xenovulene A 73.
Recently, the Abe group reported the elucidation of very complex biosynthetic steps to a variety of
other fungal meroterpenoids using heterologous expression in A. oryzae.102,103,104,105,106 They eluci-
dated the complete biosynthetic pathway of fungal meroterpenoid chrodrimanin B 74 (Penicillium
verruculosum TPU1311) by heterologous reconstitution of its biosynthesis in A. oryzae. In this study
13 different set of genes were coexpressed with up to nine genes simultaneously (Scheme 1.19 A).103
Using the same approach Abe and coworkers also elucidated the biosynthetic pathway to the two
fungal meroterpenoids ascofuranone 75 and ascochlorin 76, which branch from a common precursor,
ilicicolin A epoxide 77 (Scheme 1.19 B).105 All genes (ascABCDEFG) involved in 76 biosynthesis and
a transcriptional factor ascR are clustered together. However, the three genes (ascHIJ) required for the
steps to 75 are located in a distant BGC elsewhere in the genome.105
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Scheme 1.19 Biosynthesis of fungal secondary metabolites elucidated via heterologous expression in A. oryzae. A, biosyn-
thetic steps to chrodrimanin B 74; B, pathway to the two fungal meroterpenoids ascofuranone 75 and ascochlorin 76.
In all examples discussed above and also in this thesis, a multigene expression vector system was
used. The quadruply auxotrophic A. oryzae NSAR1 is deficient in arginine (∆argB), adenine (adeA−),
methionine (sC−) and ammonium (niaD−) metabolism. Additionally, the natural sensitivity of
A. oryzae NSAR1 towards the antibiotics bleomycin and the herbicide glufosinate (bleR, bar) enables
the use of two more selection markers. Using designed fungal expression vectors containing different
selection markers (argB, adeA, sC, niaD, bleR, bar) enables the reconstitution of larger biosynthetic
pathways by simultaneous expression of up to 26 genes.98
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Each plasmid possesses four fungal promotor/ terminator pairs for gene cloning (P/Tadh, P/Tgpd,
P/Teno and P/TamyB) (Scheme 1.20 A). The first three are flanked by an AscI site that can be used to
simultaneously add up to three tailoring genes in vivo by yeast homologous recombination, which
include at least 30 bp homologous overlap sequence that is usually introduced by PCR through tails
at the designed oligonucleotides (Scheme 1.20 B). Furthermore the fungal expression vectors contain
an origin of replication colE1 for replication in E. coli and an ampicillin resistance gene ampR as well
as an chloramphenicol gene (camR). For selection and propagation in uracil deficient S. cerevisiae
strains the vectors contain the ura3 gene, encoding orotidine 5’–phopsphate decarboxylase, and the
2µ ori (Scheme 1.20 A). A eukaryotic origin of replication is not necessary because A. oryzae integrates
the plasmid ectopically in its genome, thereby causing a stable transformation.75
Scheme 1.20 Fungal expression vectors used in this work and gateway cloning procedure: A, pTYGS vector family; B,
cloning of up to 3 genes into pTYGS vectors by in vivo homologous recombination (HR) in S. cerevisiae; C, Gateway cloning by
LR recombination between pE–YA (entry clone) and pTYGS (destination vector) yielding in expression clone (pTYGS) and
donor vector (pE-YA).
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One additional gene can be cloned after the amyB promoter (PamyB) which is induced by starch
and maltose. This cloning site is suitable for in vitro Gateway cloning, as it contains recombination
sites (attR1 and attR2) which flank a Gateway cassette consisting of the ccdB gene, encoding the
CcdB killer protein, and chloramphenicol resistance camR (Scheme 1.20 C). For gateway cloning a
LR recombinase kit (Invitrogen) is used containing a mixture of bacteriophage l integrase proteins
(integrase, integration host factor, excisionase) which interchange DNA flanked by attR sites with
DNA flanked by attL sites (e.g. E. coli–S. cerevisiae shuttle vector pE–YA). The destination vector with
the gene of interest (GOI 4) can be selected by using an E. coli TOP10 strain as well as ampicillin
as antibiotic. This is possible, as destination vectors possessing the Gateway cassette have to be
propagated in E. coli ccdB survival cells, which are resistant to the ccdB gene product.
1.3 Overall aims
The main focus of this thesis concentrates on understanding and engineering the biosynthesis of three
polyketides produced by filamentous fungi: squalestatin S1 1, strobilurin A 2 and SCH–642305 3.
Using most up to date methods such as targeted gene knockout, heterologous expression in As-
pergillus oryzae and in vitro studies with purified enzyme should uncover the order and functions of
genes involved in the three biosynthetic pathways. The particular aim for squalestatin biosynthesis is
to discover the oxygenases which are involved in constructing the highly oxidised core structure of 1.
The major focus of the biosynthetic studies of strobilurin is based on investigating the unusual oxida-
tive rearrangement to form the core β–methoxyacrylate moiety of this valuable class of agricultural
used fungicides. In addition, the aim for SCH biosynthesis is to reveal the molecular mechanism of
each chemical step in vivo, with special attention on the formation of the 6–membered ring.
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2 Biosynthetic studies of Squalestatin S1
Partial results of the presented work have been published in Chem. Sci., 2019, 10, 1227–1231.107
2.1 Introduction
Squalestatin S1 (SQS1, 1), also known as zaragozic acid (ZA) A is a fungal metabolite, discovered in
1991 and 1992 by three independent groups: Researchers from Merck12, Glaxo108 and Tokyo Noko
University/Mitsubishi Kasei Corporation.109 Glaxo isolated 1 from Phoma sp. C2932, the Tokyo
group from Setosphaeria khartoumensis and Merck from cultures of a the non–sporulating unidentified
strain MF5453. The name ’zaragozic acid’ originated from its producing strain MF5453 which was
isolated from a water sample taken from the Lalon river in Zaragoza, Spain.12
SQS1 1 belongs to a family of squalestatins that are only produced by fungi (Ascomycota). Over
20 different squalestatins have been isolated from at least eleven different taxa of fungi.110 The
first members reported from this family were ZA A 1, ZA B 79111 and ZA C 80112 (Fig. 2.1). All of
which contain the characteristic 2,8–dioxabicyclo[3.2.1]octane–3,4,5–tricarboxylic acid ’core’ which is
decorated with two lipophilic side chains. The variation is mostly due to differences in the ester side
chain at C-6 and the alkyl side chain at C-1.113
Figure 2.1 Structures of ZA B 79 and ZA C 80.
The squalestatins are potent pico–molar inhibitors of squalene synthase, an enzyme of sterol biosyn-
thesis. The discovery of squalestatins resulted from a screen of natural products for novel inhibitors
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of cholesterol biosynthesis.12 Inhibitors of cholesterol biosynthesis could be therapeutic agents with
potential for the treatment of hypercholesterolemia.
2.1.1 Biological activity
SQS1 1 shows broad antifungal activity and is used as a lead structure for cholesterol–lowering
drugs.108 Cholesterol biosynthesis in mammals starts with acetyl–CoA 11 which is converted via
over 20 enzymatic reactions to the final product cholesterol 81 (Scheme 2.1). Among these, two
enzymes: 3–hydroxy–3–methylglutaryl–CoA (HMG–CoA) reductase and squalene synthase play
key roles.114
HMG–CoA reductase is a target for cholesterol lowering drugs. This enzyme catalyses the conversion
of HMG–CoA 82 to mevalonic acid 83. HMG–CoA reductase inhibitors, also traditionally known
as statins, reduce cardiovascular disease morbidity and mortality with a high level of safety. One
example is lovastatin 6, which was shown to be an active inhibitor of cholesterol biosynthesis in rats
and dogs.13 HMG–CoA reductase inhibitors also show disadvantages as depletion of non–sterol
products lead to toxic side effects and some people do not tolerate statins or the drug is not effective
and therefore critical as treatment for coronary heart diseases.115
For this reason an alternative promising strategy for the development of novel cholesterol lowering
agents was to target the enzyme squalene synthase, which catalyses the first step in sterol biosynthesis
(Scheme 2.1). Due to the fact that squalene synthase inhibitors act at a relatively late step in cholesterol
biosynthesis they do not affect the mevalonate–farnesyl diphosphate pathway.114 SQS1 is a potent
pico–molar inhibitor of mammalian and fungal squalene synthase.109 Moreover, 1 shows broad
spectrum antifungal properties and was shown to lower serum cholesterol levels (up to 75 %) in
marmosets in vivo, which have a similar lipoprotein profile compared to humans.108,116
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Scheme 2.1 Simplified sterol biosynthetic pathway modified after Nadin and Nicolaou117; lovastatin inhibits HMG–CoA
synthase and squalestatins inhibit squalene synthase.
2.1.2 Biosynthesis of SQS1 – status quo
Since the early 1990s, the investigation of the biosynthesis of squalestatins was an area of intense
interest and research. The biosynthetic origin of squalestatins was discovered independently by
Merck and Glaxo.7,47 All squalestatins share the same unique 2,8–dioxabicyclo[3.2.1]octane–4,6,7–
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trihydroxy–3,4,5–tricarboxylic acid ring system regardless of the producing fungus. Using labelling
experiments with isotopically labelled substrates the origin of 1 was discovered (Fig. 2.2).
Isotopic labelling studies
Feeding experiments using isotope labelled precursors were conducted in 1992 and 1993 to determine
the biosynthetic origin of the heavy atoms in squalestatin S1.7,47 Significant incorporation of acetate
13, succinate 84, L–phenylalanine 85, benzoic acid 86 and cinnamic acid 87 as well as the methyl
group from L–methionine into 1 were shown by feeding 14C –labelled precursors.47 The exact sites
of incorporation of the precursors and the direction of PKS skeleton were investigated by feeding
13C–labelled substrates and carbon NMR analysis.47
Figure 2.2 Labelling patterns of 1.
The feeding experiments indicated that 1 is made of two polyketide chains: a main chain (A),
composed of a benzoate–derived starter unit and five acetate–derived extender units resulting in
a hexaketide, and a side chain (B), composed of three acetate–derived units forming a tetraketide
(Fig. 2.2, chain A + B).
The biosynthesis of chain A starts with an unusual starter unit, a benzoate unit derived from pheny-
lalanine 85 via benzoic acid 86. The incorporation of [3-13C]–phenylalanine, [U–14C]–cinnamic acid,
and different labelled 13C–benzoic acid precursors revealed that the nine carbons of phenylalanine
are metabolised losing the first two carbon atoms to retain the seven carbons of benzoic acid.7,47 The
most likely starter molecule of chain A is an activated form of benzoic acid, e.g. benzoyl CoA. Recent
feeding studies conducted by Tang and coworkers showed that cinnamoyl CoA 88 is formed early in
the SQS precursor biosynthesis.118
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Both chains (A+B) are formed of acetate units and possess four additional methyl groups which
were shown to derive from the methyl group of L–methionine transferred by S–adenosylmethionine
(SAM). [1-13C]–propionate was not incorporated into 1, whereas supplementation with L–[methyl-
13C]–methionine resulted in high levels of enrichment at all four methyl groups (Fig 2.2, bold
circles).
Carbons C-3, C-4, C-21 and C-22 of 1 derive from incorporation of an intact C4–unit from the citric
acid cycle. The precursor is likely to be an oxidised metabolite of succinate, such as oxaloacetate 89
(Fig. 2.2, green).47
In order to investigate the origin of the oxygen atoms of 1, the SQS1 producing strain was incubated
in the presence of [113C, 18O2]–acetate and 18O2 in separate experiments.7 The two ester carbonyl
groups of chain A and B were shown to derive from acetate oxygens (Fig. 2.3 A). Moreover, the
closed fermentation of the producing fungus in a 18O2 environment produced SQS1 that displayed
characteristic 18O2 carbon NMR shifts for five carbons on chain A, suggesting oxygens on carbons
C-1/-5, C-3, C-6, C-7 and C-12 to be derived from atmospheric oxygen (Fig. 2.2, orange + Fig. 2.3 B).
This outcome was supported by mass spectrometry of labelled 1, as this sample showed a number
of molecular ions +2, +4, +6, +8 and +10 mass units greater than unlabelled O2. This ion pattern
indicated the presence of up to five 18O2 atoms per molecule of 1. The lack of carbon shift at C–4
under both labelling strategies suggested that the hydroxyl group at this position is not derived from
oxygen (Fig. 2.3).7
Figure 2.3 Sections of 13C NMR spectrum of 1 labelled by [113C, 18O2]–acetate (A) and 18O2 gas (B) showing α–isotope shifts,
original spectrum taken from Jones et al., 1992.7
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On the basis of the oxygen labelling results the group of Glaxo proposed a mechanism where a
nucleophilic attack by a water molecule at C-4 triggered the ring formation through C-1 (Scheme 2.2,
route A).7 Another proposal for the ring closing mechanism is mediated by α– and β–oxidations of
an alkylcitrate 90 to give two hydroxyl groups at C-3 and C-5 as well as at C-6 to furnish intermediate
91. The carbonyl group at C-1 must arise from aliphatic oxidation and vanished during bicyclic ring
formation from the cyclic hemiketal (Scheme 2.2, route B).113 In 1995, the group of J. D. Bergstrom
and K. E. Wilson isolated the alkyl citrate, L–731,120 90, as a minor compound of the fermentation
broth of fungus MF5453 and showed that 90 is a micro–molar inhibitor of squalene synthase.119
Scheme 2.2 Proposed mechanisms (route A and B) for bicyclic ring formation by Glaxo and Merck, adapted from
Bergstrom et al., 1995.113
Gene cluster and proposed biosynthesis of SQS1
The investigation of the SQS1 gene cluster started in our group in 2000 when isolation and sequence of
the gene encoding squalestatin tetraketide synthase (pks1) were reported.120 A few years later the pks1
gene was cloned and heterologously expressed in A. oryzae and the produced tetraketide was isolated
from liquid culture.41 Recently, an important step was done in understanding SQS1 biosynthesis by
generating information using full genome sequencing which are reported by Bonsch et al., 2016.53
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Figure 2.4 Three SQS1 gene clusters from unidentified strain MF5453, Phoma sp. C2932 and Curvularia lunata in comparison
to a similar cluster found in Dothistroma septosporum; putative function as non–heme iron–(NHI) dependent oxygenases and
copper dependent oxygenase were not determined before start of the project (Section 2.4).
The genome of two closely related fungal producers of 1 (Phoma sp. C2932 and unidentified strain
MF5453) were sequenced. For both fungi a putative SQS1 gene cluster was found by analysing the
genomes for the previously characterised pks1 gene (Fig. 2.4).121 Both SQS1 clusters from MF5453
and C2932 show highly similar composition of genes and a high identity (74–93%) between proteins
with the same predicted function (Table 2.1). For further studies the sequence of MF5453 was chosen.
Recently, Tang and coworkers reported a BGC for production of 1 from fungal pathogen Curvularia
lunata which also shows nearly identical gene organisation. The only difference is displayed as an
additional gene clz8, which encodes for a protein with unknown function (Fig. 2.4).118
Using an NCBI database search a fourth putative squalestatin BGC in pine pathogen Dothistroma
septosporum was discovered.53 In contrast to the highly similar order of genes in the first three clusters,
the genes in D. septosporum are disordered and a corresponding gene for the tetraketide synthase
(pks1) is missing (Fig. 2.4). Nevertheless, the composition of genes is similar and the identity between
proteins with the same predicted function is still up to 73% (Table 2.1).
In order to link the clusters with the biosynthesis of 1 the gene for the tetraketide synthase was
knocked out in the unidentified strain MF5453, resulting in loss of SQS1 production and accumulation
of an intermediate 92, lacking the tetraketide chain.53
Unsurprisingly, two genes encoding highly reducing PKS were found in the first three SQS1 gene
clusters: pks1 and pks2 (Table 2.1). It was shown before that the tetraketide synthase is responsible
for the biosynthesis of the side chain of 1 by reconstruction of the 8 kb gene in a fungal expression
vector and heterologous expression in A. oryzae M–2–3 (argB).41,123
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Table 2.1 Gene composition with putative function of SQS clusters of three producing fungus (MF5453, C2932, C. lunata) and
of one putative SQS cluster of D. septosporum - identity is referred to MF5453 genes; putative function as non–heme iron–(NHI)
dependent oxygenases and copper dependent oxygenase were not determined before start of the project (Section 2.4)
MF5453
genes53
C2932
genes53
aa %
identity
Curvularia
lunata
genes118
aa %
identity
Dothistroma
septosporum
NZE10122
aa %
identity
Putative function
mfpks1 phpks1 87 clz2 88 N/A N/A Polyketide synthase
(SQTKS)
mfm1 cm1 93 clz3 90 dsL1 32 Copper dependent
oxygenase
mfm2 cm2 91 clz4 86 dsL3 64 MFS transporter
mfm3 cm3 80 clz5 86 dsL4 57 NADP dependent
dehydrogenase
mfm4 cm4 89 clz6 88 dsL11 47 Acyltransferase (AT1)
mfm5 cm5 82 clz7 85 dsL6 13 Zinc Finger Transcription
Factor (TF)
mfm6 cm6 81 clz9 94 dsL5 61 MFS transporter
mfm7 cm7 88 clz10 90 dsM2 17 Phenylalanine ammonia
lyase (PAL)
mfm8 cm8 90 clz11 93 dsM1 62 Hydrolase
mfm9 cm9 78 clz12 92 dsM5 61 4–coumarate–CoA ligase
mfm10 cm10 78 clz13 84 dsM6 53 Hydrolase
mfpks2 phpks2 93 clz14 91 dspks2 67 Polyketide synthase
(HRPKS)
mfr1 cr1 93 clz15 68 dsL9 73 Possible non–heme iron
dependent oxygenase
mfr2 cr2 92 clz16 93 dsL8 61 Possible non–heme iron
dependent oxygenase
mfr3 cr3 82 clz17 88 dsL7 66 Citrate synthase
mfr4 cr4 76 clz18 76 dsM3 37 Acyltransferase–3
superfamily (AT2)
mfr5 cr5 86 clz19 74 dsL10 49 MFS transporter
mfr6 cr6 74 clz20 87 dsM4 56 Squalene synthase
The second PKS gene is therefore likely to encode the squalestatin hexaketide synthase, which builds
the main polyketide chain. As shown by earlier isotopic labelling experiments, the hexaketide is
formed from benzoate, an unusual starter unit for hrPKS (Fig. 2.2). The active site residues of the
AT domain were shown to differ from hexaketide synthase AT domains which select acetate as the
starter unit.53,118
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Scheme 2.3 Proposed biosynthetic pathway for squalestatin S1 1. Oxygen atoms marked in red derived from atmosphereic
oxygen.
Moreover, the SQS1 cluster was found to contain genes putatively involved in benzoate production:
a phenylalanine ammonia lyase (PAL), encoded by mfm7, most likely catalyses the first step in
the degradation of phenylalanine 85 (Scheme 2.3). This is supported by former feeding studies as
phenylalanine 85 and benzoic acid 86 are known precursors of 1 (Section 2.1.2).7 This first step is
known from other microbial and plant systems during the biosynthesis of benzoyl–CoA. In plants,
cinnamyl CoA 88 is hydrated, oxidised and then subject to a retro–Claisen reaction (Scheme 2.4).124,125
However, recent feeding studies conducted by Tang and coworkers suggests that cinnamoyl CoA is
formed early in the SQS precursor biosynthesis.118
Scheme 2.4 Biosynthetic steps from benzoic acid 86 to benzyol CoA 25 in plants, KAT: 3–ketoacyl–CoA thiolase, PAL:
Phenylalanine ammonia lyase.124,125
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Other proteins encoded by genes of the cluster may also be involved in the benzoyl CoA synthesis;
for example Mfm3, a NADP–dependent dehydrogenase and CoA ligase Mfm9.
The produced hexaketide chain 93 is then predicted to be linked to an oxaloacetate moiety by a gene
encoding a citrate synthase–like protein (encoded by mfr3, Scheme 2.3). The linkage of a polyketide
chain to an oxaloacetate moiety by a citrate synthase has already been observed in fungal maleidride
biosynthesis (Section 2.1.3). From alkylcitrate 90 a series of oxidation steps are necessary to form 1,
but significantly the BGC appears to encode no oxygenases by BLASTp analysis.53
The cluster contains two putative acyltransferases (AT) genes. Previous work in our group con-
centrated on analysis of the two acyltransferases Mfm4 and Mfr4. In vitro analysis of Mfm4 by
Verena Belt showed that this enzyme has a broad substrate selectivity in terms of its CoA substrate
which was loaded onto the squalestatin core as the final step of biosynthesis (Scheme 2.3).53 The
other acyltransferase Mfr4, encoded by mfr4, could not be isolated in soluble form by expression
in E. coli.53 It presumably plays a role in attaching the acetate moiety to the hexaketide chain of 94
to form 92 (Scheme 2.3). As the in vitro experiment showed that the tetraketide chain could only
be transferred to the core of 1 as CoA activated thiolester, the CoA ligase Mfm9 from the cluster
(encoded by mfm9) may play a role in formation of the required tetraketide CoA. It is also possible
that Mfm9 catalyses a step in the benzoate precursor biosynthesis. As Mfm9 is the only CoA ligase
in the cluster it is possible, that this enzyme catalyses both reactions. In addition the squalestatin
BGC encodes two possible hydrolases (Mfm8 and Mfm10) which could be involved in benzoate
biosynthesis, off–loading of the hexaketide chain from the hexaketide synthase or in releasing the
activated tetraketide chain from its synthase.
In addition to the biosynthetic genes, the cluster also contains genes for transporters (mfm2, mfm6,
mfr5), an unknown gene mfm5, possibly a transcription factor in accordance to structure homology
searches, and a putative resistance gene, mfr6, encoding a squalene synthase (SS) which showed
mutations in substrate binding residues compared to housekeeping SS suggesting a role in self–
resistance (Fig 2.4).53
2.1.3 Maleidrides biosynthesis
Maleidrides, previously known as the family of carbocyclic maleic anhydrides, have been known
for almost 90 years.126 The first isolated carbocyclic maleic anhydride was glauconic acid 95 (Peni-
cillium purpurogenum) in 1931.127 In 1933, Raistrick and Smith reported byssochlamic acid 96 from
Byssochlamys fulva.128 Most family members contain two maleic anhydride moieties and were clas-
sified on the basis of their central ring. For example nonadrides such as 96, octadrides such as
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zopfellin 97129 and heptadrides such as agnestadride A 98130 have been discovered with 9–, 8– and
7–membered central rings respectively (Fig. 2.5).
Figure 2.5 Structures of key maleidrides.
An initial proposal of the biosynthesis of byssochlamic acid suggests that a polyketide or fatty
acid is linked to oxaloacetate to yield a citrate–like intermediate. This step is also proposed in
SQS biosynthesis (Scheme 2.3). In maleidrides biosynthesis, the alkylcitrate dehydrates to give the
observed maleic anhydride byssochlamic acid.131 Feeding studies with [1-14C]– and [2-14C]–acetate
by Sutherland and coworkers showed incorporation of three acetates in each C9 monomer in a
head–to–tail fashion during biosynthesis of 95. In addition, feeding of [2,3-14C2]–succinate suggests
that the remaining C3 unit derives from oxaloacetate (Scheme 2.5).132
Scheme 2.5 Biosynthetic routes to maleidrides by Sutherland.132
Reinvestigation of the original B. fulva strain showed the presence of several related compounds
to 95, such as heptadride 98, which was shown to derive from the same pathway as byssochlamic
acid. Production of a carboxymethyl maleic anhydride 99 was also reported which was shown to
be unstable to spontaneous decarboxylation in solution to yield the methyl maleic anhydride 100
(Scheme 2.6).130 In accordance to squalestatins, maleidrides, such as 96 derive from condensation of
a polyketide and oxaloacetate in a citrate synthase–like process.126
Full genome sequencing and analysis of the transcriptomic data under producing and non–producing
conditions revealed a candidate BGC encoding a fungal hr–PKS and a citrate synthase (CS), a
hydrolase, a 2–methyl–citrate dehydratase (2MCDH) and several proteins of unknown function. A
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targeted knockout experiment of the core PKS gene linked the BGC to the production of 96, 98 and
also to production of 100.84
Scheme 2.6 First steps in the biosynthesis to maleidrides.84
Our group and Oikawa and coworkers simultaneously reported that coexpression of the PKS,
hydrolase, CS and 2MCDH encoding genes in a stepwise manner in fungal host A. oryzae led to
production of the carboxymethyl maleic anhydride 99. In detail, the PKS produces polyketides
with various chain length and pattern of reduction, is then presumably released from the PKS and
linked to an oxaloacetate catalysed by the CS–like enzyme. Subsequent dehydration by the 2MCDH
homologue results in maleic anhydride decarboxylated monomers 100 (Scheme 2.6).84,133 Further
coexpression with genes of unknown function from the BGC (two putative ketosteroid isomerases
(KSI) and two putative phosphatidylethanolamine binding proteins (PEBP)) showed an increased
titre of 99 and 100 and also produced 96 (with addition of two KSIs) and 98 (with addition of both
KSIs and PEBPs) for the first time.84
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Although the biosynthetic precursors of SQS1 have been determined by labelling studies, nothing is
known of the precise molecular steps of its construction. The precursor of the hexaketide is benzoate,
derived in–turn from phenylalanine, but the molecular steps are unknown. Moreover, the oxidation
pattern of the hexaketide synthase product in not yet known. One of the major aims is to identify
gene candidates encoding oxygenases involved in the oxidative steps to form the complex core of
squalestatins and find a gene responsible of introducing the hydroxyl group at the hexaketide chain
for further acetylation. One of the two acyltransferases of the cluster, Mfr4, could not be characterised
in vitro and therefore should be investigated in vivo to verify its proposed role in attachment of the
acetyl side chain onto the hexaketide chain.
Initial in silico analysis of the unknown genes in SQS BGC should reveal putative candidates for
oxygenases by using a structural homology server Phyre2.134 Using targeted knockout experiments
in the SQS producing fungus MF5453 should uncover the oxygenases responsible for building
the characteristic core of 1 and introducing the hydroxyl group at the hexaketide chain for later
acetylation. In addition the knockout experiments should delineate the key steps of the biosynthesis
and determine the role of the second acyltransferase.
Further, in vivo reconstitution of the biosynthesis using heterologous expression experiments should
then be deployed to examine these transformations in more detail using A. oryzae as the host.
Oxygenated congeners of 1 accumulating upon knockout and expression experiments should be
isolated and analysed using high resolution mass (HRMS), MSMS analysis and nuclear magnetic
resonance (NMR) techniques in order to elucidate the structures and unrevealing the steps to form
squalestatin.
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2.3 Results – In silico analysis of putative oxygenases from SQS
BGC
The BGC of SQS in MF5453 consists of 22 contiguous genes. Initial bioinformatic studies revealed
only one gene (mfm3) enocoding a oxidoreductase despite the fact that several oxidative steps must
be required to form the core of 1 (see labelling experiments, Fig. 2.2).
2.3.1 Putative non–heme iron–dependent oxygenases Mfr1 and Mfr2
The gene mfm3 encodes an NAD(P)H–dependent short–chain dehydrogenase/reductase (SDR) which
is unlikely to be able to oxygenate.53 BLASTp analysis of Mfr1 and Mfr2 showed no significant
homology to proteins of known function.135 Nevertheless, more detailed structural analysis using
the protein fold recognition server PHYRE2134 suggested that mfr1 might encode a non–heme iron
protein as it shows some structural similarity (although less than 20% sequence identity) to CytC3
which is characterised as non–heme Fe(II) and α–ketoglutarate–dependent halogenases involved in
halogenation of aminobutyric acid in soil Streptomycetes.136
The gene mfr2 is 41.1% identical to mfr1 but showed even lower similarity to other known proteins.
But due to its high sequence homology to Mfr1, this pair of enzymes might be involved in oxygenation
to form the core of SQS1.
Figure 2.6 Protein sequence alignment of Mfr1 and Mfr2 using Clustal Omega server137, Fe–binding sites are marked in
yellow.
By protein sequence alignment of Mfr1 and Mfr2, using Clustal Omega137,138, a correlating triad
(H149, D151, H240) was observed (Fig. 2.6, shown in yellow). Nevertheless, an alignment in
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comparison with other known non–heme iron–dependent oxygenases (e.g. AndA and AndF from the
biosynthesis of meroterpenoid anditomin139 (Section 2.5.8) was not possible. The sequences seemed
to be remarkably different, although the four proteins were built from nearly the same number of
amino acids (aa) (R1 = 297 aa, R2 = 293 aa, AndA = 293 aa, AndF = 285 aa).
As other sequence homology comparisons with Mfr1 and Mfr2 only revealed proteins of unknown
function it would be likely that both might be new types of enzymes, related to non–heme iron–
dependent oxygenases, with oxidative function in SQS1 biosynthesis. Therefore Mfr1 and Mfr2 are
possible targets for further knockout studies to uncover the oxidation steps in 1 biosynthesis.
2.3.2 Putative copper–dependent oxygenase Mfm1
Initial analysis using BLASTp135 indicated no sequence homology of Mfm1 to a protein with known
function was found. More sophisticated studies using a structural server (PHYRE2134) showed that
Mfm1 possess modest structural homology (15% identity) to a peptidylglycine α–hydroxylating
monooxygenase (PHM) from Rattus norvegicus (PDB: 1OPM)53,140 The central region of Mfm1 (51% of
the residues) were modelled with over 90% confidence and showed putative copper binding sites.
PHM (EC 1.14.17.3) is one of the catalytic domains of a peptidylglycine α–amidating monooxygenase
(PAM), next to a peptidyl–α–hydroxyglycine amidating lyase domain. PAM is normally found in
higher eukaryotes and catalyses the carboxy–terminal α–amidation of bioactive peptides.141 The
PHM domain is a dicopper dependent monooxygenase, responsible for the α–hydroxylation of the
peptidylglycine substrate.142
In previous attempts to express Mfm1 heterologously in E. coli during a master’s project of Annika
Stein, in silico analysis of Mfm1 indicated a signal peptide (1–30 AA) and a transmembrane domain in
the C–terminal part of the protein (339–386 AA).143 For further in silico analysis only the cytoplasmic
part (31–338 AA) of Mfm1 was considered. A multiple sequence alignment (MSA) with HHpred144
using known protein sequences with characterised tertiary structure elements from the PDB database
and our target sequence, resulted in PHM from Rattus norvegicus (PDB:1YI9)145 being the best
template with 97.1% probability and an E–value of 0.0063 for further modelling analysis (Fig. 2.7
A). The structural model of Mfm1 was generated in cooperation with Michelangelo Marasco, using
the MODELLER program (version mod9.15)146 with a loop refinement script. The best model was
selected for further analysis and is displayed in figure 2.7 B. Based on the MSA and the structural
model, conserved motifs were shown for the first active site of Mfm1 that occupies two histidines
(His–203, His–205) and a methionine (Met–282) in proximity to the copper ion, similar to the CuM
site of the PAM (Fig. 2.7 C).147 The second active site was found to possess two conserved histidines
(His–71, His–72) as ligands (Fig. 2.7 C).143
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Figure 2.7 In silico analysis of Mfm1: A, MSA of Mfm1 with known copper–binding enzymes from the PDB database using
web–based server HHpred144; B, structural model of Mfm1 using MODELLER program (version mod9.15)146 in cooperation
with Michelangelo Marasco, with a loop refinement script (template: PDB:1YI9); C, catalytic sites showing His–203 and
His–205 (left) and His–72 and His–73 (right) coordinating the copper ion (brown balls).
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Overall, the in silico results suggests that Mfm1 is a copper dependent oxygenase which is possibly
involved in one of the oxidation steps in 1 biosynthesis. Therefore the encoding gene mfm1 is also a
promising target for knockout studies.
2.4 Results – Analysis of squalestatin metabolites produced by
wildtype fungus MF5453
The MF5453 producing strain was first reported to produce SQS1 in 1992 by the Merck group.12,47
A time course experiment showed the highest 1 production after 7 days of fermentation.47 Similar
results were also obtained by a former PhD student of our group (Beate Bonsch, unpublished data).
It was shown that 1 was produced in YMG medium and CM2 medium, but not in LB medium
(non–producing conditions).53 Previous fermentation experiments of MF5453 in YMG medium
showed not only production of 1 (tR = 8.6 min), but also production of SQS metabolite 92 (tR = 5.4
min) in our lab.53
Figure 2.8 LCMS analysis of MF5453 wildtype extract obtained from fermentation experiments in YMG+TES, 7 days: DAD;
ELSD; and ES− BPI chromatograms showing production of major compound 1 and minor compounds related to 1.
In this thesis the wildtype (wt) SQS1 producing strain MF5453 was commonly grown in YMG
medium with addition of a trace element solution (TES), as it was shown to produce 1 in higher titres,
compared to CM2 medium or YMG medium alone. Squalestatin S1 1 was shown to be the major
product of the extract obtained after 7 days of fermentation (Fig. 2.8) and was confirmed by retention
time tR = 8.6 min, the characteristic UV maximum at 210 nm and its distinctive ion 689.6 (negative
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mode, ES−), as previously reported by Bonsch et al (Fig. 2.9).53 In general 1, and all intermediates
were known to ionise better in the negative mode and were usually not, or weakly, detected in the
UV trace (DAD).
Figure 2.9 Chemical analysis of wt metabolites of MF5453 including retention times, UV and ES− BPI chromatograms for all
compounds produced from MF5453 wt fungus.
Further analysis of the wt extract also revealed production of some minor compounds 90, 92, 101
and 102 + 103, which are related to 1 (Fig. 2.8). All compounds share a common UV spectrum with
an absorption maximum of 210–220 nm (Fig. 2.9). Compound 92 and 90 were previously isolated
and characterised.53,119 However, due to low titres of 90 in the wt extract (Fig. 2.8, tR = 8.0 min, not
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observed in ELSD trace), the compound was first isolated and identified as alkyl citrate L–731,120 90
from the later–created mfr1+2 knockout strain (Section 2.5.3).
Similarly, compound 101 was first isolated from an mfm1 knockout strain and its structure elucidated
(Section 2.5.4). Compounds 102 and 103 were also detected in extracts of the same mfm1 knockout
strain. As they share the same mass and UV spectrum they are most likely isomers (Fig. 2.9). Full
structure elucidation was not possible for these compounds due to instability problems and low titres.
However, MSMS analysis and some structural features such as the phenyl ring and the dimethylated
triketide were observed in the 1H NMR (Section 2.5.4).
Another compound coeluting with 90 (tR = 7.8 min, Fig. 2.8) was shown to be unrelated to SQS1 on
the basis of its divergent UV absorption maxima (224 and 275 nm) and its even mass in the positive
mode suggesting a nitrogen atom in the chemical formula (Fig. 2.10).
Figure 2.10 Chemical analysis of an unrealted compound produced by the SQS1 wt producing fungus MF5453; retention
time, UV and ES+ BPI chromatograms.
2.5 Results – Knockout studies
The SQS1 producing strain MF5453 was shown to be successfully transformed within our group
using a protoplast–based PEG transformation method and hygromycin B as selection. The knockout
of the tetraketide gene (mfpks1) led to loss of SQS1 production and enhanced concentration of SQS1
precursor 92. Applying the bipartite marker strategy three out of ten transformants showed the
expected gene disruption.53
In order to investigate the biosynthetic steps of SQS1 biosynthesis and to uncover the role of each
gene, the following genes were targeted for disruption: mfr3 - encoding a citrate synthase; mfm3 -
encoding an NADP dependent dehydrogenase; mfr4 - encoding an acyltransferase; mfm1 - encoding
a putative copper dependent oxygenase; and the two similar genes mfr1 and mfr2 together as well as
individually, which encode putative non–heme iron–dependent oxygenases.
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Figure 2.11 SQS1 gene cluster from unidentified strain MF5453 showing targeted gene disruption.
2.5.1 Plasmid construction using yeast recombination based cloning
In order to disrupt a GOI from SQS BGC, a knockout cassette consisting of a selection marker flanked
by arms homologous to the targeted gene has to be assembled. For each GOI, a plasmid containing
a knockout cassette was built using yeast recombination. S. cerevisiae is able to recombine DNA
fragments with at least 30 bp sequence overlap by homologous recombination. Due to this ability
all vectors were constructed by cotransformation of DNA fragments and a vector backbone into S.
cerevisiae by the LiAc/SS carrier DNA/PEG method reported by Gietz et al.148
The knockout plasmids were constructed by amplifying two homologous arms (left and right,
~500 bp each) of the target gene from genomic DNA of MF5453. The resistance marker, consisting
of a fungal promotor PgpdA from A. nidulans and the hph gene of E. coli which confers resistance to
hygromycin B (hygBR), were amplified from plasmid pTH–GS–eGFP (Scheme 2.7).
Scheme 2.7 Yeast homologous recombination based cloning strategy with oligonucleotides Pa–P f used for PCR.
Sequence overlap of 30 bp for homologous recombination of the individual DNA fragments was
introduced by PCR through designed oligonucleotides (Pa–P f ). All constructs were made using
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combinations of oligonucleotides listed in Chapter 6 (Table 6.9). Corresponding oligonucleotide
sequences are found in Table 6.8.
In this work entry vector pE–YA98 was used to construct all KO vectors. Vector pE–YA consists of a
2µ origin of replication (ori), a ura3 gene (encoding an orotidine 5’-phopsphate decarboxylase) to
select uracil auxotroph S. cerevisiae in uracil and uridine free medium. Furthermore it contains an
additional ori (pUC) and selection marker (kanR) for propagation in E. coli. pE–YA was linearised by
restriction enzymes NotI and AscI and assembled with purified, amplified DNA fragments using
a LiAc/SS carrier DNA/PEG method and S. cerevisiae as a host (Scheme 2.7).149 Assembled vector
DNA was isolated from S. cerevisiae using a commercial kit and was directly used to transform
competent E. coli Top 10 cells. E. coli colonies were selected on LB medium supplemented with
kanamycin (pE–YA also occupies the nptII gene, encoding the neomycin phosphotransferase II,
which confers resistance to kanamycin, kanR). Obtained colonies were analysed by colony PCR and
confirmed by sequencing (Eurofins, Ebersberg).
2.5.2 Bipartite method and transformation of MF5453
The knockout plasmids constructed by yeast recombination were used as template for generating
the two DNA fragments (KO part 1 and KO part 2) for the bipartite method (Scheme 2.8). The
transformation protocol for strain MF5453 was developed previously by Beate Bonsch.53 In this
work, the protocol was optimised by changing minor components. Instead of growing the fungus
for three days the time was reduced to 48 hours in order to produce finer mycelium resulting in a
higher amount of protoplasts. Furthermore the washing steps for protoplasts were omitted in order
to improve the yield. For each gene knockout 8 to 24 transformants could be generated using the
optimised transformation protocol. Positive, proven knockout transformants were achieved with a
frequency of 10 to 20% depending on the construct (Table 2.2).
Scheme 2.8 Bipartite targeted knockout strategy showing amplified parts (KO part 1 and KO part 2) for fungal transforma-
tion.
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Table 2.2 Overview of transformants obtained by bipartite KO method and chemical or genetic analysis
Experiment ID GOI transformants chemically analysed genetically analysed confirmed KO
KELI28 mfr1+mfr2 8 8 3 1
KELI38 mfr1 24 1 11 1
KELI39 mfr2 18 1 10 1
KELI27 mfm1 15 10 5 1
KELI29 mfr3 7 7 3 2
KELI30 mfr4 17 10 2 2
KELI48 mfm3 20 2 8 2
2.5.3 Knockout of non–heme iron–dependent monooxygenases Mfr1 and Mfr2
In silico analysis suggests that mfr1 and mfr2 encode non–heme iron–dependent oxygenases (Sec-
tion 2.3). Due to the fact that mfr1 and mfr2 show high sequence similarity (51.6%, EMBOSS Needle
Nucleotide Alignment138) to each other and are closely located on the genome (403 bp in between)
we decided to knockout these genes both together and individually using the bipartite method
described in previous section 2.5.2.
Dual knockout of Mfr1 and Mfr2
Eight putative dual Mfr1 and Mfr2 knockout transformants were obtained from three independent
transformations. For chemical analysis the eight transformants were grown under SQS1 producing
conditions in parallel to a wt control. Each culture was extracted following a small scale (1 ml)
protocol and analysed by analytical LCMS. Production of 1 was abolished in 7 out of 8 transformants,
suggesting that in all but one transformant the targeted genes were disrupted. This implies that at
least one of the two genes is essential for SQS1 production.
To confirm that the non–producing transformants are true knockout strains, the genomic DNA of
three transformants (a1, c1, c2) was isolated. Oligonucleotides (P578+579) were used to amplify
a region from the left part of mfr1 to the right part of mfr2. The positive wt control as well as
transformants c1 and c2 showed a band for mfr1+r2 around the 2 kb standard ladder band, which cor-
responds to the size of intact mfr1+r2 genes (Fig. 2.12), therefore suggesting that the gene disruption
was not successful for transformant c1 and c2. Nevertheless, the hph gene must have integrated and
recombined ectopically, as the strains were selected on hygromycin. The integration of the resistance
gene might have taken place on a position that affects production of SQS1 and caused the abolition.
It is also feasible that insufficient SQS1 was recovered due to the small scale extraction protocol and
thus prevented its detection by LCMS analysis, but the wt control showed SQS production. Only
transformant a1 was shown to be a true knockout transformant because of a higher band matching
the size of the whole knockout cassette (5.2 kb) and no band could be observed corresponding to the
intact genes (Fig. 2.12).
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Figure 2.12 Genetic analysis of KO transformants a1, c1, c2, H2O control and wt positive control; 1% agarose gel, 1 kb ladder;
amplified mfr1+2 gene (2 kb).
Figure 2.13 Chemical analysis of mfr1+2 KO transformant a1: A, ES− traces of extracts of KO transformant a1 and a wt
control, in blue frame: SQS1 1, in orange frame: new compound 90, *unrelated compound m/z 263, extracts were obtained
from cultures grown under SQS1–producing conditions; and B, chemical characterisation of 90: tR = 8.0 min, UV spectrum,
and mass spectrum; C, MSMS analysis.
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Transformant a1 was grown in a larger scale (50 ml) in SQS producing medium. Squalestatin
production was again shown to be abolished in the KO strain, as no peak at 8.9 min with the m/z of
689 (negative mode) corresponding to SQS1 was detected. In the KO strain, a compound eluting at
tR = 8.0 min with a nominal mass of 420 was accumulated in comparison to the wt control, where it
was also detected in smaller amounts (Fig. 2.13 A, Section 2.4).
Structure elucidation of compound 90 In order to determine the structure of accumulated com-
pound isolated from MF5453∆mfr1+2, the fermentation of KO transformant a1 was scaled up to
8 x 100 ml, combined and extracted. From 270 mg crude extract, 5 mg of KO compound (m/z 419)
was purified using preparative LCMS (peak eluting at tR = 8.5 min, Fig. 2.14 A). Initial attempts to
acquire suitable NMR data for structure elucidation was unsuccessful, as the compound was not
pure enough. Impurities were identified by analysing the corresponding mass traces of the collected
ELSD peak. Another unrelated compound "a" with m/z = 478 (ES+) and m/z = 420 (ES−) coeluted
with desired compound 90 (Fig. 2.14 B).
Figure 2.14 LCMS data obtained from crude extract of mfr1+2 KO transformant: A, ELSD and mass traces showing major
compound and impurity "a" eluting at tR = 8.5 min on preparative column; B, mass spectra of impurity coeluting with 90.
In order to acquire good NMR data suitable for structure elucidation the mix was treated with
trimethylsilyl (TMS) diazomethane 104 in methanol. Predicted carboxyl groups were converted to
their corresponding methyl esters (Scheme 2.9).150 The methylated compound 105 eluted at tR = 9.4
min and could be separated from the impurity (eluting at tR = 8.5 min) using preparative LCMS.
Due to the preparative column the retention times vary from previous LCMS results obtained from
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analytical runs. Methylation was confirmed by corresponding mass (Fig. 2.15). NMR data was
acquired and analysis identified the structure of compound 105 was identical to the previously
reported alkyl citrate L–731,120 (plus methyl esters) which was isolated as a minor component from
fungus MF5453 by the group of J. D. Bergstrom and K. E. Wilson in 1995 (Section 2.4, Assignment in
figure 2.16).119 This compound corresponds to the proposed (Scheme 2.3) product of SQHKS linked
to citrate and is thus likely to be an early intermediate.
Scheme 2.9 Methylation of 90 with TMS diazomethane (104) in methanol yielded product 105.
Figure 2.15 LCMS data for compound 105: A, Extracted ion chromatogram (ES+ 463.4); B, UV chromatogram; C, mass
spectrum (ES+).
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Figure 2.16 Structure elucidation of 105: A, displayed structure of 90 and 105; B, with corresponding NMR assignment
compared to literature known compound L–731,120 90.119
The double knockout of non–heme iron–dependent oxygenases Mfr1 and Mfr2 led to abolition of 1
biosynthesis and formation of compound 90. This shows that Mfr1 and Mfr2 must act early in the
pathway, and that the squalestatin hexaketide synthase (SQHKS) fully reduces at the carbon chain.
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Single knockout of Mfr1 and Mfr2
The double knockout of the similar genes mfr1 and mfr2 led to the accumulation of intermediate 90. In
an attempt to determine the function of the individual genes, both were knocked out independently
by the bipartite marker strategy as described in section 2.5.2. Because both genes are in close
proximity on the genome, the left and right part of the genes for homologous yeast recombination
cloning were reduced from 500 bp to ~350 and 400 bp. For the disruption of mfr1, 24 transformants
were achieved and for the disruption of mfr2, 18 putative KO transformants were generated with
two rounds of transformations. The reduction of the size of the recombination sites was shown to
have no negative effect on the number of generated transformants.
Genetic analysis of knockout transformants In an inital experiment the genomic DNA of eleven
putative mfr1 KO transformants and ten putative mfr2 KO transformants were isolated and tested
for disruption of the GOI, using oligonucleotides P767+768 (for amplifiying mfr1 = 1020 bp) and
P769+770 (for amplifiying mfr2 = 904 bp).
Figure 2.17 Genetic analysis of putative mfr1 KO transformants: A, amplified mfr1 gene (1020bp) with P767 + P768; B,
repetiton of PCR shown in "A" for transformant b8; H2O control and wt positive control; 1% agarose gel; 1 kb ladder.
All, except one (b8), putative KO candidates for Mfr1 were shown to contain an intact mfr1 gene
(Fig. 2.17 A). As a second band (around 2 kb) was detected for transformant b8, the amplification
was repeated and it is likely that this band is due to non–specific binding to a place somewhere else
in the genome as it is also present in wt positive control (Fig. 2.17 B). Nevertheless, transformant b1
is likely to be a true knockout strain, as the gene mfr1 could not be amplified from the genome.
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Figure 2.18 Genetic analysis of putative mfr2 KO transformants: A, amplified mfr2 gene (904 bp) with P769 + PP770; B,
repetition of PCR shown in "A" for putative mfr2 KO transformants b1, b4, b8; H2O control and wt positive control; 1% agarose
gel; 1 kb ladder.
Genetic analysis of putative mfr2 KO transformants revealed that transformants b1, b4 and b8 did
not show a band for the intact mfr2 gene in an initial PCR. Instead a band with correct size of the
whole knockout cassette was observed for transformant b4 indicating a true KO (Fig. 2.18 A). The
PCR was repeated as for b4 and b8 no higher band was observed. Instead intact mfr2 bands for b1
and b8 were detected. This contradicts the previous result and implies that both transformants are
not true KOs (Fig. 2.18 B).
In general, the genetic analysis showed that the attempt to individually disrupt the two similar
genes was more difficult than the double knockout. For some transformants a band with the size of
the whole KO cassette (5 kb) was observed next to a band corresponding to the intact mfr1/2 gene
(transformant a1 and b5 of putative mfr1 KO transformants and transformant b6 of putative mfr2
KO transformant, Fig. 2.17+2.18). Either the cassette integrated ectopically, probably in the other
non–heme iron encoding gene from the cluster due to high sequence homology, or they are not
genetically pure single KO mutants but a mixture of wt and mutant.
Chemical analysis of mfr1 KO transformant b8 Individual KO of mfr1 alone showed an identical
chemotype as the double KO, after extraction and LCMS analysis (Fig. 2.19).
54
2.5 Results – Knockout studies
Figure 2.19 Chemical analysis of mfr1 KO transformant b8: ES− traces of extracts of mfr1 KO transformant b8 and a wt
control; in blue frame: SQS1 1; in orange frame: compound 90; extracts were obtained from cultures grown in YMG+TES
medium for 7 days; *unrelated compounds.
Chemical analysis of mfr2 KO transformant b4 Disruption of mfr2 individually resulted in a
mixture of 90 plus several new compounds in very low titres with m/z values ([M-H]−) of 431.2,
433.2, 435.2 (very weak) and 447.2, which likely corresponded to putative oxygenated congeners of
90 (Fig. 2.20).
Figure 2.20 Chemical analysis of mfr2 KO transformant b4: ES− traces of extracts of mfr2 KO transformant b4 and a wt
control; in blue frame: SQS1 1; in orange frame: compound 90; in green frame: compound 109; in red frame: compound 106;
and in yellow frame: compound 108; extracts were obtained from cultures grown in YMG+TES medium for 7 days; *unrelated
compound and traces of 107.
For structure elucidation of the new compounds, the mfr2 KO strain was grown again. For inoculation
of the main culture (14 x 500 ml flasks with 100 ml YMG+TES medium, 7 days), a seed medium
(CM2) was inoculated from glycerol stocks and grown for 4 days. Isolation of the new compounds by
preparative LCMS resulted in less than 1 mg product for each putative oxidative congener of 90.
The acquired NMR data did not enable a full characterisation of 106. However some key signals
from 1H NMR data could be assigned to structural features including the phenyl and dimethylated
triketide (Table 2.3), but further structural information could not be determined by NMR for these
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compounds. Furthermore, NMR analysis showed that impurities were excessive in each sample.
Due to very low titres, further structure elucidation by NMR was prevented. Multiple attempts
to isolate higher amounts of desired products failed and proved purification of these oxygenated
congeners of 90 as extremely difficult.
Table 2.3 Partial NMR assignment of compound 106 (CD3OD); C-1–C-9, C-11 and C-19 to C-21 could not be assigned,
corresponding putative structure in figure 2.22
Position δC / ppm (125 MHz) δH / ppm (500 MHz) J / Hz
10 129.5 5.36 m
11 - - m
12 43.7 2.47–2.54 m
13 141.0 q -
14 129.2 7.17 m
15 127.7 7.28 m
16 125.8 7.17 m
17 20.6 0.92 m
18 15.4 1.37 m
However, LCMS analysis of the new compounds revealed similar retention times and UV spectra
compared to 90. Further evidence for the existence of oxygenated congeners of 90 were obtained by
HRMS and MSMS analysis of m/z 435, 433, 431 and 447 compounds (Table 2.4). The fragmentation
pattern in mass spectra (ES− mode) showed losses of CO2 and H2O. Besides facile loss of the
oxaloacetate moiety (m/z = 132) by retro aldol fragmentation proving the oxidations to have occurred
on the hexaketide backbone, as described in scheme 2.10 (Fig. 2.21, 2.22, 2.23, 2.24).
Table 2.4 HRMS analysis of oxygenated congeners of 90
HRMS results [M-H]−
Compounds calculated measured ion formula
107 435.2019 435.202 C23H32O8
106 433.1862 433.1861 C23H30O8
108 431.1706 431.1702 C23H28O8
109 447.1655 447.1655 C23H28O9
Scheme 2.10 Characteristic loss of oxaloacetate (M = 132) in the ES− mode for oxygenated congeners of 90.
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Figure 2.21 Chemical analysis of 107 isolated from mfr2 KO transformant b4: A, extracted ion chromatogram (ES− 435); B,
UV chromatogram; C, mass spectrum (ES−); D, MSMS fragmentation pattern of compound 107.
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Figure 2.22 Chemical analysis of 106 isolated from mfr2 KO transformant b4: A, extracted ion chromatogram (ES− 433); B,
UV chromatogram; C, mass spectrum (ES−); D, MSMS fragmentation pattern of compound 106.
58
2.5 Results – Knockout studies
Figure 2.23 Chemical analysis of 108 isolated from mfr2 KO transformant b4: A, extracted ion chromatogram (ES− 431); B,
mass spectrum (ES+/ES−); C, UV chromatogram, D, MSMS fragmentation pattern of compound 108.
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Figure 2.24 Chemical analysis of 109 isolated from mfr2 KO transformant b4: A, extracted ion chromatogram (ES− 447); B,
mass spectrum (ES−); C, MSMS fragmentation pattern of compound 109.
In conclusion, the experiments showed that both genes (mfr1, mfr2) are involved in SQS1 biosynthesis
and that Mfr1 acts first, and appeared to be involved in oxygenations. It was not possible to determine
any structure of congener of 90. Likely due to the low titres and formation of shunt products as
a result of their electrophilic nature. Nevertheless, the identity of the compounds formed in mfr2
knockout experiment was confirmed by tR, UV, HRMS and MSMS analysis and give confidence that
these are true intermediates of the SQS1 biosynthesis. Probably 107 (only observed in traces, fig. 2.20)
is built first and then undergoes further oxidations to form 106, 108 and finally 109. In order to form
the core ring structure of SQS further oxidation steps are required.
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2.5.4 Knockout of copper dependent monooxygenase Mfm1
The gene mfm1 is predicted to encode a putative oxygenase. Futher analysis using the web–based
structural homology server PHYRE2134 showed that Mfm1 belongs to the class of copper dependent
monooxygenases (Section 2.3).53
In order to investigate the function of Mfm1 in the biosynthesis of 1 the gene mfm1 was disrupted.
Using the bipartite method described before (Section 2.5.2) 15 transformants were generated. The
extracts of ten putative knockout transformants were analysed by LCMS and compared to a wt
control. Eight transformants showed no SQS1 production, whereas two of them (b4, b8) still produced
1 (Fig. 2.25).
In comparison to the wt chromatogram, five transformants (b1, b2, b3, b9, c1) showed an unambigu-
ous accumulation of a new compound eluting at 5.7 min with m/z 479 (ES−) and no SQS1 production
(Fig. 2.25). Traces of the accumulated compound were also detected in the wt chromatogram (Sec-
tion 2.4). A second compound eluting at tR = 8.0 min with a nominal mass of 420, was shown to
be the previously characterised 90 (Section 2.5.3). Another compound eluting at tR = 5.6 min was
shown to be unrelated as it was also detected in wt control and its corresponding mass (m/z 263, ES−)
is too small to belong to a SQS intermediate. Furthermore, the corresponding UV spectrum showed
maxima of 419, 266 and 346 nm, which is not characteristic for SQS intermediates (UV maxima
~210 nm, Fig. 2.25).
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Figure 2.25 ES− BPI chromatograms of extracts of ten putative mfm1 KO transformants (b1–b9, c1) and a wt control; extracts
were obtained from cultures grown in SQS production medium for 7 days and were extracted according to a small scale (1 ml)
procedure; in blue frame: SQS1 1; in orange frame: compound 90; in red frame: new accumulated compound 101; unrelated
compound eluting at 5.6 min, m/z 263 (ES−): UV spectrum with maxima at 419, 266 and 346 nm.
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To confirm that the transformants which are not able to produce 101 are real knockout strains, the
genomic DNA of transformant c1, b1, b5, b6 and b9 was isolated and tested by PCR. Oligonucleotides
P584 and P585 were used to amplify the gene mfm1 which should be disrupted in the knockout
transformants. The wt positive control showed a band for mfm1 above the 1 kb marker band (size of
mfm1 = 1161 bp). In addition transformants b1, b6, c1 and b9 showed no band for mfm1 suggesting
that the gene was disrupted and the transformants are real knockout strains. In contrast transformant
b5 was shown to possess an intact mfm1 gene and is therefore a false positive transformant (Fig. 2.26
A). Transformant b1 was further analysed as no band for the whole KO cassette was shown in gel A.
Conditions of PCR "A" were repeated with extended elongation time in order to be able to detect a
larger band corresponding to mfm1 KO cassette (5 kb). The second amplification indeed showed a
band for the whole KO construct in the genome of transformant b1 (Fig. 2.26 B). Further analysis
using a forward primer (P411) binding the 3’ end of mfpks2 (gene upstream of mfm1 on the genome)
and the reverse primer (585) of mfm1 gave a desired 2.6 kb fragment for the wt. For a correct KO
transformant the predicted size would be around 8 kb, which is very unlikely to be amplified by
PCR in this study (Fig. 2.26 B).
Figure 2.26 Genetic analysis of mfm1 KO transformants c1, b1, b5, b6, b9 compared to wt control: A, amplified mfm1 gene
(1161 bp, P584+585); B, amplified mfm1 gene (1161 bp) and KO cassette of transformant b1 (5 kb) and amplified section outside
the gene (wt: 2.6 kb); KO cassette would be almost 8 kb; H2O control and wt positive control; 1% agarose gel; 1 kb ladder;
amplified mfm1 gene (1161 bp, P584+585).
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Isolation and structure elucidation of 101
In order to elucidate the structure of the major compound (tR = 5.7 min) accumulating upon disrup-
tion of mfm1 (Fig. 2.25), MF5453 ∆mfm1 (transformant b1) was grown in 8 x 100 ml YMG medium.
Extraction of supernatant and cells yielded 240 mg raw extract. 4.8 mg of the accumulated compound
were purified using preparative LCMS. An analytical run of the extract obtained from large extraction
of mfm1 KO transformant b1 showed in addition to the major compound 101, three new compounds
eluting at tR = 6.2 min (102), R = 7.1 min (103) and tR = 9.3 min (110) (Fig. 2.27). Isolation and structure
elucidation of these three compounds is discussed in section 2.5.4.
Figure 2.27 ES− BPI chromatogram of extract of mfm1 KO transformant b1: extract was obtained from a large scale
fermentation (800 ml) grown in YMG medium for 7 days; in orange frame: compound 90; in red frame: major compound 101;
unrelated compound eluting at 7.83 min, m/z 490 (ES−); and new compounds 102 (tR = 6.2 min); 103 (tR = 7.1 min); and 110
(tR = 9.3 min).
Initial chemical characterisation of major compound 101 was carried out by LCMS analysis (Fig. 2.28).
HRMS analysis of the accumulated intermediate gave 479.1552 [M-H]− which suggested C23H27O11
as the ion formula (calculated 479.1553) of 101. This indicates that hydroxylation is missing from the
fully hydrolysed SQS1 core 94, which was previously characterised by Bonsch et al. (Scheme 2.11 A).
NMR data revealed that the chemical shift of H-10 is δ = 5.06, in comparison to H-10 of 94 (δ = 3.93)53,
indicating a loss of oxygen at this position. The C-9/C-10 region isomerised in 101 (Fig. 2.29). The
structure of 101 was elucidated using 1D and 2D NMR data, but full assignment of quaternary
carbons was not possible, as almost no HMBC correlation was detected (Fig. 2.29, marked in blue).
64
2.5 Results – Knockout studies
Figure 2.28 Chemical analysis of 101 isolated from mfm1 KO transformant b1: A, extracted ion chromatogram (ES− 479); B,
UV chromatogram; C, mass spectrum (ES−); D, MSMS fragmentation pattern of compound 101.
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Figure 2.29 Structure elucidation of 101: A, key HMBC correlations observed for 101 marked with purple arrows; B,
corresponding NMR assignment of 101; marked positions were assigned later after methylation with TMS diazomethane 104
(blue).
To assign the five missing quaternary carbon atoms (C-4, C-5, C-19, C-20 and C-21), purified 101 was
treated with TMS diazomethane 104 in methanol following the protocol of Presser and Hüfner.150
Product 111 was re–purified using preparative LCMS (Scheme 2.11 B). Chemical analysis of the
compound using HRMS showed successful methylation of compound 101 (HRMS (ESI+) m/z calc.
for C26H34O11Na [M+Na]
+ 545.1999, found 545.1998, Fig. 2.30). 1D and 2D NMR data was used to
elucidate the structure of 111, showing key characteristic signals for the three methylesters at 3.76
(C-22), 3.91 (C-23) and 3.81 ppm (C-24). Associated HMBC signals revealed the missing carbon atoms
of 111 (Fig. 2.31 + 2.32).
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Scheme 2.11 Structure elucidation of 101: A, fully hydrolysed SQS1 core 9453; B, elucidated structure of intermediate 101,
isolated from mfm1 KO strain treated with TMS diazomethane 104 revealed methylated compound 111.
Figure 2.30 Chemical analysis of 111: A, extracted ion chromatogram (ES+ 545.4); B, UV chromatogram; C, mass spectrum
(ES+).
67
2.5 Results – Knockout studies
Figure 2.31 Structure elucidation of 111: A, displayed structure of 111 with key HMBC correlation; B, corresponding NMR
assignment.
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Figure 2.32 Zoomed in HMBC of 111 showing missing quaternary carbon atom correlations.
On the basis of the structure of 101 it likely that mfm1 encodes an enzyme which is an oxygenase. In
comparison to 1 the intermediate 101 lacked the hydroxyl group at C-10 as well as the 10-O–acetate
unit and the 4-O–tetraketide moiety. Therefore Mfm1 does not act on the core ring of SQS1 but
after cyclisation on the hexaketide chain on C-10. Oxidation of the 9,10–olefin of 101 is proposed
to involve epoxidation catalysed by the copper–dependent oxygenase Mfm1 and rearrangement to
give the allylic alcohol 94 (Scheme 2.12).
Scheme 2.12 Oxidation of the 9,10–olefin of 101 by Mfm1 and rearrangement to give the allylic alcohol 94.
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Isolation and structure elucidation of 103 and 110
In addition to 101, compound 102 and 103 (different tR, same mass) were also produced in lower
yields (less than 1 mg/l each) and purified using preparative LCMS. Initial LCMS analysis showed
that the two new compounds eluting at different retention times (6.2 min and 7.1 min), showed
the same HRMS (ESI- m/z calc. for C23H27O10 [M-H]
− 463.1604, found 463.1605) and very similar
MSMS fragmentation patterns (Fig. 2.33).
Figure 2.33 Chemical analysis of 102 = I and 103 = II: A, mass spectrum (ES−) of I and II; B, extracted ion chromatogram
(ES− 463); C, UV chromatogram of I and II; D, MSMS analysis of I and II.
70
2.5 Results – Knockout studies
Evidence that they are both oxygenated congeners of 90 were displayed by HRMS analysis and
corresponding chemical formula. Losses of CO2, H2O, and facile loss of the oxaloacetate moiety
found by MSMS analysis proving the oxidations to have occurred on the hexaketide backbone. They
are probably isomers (Fig. 2.33 D).
Figure 2.34 Proposed structure of 103, corresponding partly NMR assignment shown in Table 2.5.
Table 2.5 Partial NMR data (500 MHz, CD3OD) for compound 103 isolated from mfm1 KO strain, C-1 to C-8 and C-19 to 21
could not be assigned
Atom δC / ppm δH / ppm J / Hz 1H–1H
COSY
HMBC
9 135.2 q - - 18
10 131.3 5.02-5.06 m 11, 18 8, 11, 17, 18
11 36 2.66 m 10, 17 10, 12, 17
12 45.1 2.46-2.58 m 11 11, 13, 14, 14’, 17
13 142.3 q - - 12, 15, 15’
14, 14’ 130.2 7.14 m 15, 15’ 15, 15’, 16
15, 15’ 128.8 7.24 m 14, 14’ 14, 14’, 13
16 126.4 7.14 m 14, 14’, 15, 15’
17 21.6 0.97 m 11 10, 11, 12
18 16.3 1.43 d - 8, 9, 10
Full NMR characterisation was difficult due to the low amount of substance isolated and impurities.
However, structural features including the characteristic phenyl signals at 7.14 ppm (C-14/14’+C-16)
and 7.24 ppm (C-15/15’) and dimethylated triketide with distinctive methyl signals at 16.3 ppm
(C-18) and 21.6 ppm (C-17) could be assigned (Table 2.5).
Further indication for a SQS–like structure showed successful methylation of putative carboxyl
groups of 103 with TMS diazomethane, resulting in trimethylester 112 (Scheme 2.13 A). Compound
112 was re–purified by preparative LCMS, resulting in 0.4 mg compound (Scheme 2.13 B–D), but full
characterisation by NMR was still prevented due to multiple coeluting compounds. Again 1H NMR
showed characteristic structural features including the phenyl and dimethylated triketide moiety as
well as distinctive signals for the three methylesters (C-22 to C-24) at 3.96, 3.74, 3.73 ppm (Fig. 2.35).
Compound 102 could not be purified without another unrelated compound coeluting (containing N,
odd mass) thus NMR structure elucidation was not possible.
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Scheme 2.13 Structure elucidation of 103: A, reaction of 103 with TMS diazomethane to form its trimethylester 112; B,
extracted ion chromatogram of 112 (ES+ 507); C, UV chromatogram; D, mass spectrum (ES+).
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Figure 2.35 Structure elucidation of 112: A, displayed structure of 112; B, corresponding partly NMR assignment, C-1 to C-9
and C-19 to C-21 could not be assigned and 1H NMR spectrum of 112.
The ∆mfm1 strain showed also production of a new compound 110 with a nominal mass of 632 (titre
2.7 mg/l), eluting at 9.34 min (Fig. 2.27). Isolation and full characterisation by 1D and 2D NMR
analysis confirmed the structure to be 110. Compound 110 has identical structural features as 101,
but the tetraketide chain at C-6 was shown to be attached (Fig. 2.36).
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Compound 110 is most likely a shunt intermediate as former in vitro studies showed that the
tetraketide 24 was attached to the core of 1 as CoA activated compound by acyltransfrase Mfm4
as the final step of the biosynthesis.53 In this in vivo experiment the tetraketide chain was attached
before hydroxylation and acetylation of the hexaketide chain as the gene expressing Mfm1 was
blocked. The accessibility of 101 instead of natural substrate 94 probably led to attachment of the
tetraketide by Mfm4, as a broad substrate selectivity was previously observed for this enzyme.53
Figure 2.36 Structure of isolated compound 110 from mfm1 KO strain, NMR assignment shown in table 2.6.
Table 2.6 NMR data (500 Mhz, CD3OD) of compound 110 isolated from mfm1 KO strain
Atom δC / ppm δH / ppm J / Hz 1H–1H
COSY
HMBC
1 83 4.06 m 6 -
2 106.6 q
3 130.5 5.35 m - -
4 q q - - -
5 q q - - -
6 81.9 6.43 m 1 1
7 35.6 1.92-1.96 m 1, 8 2, 8
8 33.7 2.19-2.26 & 2.27-2.32 m, m 7 9, 10, 18
9 135.4 q - - 18
10 131.2 5.02-5.06 m 11, 18 8, 11, 17, 18
11 36 2.65 m 10, 17 10, 12, 17
12 45.1 2.43-2.59 m 11 11, 13, 14, 14’, 17
13 142.3 q - - 12, 15, 15’
14, 14’ 130.3 7.13 m 15, 15’ 15, 15’, 16
15, 15’ 129 7.22 m 14, 14’ 14, 14’, 13
16 126.5 7.13 m 14, 14’, 15, 15’
17 21.3 0.96 d, 6.6 11 10, 11, 12
18 16.3 1.43 d 8, 9, 10
19 q - - -
20 q - - -
21 q - - -
22 167.8 - - - 23, 24
23 120.6 5.85 d, 15.6 24 22, 25
24 157 6.86 dd, 15.7, 8.4 22, 25, 26, 31
25 35.6 2.39-2.49 m 24, 26, 31 23, 24, 26, 31
26 44.5 1.11-1.17 & 1.39 m 25, 27 25, 27, 30, 31
27 33.2 1.27-1.39 m 26, 28, 30 26, 28, 30
28 30.8 1.10-1.15 & 1.24-1.38 m 27, 29 26, 27, 29, 30
29 11.6 0.88 m 28 27, 28
30 19.3 0.87 m 27 26, 27, 28
31 20.6 1.04 d, 6.6 25 24, 25, 26
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Mfm1 cofactor dependency
Initial analysis using pBLAST showed no sequence homology of Mfm1 to a protein with known
function. More sophisticated studies using a structural server (PHYRE2134) showed that Mfm1
possess modest structural homology (15% identity) to a PHM from Rattus norvegicus (PDB: 1OPM,
section 2.3).53,140
In a fermentation experiment in which the wt strain was grown in YMG medium without trace
elements (no copper), SQS1 was only observed in traces compared to compound 101 (Fig. 2.37). The
mfm1 KO strain showed a very similar chemo–type apart from no production of 1. Fermentation
experiments underlined the hypothesis of Mfm1 being a copper dependent monoxygenase as it was
shown that the MF5453 wt strain produced almost exclusively SQS1 1 by growing in YMG medium
supplemented with trace element solution (containing copper amongst others).
In further experiments a to investigate the cofactor dependency of Mfm1, 29 fermentation experiments
were designed, each containing a different combination of trace elements in YMG medium. All
experiments containing copper or a mixture of trace elements including copper in the medium (13
experiments), showed an improved SQS1/101 ratio. Therefore, and in accordance with the in silico
prediction showing conserved histidine residues in the active site, it can be assumed that copper is
the cofactor of Mfm1.
Figure 2.37 ELSD chromatograms (1-15 min) of wt extract from YMG medium and YMG medium supplemented with trace
element solution (TES) and ∆mfm1 mutant.
2.5.5 Knockout of acyltransferase Mfr4
The SQS1 gene cluster contains two genes encoding putative acyltransferases (ATs). One of the
them (Mfm4) was already investigated by expression and purification from E. coli and its activity
aconducted by Simon Blazy, master student
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was tested in in vitro assays. Mfm4 was shown to be responsible for loading acyl groups from CoA
onto the squalestatin core as the final step of biosynthesis.53 In previous studies the attempt to
obtain soluble protein from expression of mfr4 in E. coli was unsuccessful (Section 2.1).53 In order to
investigate the second AT from the SQS1 BGC the gene mfr4 was disrupted in this work using the
bipartite method described in section 2.5.2.
Figure 2.38 ES− BPI chromatograms of initial small scale extraction of ten mfr4 KO transformants and a wt control.
Gene disruption of mfr4 resulted in 17 putative KO transformants. Initially 10 transformants were
grown in small scale under SQS1–producing conditions in order to detect possible KO strains.
LCMS analysis showed that three mutants (b1, b4 and b10) led to complete loss of SQS1 production
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(Fig. 2.38). In the remaining extracts 1 was still detected suggesting no disruption of the gene. Genetic
analysis revealed that the mfr4 gene of transformant b1 and b4 was disrupted (Fig. 2.39).
Figure 2.39 Genetic analysis of mfr4 KO transformants b1 and b4, H2O control and wt positive control, amplified mfr4 gene
(1.9 kb, P578+579); 1% agarose gel, 1 kb ladder.
For closer analysis of metabolites produced by the ∆mfr4 strain, a 50 ml culture, grown under pro-
ducing conditions was extracted. Three previously characterised intermediates of SQS1 biosynthesis
were found in the extract of transformant b1. Compound 90 which was highly accumulated in
∆mfr1+2 strain (proved by HRMS, calc. 419.2070, found 419.2070) and compound 101 which was
identified by HRMS [calc. 479.1548, found 479.1550] (Fig. 2.40). A third compound was detected
with a nominal mass of 496 eluting at tR = 4.4 min, which has not been previously observed in any
other KO mutant. Analysis by LCMS including HRMS and MSMS indicated that new compound
94 is the fully hydrolysed SQS1 core. This was confirmed by comparison to a synthetic standardb
(Fig. 2.41).
Figure 2.40 ES− BPI chromatograms of mfr4 KO transformant (b1) and a MF5453 wt control.
bkindly provided by Dr Christoph Bartel
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Figure 2.41 LCMS data for compound 94 in comparison to a synthetic standard of 94: A, extracted ion chromatograms (ES−
495); B, UV chromatogram; C, mass spectrum (ES−); D, MSMS fragmentation pattern of compound 94 in comparison to a
synthetic standard of 94.
As three of the late intermediates of SQS1 biosynthesis were found, it is likely that the transfer of the
acetate to the hydroxyl group at position C-10 of the hexaketide occurs after installation of hydroxyl
group by Mfm1 and before the tetraketide is attached to the core of 1 (Scheme 2.14).
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Scheme 2.14 Final steps during SQS1 biosynthesis, Mfr4 catalysed reaction marked in blue.
2.5.6 Knockout of citrate synthase Mfr3
The formation of the 4,8-dioxa-bicyclo[3.2.1]octane core involves linkage of the hexaketide to ox-
aloacetate by citrate synthase Mfr3, which is proposed to act early in biosynthesis of 1. Mfr3 is a
good candidate for a knockout experiment, as timing and precise substrates of this step are unknown.
By disrupting mfr3, associated KO strains were expected to produce a polyketide produced by the
SQHKS.
In comparison to the other constructs described previously it was more difficult to generate ∆mfr3
mutants. After five transformation procedures seven putative KO transformants were generated
using the bipartite protocol described in section 2.5.2. By comparison to a wt control it was shown
that three of the seven transformants led to loss of SQS1 (Fig. 2.42). However, genetic analysis
showed that disruption of mfr3 was only successful in two transformants a4 and b1 (Fig. 2.43).
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Figure 2.42 ES− BPI chromatograms of extracts obtained from three ∆mfr3 mutants compared to a wt control, m/z values
of unrelated compounds are indicated in the chromatogram of mutant d2.
Figure 2.43 Genetic analysis of KO transformants a4, b1, d2, H2O control and wt positive control; 1% agarose gel, 1 kb
ladder; amplified mfr3 gene (2.5 kb, P580+581).
Although it was expected to find a hexaketide related peak accumulating with a nominal mass around
300, depending on oxidation states of the polyketide chain, no new compounds were identified under
"normal" conditions. Even further analysis, such as fermentation in different media (CM2, YMG
and YMG+TES) and extracting cells and supernatant separately as well as at different time points
(after 3, 5 and 7 days), did not result in new compounds. This may indicate that the CS is possibly
involved in chain–release from the PKS, or the free polyketide is rapidly degraded. Unmethylated
squalestatin tetraketide was previously shown to be rapidly digested.123
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2.5.7 Knockout of NADP dependent dehydrogenase Mfm3
Since it is unknown in which step of the biosynthesis the predicted NADP dependent dehydrogenase
Mfm3 plays a key role, or if the enzyme is involved at all, the gene mfm3 was disrupted using the
bipartite protocol described in section 2.5.2.
Using the bipartite method with targeting sequences of 500 bp one transformant (KELI33d1) was
shown to be a true KO by genetic analysis. However, the ∆mfm3 mutant was shown to produce
1. In order to verify this result, more transformants should be generated, this time the targeting
sides were elongated to 1 kb at each side of mfm3. Using the bipartite method 20 putative KO
transformants were generated. Genomic DNA of 9 mutants were isolated and tested by PCR using
oligonucleotides P822+823 (tA = 1 min). Genetic analysis confirmed that 7 of the 9 investigated
putative KO transformants were no real KO transformants because the gene for mfm3 was still intact
(band around 1 kb, mfm3 = 1.1 kb). Only transformant 5 and 7 showed no bands at 1 kb (Fig. 2.44
A). A second round of PCR using the same set of oligonucleotides, but longer elongation time
(tA = 3 min), showed bands corresponding to the size of the whole 5 kb–KO cassette (Fig. 2.44 B),
suggesting that transformant 5 and 7 are true KO transformants.
Figure 2.44 Genetic analysis of putative mfm3 KO transformants, and wt positive control, amplified mfm3 gene (1.1 kb,
P822+823), 1% agarose gel, 1 kb ladder: A, first PCR, transformant 0 to 8, tA = 1 min; B, second PCR, transformant 2, 5, 7,
tA = 3 min; C, legend for PCR including oligonucleotide positions.
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Figure 2.45 ES− BPI chromatograms of extracts obtained from two ∆mfm3 mutants (KO 5, KO 7), compared to a wt control,
m/z values of unrelated compounds are indicated in the chromatogram of mutant KO 5.
The ∆mfm3 mutants 5 and 7 were grown in SQS1–producing conditions and analysed by LCMS.
Extract of transformant 5 showed production of1, 90, as well as small amounts of 109. In addition
some unrelated peaks were observed. Also transformant 7 showed production of 1 and 90, but only
in traces. However, SQS1 intermediate 109 was produced (Fig. 2.45). The chemical analysis revealed
that SQS1 is still observed notwithstanding that genetic analyses proved the disruption of mfm3.
2.5.8 Discussion
In previous biosynthetic studies of 1 Bonsch and coworkers have already shown, that the producing
fungus Mf5453 is genetically tractable. A transformation protocol was established and by using the
bipartite method the gene encoding the tetraketide synthase was successfully disrupted.53
In this work seven more targeted gene knockouts of other genes from SQS1 BGC were generated.
The Bonsch transformation was optimised.53 The efficiency to obtain a true KO mutant applying
the bipartite method was around 10 to 20% (Table 2.2). The gene–targeting efficiency obtained with
bipartite substrates was shown to be two- to threefold higher compared to those obtained with the
continuous substrates.81 However, generated KO mutants and subsequent structure elucidation of
isolated compounds accumulated upon these KOs, provided the order and role of each analysed
enzyme involved in SQS1 biosynthetic pathway and identified oxidative enzymes, which build the
highly oxidised core of 1.
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Early steps of SQS1 biosynthesis
Feeding studies suggested a benzoate precursor as substrate for SQHKS, as benzoic acid and pheny-
lalanine are incorporated (Section 2.1.2).7 The SQS1 cluster possesses genes which could be involved
in benzoate production. The gene mfm7, encoding a PAL is predicted to catalyse the first step in
the degradation of phenylalanine 85. This step is known from other microbial and plant systems
during the biosynthesis of benzoyl–CoA 25, where cinnamate 87 is hydrated, oxidised and then
subject to a retro–Claisen reaction (Chapter 1, Fig. 2.4). In order to test whether NADP dependent
dehydrogenase Mfm3 is involved in this precursor biosynthesis the corresponding gene mfm3 was
disrupted. Chemical analysis of genetically confirmed mutant revealed that SQS1 is still observed,
indicating that NADP dependent dehydrogenase Mfm3 is not essential for the biosynthesis of 1.
Therefore if it is involved in benzoate precursor biosynthesis it must also be complemented by
an enzyme of primary metabolism. Further evidence that Mfm3 is involved in SQS1 biosynthesis
is given by the fact that the encoding gene mfm3 is conserved in all 4 SQS1 BGC (Section 2.1.2,
Fig. 2.4).
In addition to the benzoate precursor pathway, production of the hexaketide 93 and linkage with
oxaloacetate 89 are predicted as the first steps in the biosynthesis of 1 (Scheme 2.15 A). A knockout of
putative citrate synthase encoding gene mfr3 from the cluster was shown to abolish SQS1 production,
but no new putative precursors/ intermediates of the pathway were detected, possibly due to
instability of the precursor PKS chain. lt has been shown by in vitro biomimetic synthesis that linear
polyketide chains are very unstable and cyclise spontaneously in an aqueous environment.151 Citrate
synthases are known in nearly all living cells, as part of the citric acid cycle, which plays a key role
in the central metabolic pathway of aerobic organisms.152 In natural product biosynthesis citrate
synthase genes are relatively rare. However, a similar reaction proposed for the first step in SQS1
biosynthesis was found in maleidride biosynthesis (Section 2.1.3). A citrate synthase–like enzyme
was shown to catalyse a reaction between a hrPKS and oxaloacetate (Scheme 2.15 C).84 Moreover,
in recent investigations of the biosynthesis of phomoidride A (another gene cluster containing a
hrPKS), a CS–like enzyme together with other genes was found to be likely involved in maleidrides
production.133
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Scheme 2.15 Linkage of a polyketide chain to oxaloacetate 89 in polyketide biosynthesis: A, proposed first step in 1
biosynthesis; B, structure of viridiofungin A 113; C, first step in maleidrides biosynthesis.
Furthermore isolation of alkylcitrate 90 from mfr1+mfr2 double KO mutant suggests the linkage
of hexaketide 93 to oxaloacetate 89, presumably by Mfr3 (citrate synthase), to occur early during
biosynthesis. Due to structural similarity to another fungal metabolite, viridiofungin A 113, the
linkage of the HKS product and oxaloacetate was predicted to be the first step in the biosynthetic
pathway to 1 (Scheme 2.15 B).153,154
Evidence for new oxygenases Mfr1 and Mfr2 in SQS1 biosynthesis
The genetic co–disruption of mfr1 and mfr2 as well as the individual knockouts led to loss of SQS1
production. This confirms that both are involved in SQS1 biosynthesis. Subsequent isolation of
accumulated compound 90 from ∆mfr1+2 strain and homology studies suggested that both enzymes
play a role in oxidation of the open hexaketide–citrate 90 prior to cyclisation, or take part in cyclisation
itself. Furthermore, with the identification of 90 it was shown that the linkage of the hexaketide
to oxaloacetate or another intermediate, presumably by Mfr3 (citrate synthase) occurs before the
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Mfr1 and Mfr2 catalysed steps. Structure elucidation of SQS precursors 90 was not possible prior
to methylation of the carboxl groups. Methylation using TMS diazomethane 104 was shown to
be a powerful tool in order to purify SQS1 related compounds and to elucidate their structure,
particularly to determine the carboxyl groups and quaternary C–atoms surrounding the core of
SQS. The isolated intermediate 90 was shown to be a known compound, L–731,120, first isolated as
a minor co–metabolite of 1 from the SQS1 producing strain MF5453 (Section 2.4). 90 is an acyclic
analogue of SQS1 containing the alkyl side chain and the tricarboxylic acid groups. It represents the
entire backbone of 1 prior to extensive oxidation and cyclisation.
It is possible, but rather unlikely, that 90 is not a real intermediate of SQS1 biosynthesis but a shunt
product which perchance misses one or more oxidations. Shunt products are often observed in
knockout or heterologous expression experiment, e.g. during citrinin biosynthesis.155 Due to the fact
that it was accumulated in high amounts in ∆mfr1+2 strain and was also detected in the individual
KO strain of mfr1 and mfr2 as well as in wt (Section 2.4), it is likely that 90 is a true biosynthetic
intermediate of 1 and would invalidate the proposed ring closure mechanism proposed by the
Glaxo group (Section 2.1, Scheme 2.2, route A).7 The ring closure could also proceed through the
intermediate 91 after oxidation of 90 which is expected to lead to SQS1 acid bicyclic ring (Scheme 2.2,
route B).
Further experiments using in vitro assays with purified enzymes (Mfr1, Mfr2) and purified substrate
90 could answer the question about shunt or not shunt product and might additionally uncover
possible products and specific mode of action of each enzyme, in particular the products of Mfr2.
Individual KO of mfr1 resulted in the same chemo–type as the dual KO of mfr1 and mfr2 showing
Mfr1 comes first (Section 2.5.3). But upon individual KO of mfr2 a series of new putative oxygenated
congeners of 90 were detected by LCMS. HRMS and MSMS data showed that 90 is the substrate
for stepwise oxidation by the putative non–heme iron oxygenase Mfr1, most likely to an alcohol
107, a ketone 106 and then an unsaturated ketone 108 (Scheme 2.16). Further oxidation could result
in the 3,4–epoxide 109. Two peaks corresponding to the calculated mass of 109 may correspond to
the keto and hemiacetal forms. These oxidised compounds were present in very low titres in the
MF5453 KO strain and proved extremely difficult to purify. This is likely caused by facile shunts and
degradations due to their electrophilic nature. However MSMS data convincingly showed that the
oxidative modifications performed by Mfr1 leading to 107 to 109 occur on the hexaketide and not on
the oxaloacetate moiety of 90, as retro–aldol loss of unmodified oxaloacetate (m/z 132) was observed
for all of them (Section 2.5.3, Fig. 2.21 to 2.24).
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Scheme 2.16 Proposed sequence of oxidative steps catalysed by non–heme iron–depenedent oxygenases Mfr1 and Mfr2
during 1 biosynthesis.
From KO of mfm1, encoding a copper–dependent monooxygenase two further putative oxygenated
congeners were identified 103 and 101. MS analysis of these compounds is consistent with Mfr2
hydroxylating at C-4 and C-2 to result in 103 and 114 although low titres and instability of these
compounds did not allow full structural elucidation by NMR. Retro–aldol loss of unmodified
oxaloacetate (m/z 132) was not observed for the major compound accumulated upon Mfm1 KO 101.
This indicates, that hydroxylation at C-2 of 114 is probably the final oxidative step catalysed by Mfr2.
Facile Payne rearrangement of 114 would furnish 115 which could undergo acetal formation and
concomitant transannular epoxide opening to give the observed intermediate 101 (Scheme 2.16).
In fungal PKS biosynthesis, many oxygenases have been found to work iteratively catalysing
multiple similar reactions on different sites of the substrate, e.g. in lovastatin 6, chaetoglobosin A,
cytochalasin E, and aurovertin E 116 biosynthesis.156,157,158 The definition for an iterative enzyme in
natural product biosynthesis can be defined as a protein with active sites that can catalyse multiple
rounds of structural modifications.159 In particular, many multifunctional Fe(II)/αKG–dependent
oxygenases have been found in fungal meroterpenoid biosynthesis, where a single enzyme was
shown to catalyse a variety of chemistry ranging from simple hydroxylations to remarkable skeletal
rearrangements (Section 1.2.3).102,139,160,161,162
Interestingly, aurovertin E 116, a fungal polyketide of the family of aurovertins, possess a 2,6–
dioxabicyclo[3.2.1]–octane ring, similar to SQS1 core structure. In the case of 116, it is attached to a
methylated α–pyrone and derived through iterative epoxidation of a polyene precursor and a cascade
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of concerted epoxide openings. AurC plays a multifunctional role. It is an iterative oxygenase, which
catalyses the epoxidation of three double bonds in two separate steps in the biosynthesis of 116
(Scheme 2.17).158
Scheme 2.17 Multifunctional role of AurC in aurovertin E 116 biosynthesis, adapted from Tang et al.163.
During anditomin 117 biosynthesis two multifunctional non–heme iron–dependent dioxygenase
(AndA and AndF) were found to be part of the pathway (Scheme 2.18). Anditomin possesses a
unique, highly oxygenated bridged–ring system, like SQS1. The dioxygenase AndA was shown to
synthesise the bicyclo[2.2.2]octane core of 117 by an unprecedented rearrangement.139 It maintains a
conserved 2–His–1–carboxylate iron–binding facial triad (H135, D137, H213), which is conserved in
non–heme iron–dependent dioxygenases. An iron at this site would play a key role in the enzyme–
catalysed oxygenation.164 Another dioxygenase, AndF, generates the product 117 by an oxidative
rearrangement (Scheme 2.18).139
Scheme 2.18 Biosynthetic steps in anditomin 117 biosynthesis catalysed by two non–heme iron–dependent dioxygenases
AndA and AndF.
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Four α–ketoglutarate and iron(II)–dependent dioxygenases in the rubratoxin 118 pathway were re-
cently shown to hydroxylate similarly unactivated carbons, but not in an iterative fashion (Scheme 2.19).165
Scheme 2.19 Biosynthetic steps in rubratoxin 118 biosynthesis catalysed by four α–ketoglutarate and iron(II)–dependent
dioxygenases.
Identification of a copper dependent oxygenase Mfm1 in SQS1 biosynthesis
By disrupting mfm1, which encodes a putative copper dependent oxygenase, it was shown that
Mfm1 is part of the SQS1 cluster as no 1 was detected in the KO transformant. Furthermore structure
elucidation of the accumulated compound 101 of KO strain, lacking the hydroxyl group at C-10, led
to the conclusion that Mfm1 is involved in oxidation of the C-9,10–olefin of 101 in order to give the
hydroxylated, unacetylated SQS precursor 94. The mechanism probably involves epoxidation by
Mfm1 and subsequent rearrangement to allylic alkohol 94 (Scheme 2.20 A). Over 20 years ago several
squalestatin analogues were found that lack the oxygen at C-10 and contain a 9,10-vinylic methyl
group at C-9 instead of a methylene.166 The existence of these compounds already led to the proposal
that, after ring formation, an oxidation of the C-9,10 olefin results in a hydroxyl group at C-10 and
a double bond at C-9,18.113 This proposed biosynthetic step was elucidated and confirmed in this
work. Literature reports a similar epoxidation/rearrangement sequence during the biosynthesis of
lovastatin 6, which is performed by the cytochrome P450 oxygenase LovA (Scheme 2.20 B).
The ∆mfm1 strain showed also production of a new compound 110. NMR data confirmed the
structure to be 101 with the tetraketide chain already attached. Former in vitro studies showed that
the tetraketide 24 was attached to the core of 94 as CoA activated compound by acyltransfrase Mfm4
in the final step of the biosynthesis (Section 2.1).53 In this in vivo experiment the tetraketide chain
was attached before hydroxylation and acetylation of the hexaketide chain as the gene expressing
88
2.5 Results – Knockout studies
Mfm1 was blocked. Presumably 101 was used as substrate of acyltransferase Mfm4 as its natural
substrate was not present and 101 was available in high titres.
Scheme 2.20 A, Biosynthetic step from 101 to 94 catalysed by Mfm1 in SQS1 biosynthesis; B, Biosynthetic step from lovastatin
biosynthesis catalysed by LovA.
Moreover, fermentation studies using different trace elements, strongly suggested copper as cofactor
for Mfm1, as predicted from structure homology studies. Copper is a rarely used metal cofactor
in enzyme catalysis.163 It has relevance to metabolism in a few examples such as cytochrome c
oxidase,167, laccase168 and tyrosinase.169 There are also known fungal–derived types, like copper
dependent polysaccharide monooxygenases (PMOs), that catalyze the O2–dependent oxidative
cleavage of recalcitrant polysaccharides.170 The oxidative chemistry catalysed by fungal PMOs likely
leads to incorporation of molecular oxygen into C–H bonds.171 The metal center of these enzyme
class contains a conserved type II copper binding site. Bound copper is coordinated by a bidentate
N–terminal histidine residue through the amino terminus and Nδ and the Ne of another histidine
residue and a water molecule together with a buried proximal tyrosine.170 The same residues were
also found in Mfm1 structure prediction using PHYRE2134 (Section 2.3). Another copper dependent
enzyme which is known from fungal secondary metabolism is dihydrogeodin oxidase (DHGO).
The purified enzyme showed an intense blue color and had an absorption maximum at 600 nm. It
was shown to catalyse the reaction of dehydrogeodin 119 to (+)–geodin 120 in the final step of the
biosynthesis in A. terreus (Scheme 2.21).172
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Scheme 2.21 Last step of (+)–geodin 120 biosynthesis catalysed by DHGO.
The PHYRE2 calculated model of Mfm1 showed structural homology to two oxidoreductases. The
first one is a copper dependent peptidylglycine alpha–hydroxylating monooxygenase2 (PHM) from
Rattus norvegicus142 with 15% identity and 90.9% confidence in the model. The second is an human
dopamine beta–hydroxylase, which is the enzyme which converts dopamine to norepinephrine,173
with 13% identity and 89.1% confidence. Both enzymes possess two copper–binding sites in the
closed active site structure (Section 2.3).140,142,173
Accompanying the bioinformatic analysis, the studies with different trace salts in the medium led to
the conclusion that Mfm1 is a copper–dependent oxygenase which catalyses one of the later steps in
SQS1 biosynthesis by conversion of 101 to 94 (Scheme 2.20).
Last steps of SQS1 biosynthesis are unravelled – KO of Mfr4 acyltransferase
Previous studies of SQS biosynthesis have already suggested that modifications of the acyl and alkyl
chain of 1 occur late in biosynthesis as all minor components reported for squalestatins vary in the
degree of oxidation and methylation of the acyl side chain and alkyl chain.166
Moreover, the appearance of 4’–desacetyl- and 4’–desacetoxy–ZA–A and –C suggests that the
acetylation at the hexaketide chain may be one of the final steps in SQS1 biosynthesis.113 Bonsch et al.
showed by in vitro studies that acyltransferase Mfm4 is responsible for loading acyl groups from
CoA onto the squalestatin core at O-6 as the final step of the biosynthesis.53 Knocking out the gene
for the other transferase Mfr4 led to loss of 1 and identification of intermediates 90, 101 and 94.
These findings suggested that the Mfr4–catalysed step is the penultimate step of biosynthesis. The
results from Bonsch et al. that Mfm4 catalyses the last step was confirmed, as no intermediate was
found with added acyl chain in the extract of Mfr4 KO transformant.
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2.6 Results – Heterologous expression of SQS genes in A. oryzae
NSAR1
Previous knockout studies revealed the order of genes involved in SQS1 biosynthesis (Section 2.5).
In order to gain more information, heterologous expression experiments were deployed using
quadruply auxotrophic A. oryzae as the host and the modular fungal expression system described by
Lazarus and coworkers (Section 1.2.3).98
2.6.1 Yeast recombination, Gateway cloning and Transformation of A. orzyae
In this study the fungal expression vectors pTYGSarg, pTYGSade and pTYGSmet were used, which
each contain a corresponding gene (e.g. argB) to complement one of the NSAR auxotrophies, allowing
selection on minimal media lacking, e.g. arginine (Section 1.2.3).
As shown for construction of knockout cassettes (Section 2.5), pE–YA can be used for the assembly
of large DNA fragments by yeast homologous recombination. Here, the vector pE–YA was used to
assemble the large mfpks2 gene (7.7 kb), from four DNA fragments of around 2 kb (Scheme 2.22 A).
The assembled PKS gene was then transferred to a fungal expression vector by Gateway cloning
(Section 1.2.3).
Therefore the entry vector (pE–YA) containing mfpks2 (KELI47) and one vector of the pTYGS family
(destination vector) were incubated with the LR recombinase enzyme mixture, resulting in two new
plasmids. The desired expression clone contains mfpks2 and the donor vector occupies the Gateway
cassette ccdB, camR (Scheme 2.22 B).
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Scheme 2.22 Fungal expression vectors used in this work and gateway cloning: A, assembly of the large PKS gene mfpks2 by
in vivo HR recombination (S. cerevisiae) in the gateway entry clone pE–YA KELI47; B, Gateway cloning by LR recombination
between pE–YA KELI47 and pTYGS (destination vector).
Cloning overview of fungal expression vectors
According to the knockout results and the proposed biosynthesis of SQS1, the first gene involved
in the biosynthesis is mfpks2 encoding the hexaketide synthase (SQHKS). It also appears likely that
there must be a system for creation of benzoyl CoA from phenylalanine. As SQHKS possesses no
thiolesterase (TE) domain for off–loading of the PKS chain, one of the two genes encoding hydrolases
Mfm8 and Mfm10 could also be involved in the early steps, as well as the citrate synthase Mfr3.
For initial expression experiments mfpks2 was assembled from four cDNA fragments (RNA was
isolated by Beate Bonsch) in pE–YA using homologous recombination in S. cerevisiae (Scheme 2.22 A,
KELI47) and was further cloned into the fungal expression vector pTYGSarg via gateway cloning
(Scheme 2.22 B, KELI47LR). Genes from MF5453 SQS1 gene cluster with predicted function for en-
coded proteins used in heterologous expression experiments are summarised in table 2.7. For further
sequential coexpression of the early genes from the pathway different combinations (mfpks2+mfm10,
mfpks2+mfm10+mfm8, mfpks2+mfm10+mfr3, mfpks2mfm8+mfr3 were cloned in pTYGSarg (Fig. 2.46).
The three genes involved in putative oxidations encoded by mfr1, mfr2, mfm1 were cloned into the
pTYGSmet vector in different combinations (mfr1, mfr2, mfr1+mfr2, mfr1+mfr2+mfm1, Fig 2.46). All
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Table 2.7 Genes from MF5453 SQS1 gene cluster with predicted function for encoded proteins used in heterologous
expression experiments
MF5453 Gene Putative function
m1 Copper dependent oxygenase
m8 Hydrolase
m10 Hydrolase
mfpks2 Hexaketide synthase
r1 Possible non-heme iron–dependent
r2 Possible non-heme iron–dependent
r3 Citrate synthase
pTYGS vectors for expression of the SQS1 BGC were constructed by in vivo homologous recom-
bination in S. cerevisiae and in vitro recombination (Section 1.2.3, Scheme 1.20). Dedicated genes
were amplified by PCR using Mf5453 cDNA or gDNA as template with denoted oligonucleotides
(Table 2.8), which were designed to introduce the 30 bp homologous overlaps (oligonucleotide
sequences: Chapter 6, Table 6.8).
Table 2.8 Construction details for fungal transformation vectors used for heterologous expression of SQS genes in A. oryzae
NSAR1
Construct ID Vector backbone Template Oligonucleotides for construction
in S. cerevisiae
KELI47 pE-YA cDNA
sqhks part1: P57+861; sqhks part2:
P862+863;
sqhks part3: P864+60; sqhks part4:
P61+62;
KELI47LR pTYGSarg - LR with KELI47
KELI31 pTYGSarg cDNA mfm10: P607+608; mfr3: P609+P610
KELI31LR pTYGSarg - LR with KELI47
KELI34 (BB) pTYGSarg cDNA Beate Bonsch
KELI34LR pTYGSarg - LR with KELI47
KELI42 pTYGSarg cDNA mfm10: P607+608; mfm8: P841+P842
KELI42LR pTYGSarg - LR with KELI47
KELI50 pTYGSarg cDNA mfr3: P609+610; mfm8: P886+P887
KELI50LR pTYGSarg - LR with KELI47
KELI52A pTYGSmet cDNA mfr1: P613+614; Patch_PadH:
P89+90; Patch_Peno: P87+88
KELI52B pTYGSmet cDNA mfr2: P615+616; Patch_PadH:
P89+90; Patch_PgpdA: P91+92
KELI52C pTYGSmet cDNA mfr1: P613+614; mfr2: P615+616;
Patch_PadH: P89+90
KELI52D pTYGSmet cDNA mfr1: P613+614; mfr2: P615+616;
mfm1: P611+612
Correct cloning and splicing was confirmed by sequencing (Eurofins, Ebersberg). An additional
vector pTYGSade–str11-str8–str10 (provided by Dr. Risa Nofiani from Bristol) contains the benzoyl
CoA biosynthesis–encoding genes from Strobilurus tenacellus (Chapter 3). Coexpression in A. oryzae
enables production of benzoyl CoA and complements the panel of expression clones used for
subsequent A. oryzae NSAR1 transformation (Fig. 2.46).
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Figure 2.46 Overview of constructed vectors used for fungal expression (pTYGSarg, met, ade) and gateway entry vector
pE–YA (KELI47).
Gene combinations, A. oryzae NSAR1 transformation and genetic analysis of transformants
In order to transform A. oryzae NSAR1 with combinations of constructed vectors (Section 2.6.1) a
CaCl2/PEG mediated protoplast protocol was used. Cotransformation of one, two or three vectors
were carried out in a single transformation step using selection medium which was adapted to the
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vectors used in the individual transformation. The resulting colonies were picked onto secondary
selection plates and further separated by streaking for single colonies on a third selection plate.
Overall 10 combinations of genes from SQS1 BGC on different fungal expression vectors were used
to cotransform A. oryzae NSAR1, resulting in 10 strains carrying genes from 1 BGC (Table 2.9).
Table 2.9 Overview of A. oryzae NSAR1 transformations with different combinations of genes from SQS1 BGC, a Coexpression
with genes from strobilurin biosynthesis (str10, str8, str11) encoding benzoyl–CoA producing enzymes; Hyd: Hydrolase, CS:
citrate synthase, NHI: non–heme iron–dependent oxygenase, CDM: copper dependent monooxygenase
Exp.
No
Exp. ID Selection
marker
Transformed
expression
vector(s)
Genes mf Fed
benzoyl
SNAC
pks2 m10 m8 r3 r1 r2 m1
PKS Hyd Hyd CS NHI NHI CDM
1 KELI47 arg KELI47LR X - - - - - - X
2 KELI34 arg KELI34LR X X - - - - - X
3 KELI42 arg KELI42LR X X X - - - - X
4 KELI31 arg KELI31LR X X - X - - - X
5 KELI5- arg KELI5-LR X - X X - - - X
6 KELI52 arg, ade KELI5-LR,
Risa2
X - X X - - - -
7 KELI52Aa arg, ade, met KELI52A,
Risa2
X - X X X - - -
8 KELI52Ba arg, ade, met KELI52B,
Risa2
X - X X - X - -
9 KELI52Ca arg, ade, met KELI52C,
Risa2
X - X X X X - -
1- KELI52Da arg, ade, met KELI52D,
Risa2
X - X X X X X -
The genomic DNA of A. oryzae NSAR1 expression strains was isolated and analysed by PCR for the
intended integration of genes using gene specific oligonucleotides. Subsequent bands corresponding
to DNA fragment sizes of amplified genes confirmed the integration of genes within the A. oryzae
NSAR1 genome (Appendix, Fig. 7.1). In order to analyse the secondary metabolite produced by
genetically confirmed transformants, the colonies were grown in induction medium for PamyB (DPY
+ 0.15% methionine) for 6 days at 28 ◦C and 110 rpm. The extracts were analysed by LCMS.
2.6.2 Expression of early SQS genes in A. oryzae
From previous knockout studies no hexaketide product was observed in extracts of ∆mfr3 (citrate
synthase) mutants (Section 2.5.6). In order to investigate the function and products of the early
genes of the cluster, SQHKS encoding gene (mfpks2) was cloned into four pTYGSarg expression
vectors (arg) possessing different sets of tailoring genes (Table 2.9). The first constructed expression
vector contained the PKS gene only (KELI47LR), whereas the second one additionally contained
the hydrolase gene mfm10 from the cluster (KELI34LR). The hydrolase gene was included into
the expression system as SQHKS possesses no thiolesterase domain. Therefore Mfm10 could be
necessary for off–loading of the PKS chain from the enzyme. The third expression vector consists
of both hydrolase genes of 1 BGC (mfm10 and mfm8) in addition to mfpks2. Either hydrolase could
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possibly be involved in off–loading of the PKS chain. In favour of eliminating the opportunity
that the PKS product on its own is unstable or degraded, the putative next acting enzyme of the
biosynthesis, mfr3 (citrate synthase) was included into the expression system with mfpks2 and mfm10
(KELI31LR). The expected product would be a compound like 90, which was the major intermediate
of the double mfr1+mfr2 KO strain (Section 2.5.3).
Genetically confirmed transformants and an A. oryzae NSAR1 wt control were grown in liquid PamyB
induction medium. Because of missing genes for the predicted benzoyl–CoA 25 precursor in A. oryzae,
benzoyl–SNAC 121 was synthesised and fed to the medium [final concentration 1 mM] on days 2,
3 and 4 of fermentation, as a mimic of benzoyl–CoA 25 (Section 1.1.1). The synthesis of benzoyl–
SNAC 121 is described in this section. After 5–7 days of fermentation, extracts were submitted
to LCMS and subsequent chromatograms analysed for early intermediates of SQS1 pathway. In
comparison to A. oryzae wt control grown under identical conditions, no new peaks were detected
for all four experiments (Appendix, Figure 7.3). As genetic analysis revealed that all desired genes
were integrated successfully, it is likely that the synthetic precursor benzoyl–SNAC 121 did not reach
SQHKS or is not accepted by the synthase. A stability problem of the hexaketide product can be
almost certainly excluded as coexpression of the citrate synthase did not lead to the putative product
90, which was shown before to be stable in MF5453.
While conducting these experiments, Tang and coworkers showed that intermediate 90 is the first
enzyme–free intermediate of SQS1 biosynthesis and only three enzymes (SQHKS, citrate synthase
and one hydrolase) are needed to produce 90 heterologously in A. nidulans.118 They identified a
homologous BGC of 1 in the fungal pathogen Curvularia lunata (also known as Cochliobolus luna-
tus ATCC 74067), which was previously identified as a producer of 1 (Section 2.1.2).110 In comparison
to our expression experiment with A. oryzae, their expression host A. nidulans was shown to produce
benzoyl–CoA 25 endogenously. Furthermore, they showed that in addition to the PKS (Clz14) and CS
(Clz17), the hydrolase homologue to Mfm8 (Clz11) is also required to produce 90.118 The homologous
gene combination from MF5453 1 BGC (sqhks, mfm8 and mfr3) was not tested in our experiments
and therefore, in agreement with results of the Tang group, initial studies to reconstitute the SQS1
biosynthesis resulted in no intermediates of the pathway. However, Tang and coworkers isolated 90
in very low yields (titre of around 0.1 mg/L) which might arise from using the low natural pool of
benzoyl–CoA 25 occurring in A. nidulans.
Our aim was to repeat Tang’s expression experiment using homologous genes from SQS producing
strain MF543 in order to reproduce their result and moreover achieving better yields for 90 to have a
good starting point for adding more genes involved in oxidation to the expression system.
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Synthesis of benzoyl–SNAC 121
Benzoyl–SNAC 121 was synthesised, in order to provide a synthetic CoA–mimic of naturally precur-
sor benzoyl–CoA which can be fed to the expression medium of SQHKS transformants. Benzoyl–
SNAC 121 was synthesised from its corresponding carboxylic acid 86 in two steps with an overall
yield of 30% (Scheme 2.23). The formation of HSNAC 15 was carried out following the protocol of
Piasecki et al.174 Corresponding experimental details and NMR data are shown in chapter 6.5.5.
Scheme 2.23 Synthesis of benzoyl–SNAC 121: first step, synthesis of N–acetylcysteamine (15) from cysteamine hydrochloride
122 and acetic anhydride yielded in 121 (34%); second step, synthesis of 121 from benzoic acid 86 (87% yield).
2.6.3 Coexpression of mfpks2, mfm8, mfr3
In order to reproduce Tang’s result, a fungal expression plasmid was constructed containing mfpks2,
mfr3 and mfm8 using yeast recombination and LR recombination (KELI50LR, exp. 5/6). The desired
plasmid was confirmed by sequencing and used for transformation of A. oryzae NSAR1 resulting in 5
transformants. As A. oryzae is not capable of producing benzoyl–CoA 25175, a mimic of the starter
unit, benzoyl–SNAC 121 was pulse fed to the fermentation (day 2, 3, 4; 1 mM final concentration).
On day six the culture broth was extracted using ethyl acetate after acidifying to pH 4. As in previous
experiments, no new product was detected by LCMS compared to a NSAR1 wt control (Fig. 2.47).
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Figure 2.47 LCMS analysis of transformants containing 3 genes (mfpks2, mfr3 and mfm8) in comparison to NSAR1 wt (exp. 5,
table 2.9), DAD chromatograms (top) and ES− traces (bottom), *unrelated compound (tR = 5.5 min), m/z 163 (ES−), bottom:
peak (tR = 6.1 min) also in wt control (traces), extracts were obtained from cultures grown in DPY + 0.15% methionine and
pulse fed with 1 mM benzoyl–SNAC 121 and grown for 6 days.
To overcome the possibility that 121 is not accepted as starter unit for SQHKS and therefore no
expression product could be detected in previous experiments, a different strategy was used. In
the following expression experiments 6 to 10 (Table 2.9), the precursor 25 was produced in situ
by coexpression of benzoyl–CoA biosynthesis–encoding genes (str8, str10, str11) from Strobilurus
tenacellus (Chapter 3). The plasmid containing the 25 producing genes was provided by Risa Nofiani
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(Cox group, University of Bristol) on an pTYGSade expression vector (Fig. 2.46, Risa2). Additional
information about the benzoate pathway in S. tenacellus is given in chapter 3. Cotransformation
of A. oryzae NSAR1 with pTYGSarg–mfpks2–mfr3–mfm8 (KELI50LR) and pTYGSade–str8–str10–
str11 (Risa2) resulted in 8 transformants. Transformant 6 was shown to have all desired genes
integrated (Appendix, Fig. 7.2). Four strains (Transformant 4, 5, 6 and 7 (traces)) were shown to
produce a new compound eluting at tR = 8.0 min (Fig. 2.48). The retention time corresponded
to the known compound 90 which was previously isolated from mfr1+2 KO mutant. Further
chemical characterisation by comparing the MSMS fragmentation pattern to a synthetic standard of
90 proved the new peak to be hexaketide citrate 90 (Fig. 2.49). Purification of compound 90 from
1 L fermentation of transformant KELI50_6 yielded 1 mg of pure 90. The titre of 90 was around ten
times higher than in Tang’s experiment (titre ca 0.1 mg/L).
Figure 2.48 LCMS analysis of transformants containing 6 genes (mfpks2, mfr3, mfm8, str8, str10, str11) in comparison to
NSAR1 wt and an analytical standard of 90 obtained from mfr1+2 KO mutant (exp. 6, table 2.9), extracted ion chromatograms
of 419.2, extracts were obtained from cultures grown in DPY + 0.15% methionine.
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Figure 2.49 MSMS data of compound produced in transformant KELI50_6 (tR = 8.0 min) in comparison to an analytical
standard of 90 obtained from mfr1+2 KO mutant.
2.6.4 Expression of genes involved in oxidations during SQS1 biosynthesis
Previous knockout studies revealed that Mfr1 and Mfr2, two putative non–heme iron dependent
oxygenases, must be involved in the several oxidative steps which are required to form the core
of 1. A copper–dependent oxygenase Mfm1 was then shown to oxidise the hexaketide chain after
cyclisation to give intermediate 94. In order to investigate the oxidative steps in more detail, mfr1,
mfr2 and mfm1 were added to the expression system in various combinations (Table 2.9, exp. 7 to
10).
Yeast recombination was used to construct four different constructs for expression in A. oryzae,
pTYGSmet–mfr1 (KELI52A), pTYGSmet–mfr2 (KELI52B), pTYGSmet–mfr1–mfr2 (KELI52C) and
pTYGSmet–mfr1–mfr2–mfm1 (KELI52D) (Fig. 2.46, Table 2.7). The vector pTYGSmet was chosen
for all constructs as it can be coexpressed with the expression system producing precursor 90
(pTYGSarg–sqhks–mfr3–mfm8 + pTYGSade–str8–str10–str11) and transformants can be selected on
medium lacking arginine, adenine and methionine.
Addition of mfr2 to the expression system producing 90 resulted in no new compound (Fig. 2.50, exp.
8), but expressing mfr1 in presence of 90 resulted in a mixture of several new compounds in very
low titres with m/z values of 432.2, 434.2, 435.2 and traces of 447.2 (Fig. 2.50, exp. 7). HRMS data
confirmed these to be oxidised congeners of 90, which were also found in mfr2 knockout experiment
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(Section 2.5). An overview of compared HRMS and MSMS data of new compounds isolated from
∆mfr2 strain and expression experiment 7 is summarised in figure 2.51. Retention times of new
expression compounds slightly vary (max. 0.2 min) from former KO studies, as measurements were
carried out using a new LCMS column.
Figure 2.50 Chemical analysis of transformant KELI52_B1x1 (exp. 8, table 2.9) and KELI52_A3x4 (exp. 7, table 2.9) in
comparison to an A. oryzae wt control by LCMS (ES− BPI chromatograms shown); in orange, 90; in yellow, 108; in red, 106;
in green, 107; and in traces 109; retention times are not identical to former KO studies (max. variation = 0.2 min), because
measurements were carried out using a new LCMS column.
When both putative non–heme iron expressing genes (mfr1 and mfr2) were coexpressed with the
established expression system for 90 production, two additional new compounds 101 (m/z 479.2,
ES−), 103 (m/z 463.2, ES−) were detected in low titres (Fig. 2.52, exp. 9). Using HRMS and MSMS
analysis they were shown to be identical to the compounds previously isolated from mfm1 knockout
strain (Fig. 2.53). Subsequent addition of mfm1 to the system did not result in any new compound
(Fig. 2.52, exp. 10). This outcome was not unexpected as KO experiments with mfr4 revealed the
expected compound 94 only to be produced in low titres. This suggests it to be unstable and therefore
not possible to detect in the extract of the expression system. In addition the titre was already low
for expression products of coexpression of up to 9 genes.
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Figure 2.51 Comparison of compounds isolated from ∆mfr2 mutant and expression experiment 7 (mf-
pks2+mfr3+mfm8+str10+str8+str11+mfr1). HRMS and MSMS fragmentation pattern of new compounds, HRMS and
MSMS data of 109 from expression strain is missing due to very low amount produced.
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Figure 2.52 A, coexpression overview; B, chemical analysis of transformant KELI52_C1x2 (exp. 9) and KELI52_D3x3 (exp. 10)
in comparison to an A. oryzae wt control by LCMS (ES− BPI chromatograms shown); in orange, 90; in green, 107; in yellow,
101; in red: 103 (coelution with m/z 449 ES−); and traces of 109; retention times are not identical to former KO studies (max.
variation = 0.2 min), because measurements were carried out using a new LCMS column.
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Figure 2.53 Comparison of compounds isolated from ∆mfm1 mutant and expression experiment 9 (mf-
pks2+mfr3+mfm8+str10+str8+str11+mfr1+mfr2). HRMS and MSMS fragmentation pattern of new compounds.
Isolation and therefore full structure elucidation of new produced oxidative congeners of 90 was
prevented due to very low titres in expression strains. Nevertheless, it was shown that heterolo-
gous expression of up to 6 genes from SQS BGC, coexpressed with benzoyl–CoA producing genes
from strobilurin biosynthesis, yielded in several previously characterised oxygenated intermediates
of squalestatin biosynthetic pathway. The expression results reinforce the outcome of the knock-
out studies and together showing the order and function of oxidative enzymes involved in SQS1
biosynthesis.
2.6.5 Discussion
Expression results confirmed the outcome of the knockout studies and showed that 90 is the substrate
for stepwise oxidation on C-5 by putative non–heme iron dependent oxygenase Mfr1, most likely to
an alcohol 107, a ketone 106, and then an unsaturated ketone 108. Subsequent oxidation would result
in the 3,4–epoxide 109 (Scheme 2.24). The detected intermediates were also observed in extracts of
the ∆mfr2 strain. Both, the MF5453 KO strain and the A. oryzae expression strain (KELI52_A3x4),
produced theses compounds in very low titres. Therefore, the oxygenated congeners of 90 were
proven extremely difficult to isolate, most likely because of facile shunts and degradations due to their
electrophilic nature. However, obtained intermediates from both experiments were confirmed by tR,
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HRMS and MSMS analysis and give confidence that these are true intermediates of the biosynthetic
pathway to 1. MSMS analysis definitively showed that the oxidative modifications performed by
Mfr1 leading to 107, 106, 108 and 109 occur on the hexaketide and not on the oxaloacetate moiety of
90, as retro–aldol loss of unmodified oxaloacetate (m/z 132) was detected, which was not observed
for 101 indicating that hydroxylation at C-2 of 114 is probably the final oxidative step catalysed by
Mfr2.
Scheme 2.24 Proposed sequence of oxidative steps during the formation of 94.
The HRMS analysis suggests hydroxylating at C–2 and C–4 by Mfr2 to give 103 and 114. Both
intermediates were produced in low titres and due to instability of 103 full structural elucidation by
NMR was prevented. An alternative pathway could involve hydroxylation at C–4 first followed by
hydroxylation at C–2 (Scheme 2.24). In both cases, facile Payne rearrangement of 114 would yield
115 which could form the acetale and concomitant transannular epoxide opening would give the
stable intermediate 101 (Scheme 2.24). This series of oxidation events is in accordance with previous
18O2 feeding experiments (Section 2.1.2)7 and with the knockout studies (Section 2.5). Oxidation of
the 8,9–olefin probably involves epoxidation catalysed by the copper–dependent oxygenase Mfm1
and rearrangement to give the allylic alcohol 94 (Scheme 2.24).
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Knockout as well as expression experiments revealed that oxygenated intermediates on the pathway
to form the core of 1 are highly unstable (apart from 101). The question to be answered is how such a
pathway could have evolved as the oxidised congeners of 90 appear to be transient species. However,
intermediate 90 was isolated before from producing organisms as a minor cometabolite of 1 and it
is known to be a micro–molar inhibitor of squalene synthase.119 Accordingly, the pathway to SQS1
benefits by Mfr1 and Mfr2 (possibly evolved by duplication), as these two enzymes significantly
increases the potency of the pathway product, as 1 is a pico–molar inhibitor of SS.12
Synthetic studies towards the squalestatins demonstrated the requirement for protecting groups,
when nucleophilic and electrophilic compounds are in close proximity.176 This fact affirm the insta-
bility of oxidative intermediates of 90. Nature, anyhow, appears to bypass this problem by using
catalysts which can guide unstable intermediates rapidly from 90 towards stable products such
as 101. Hence, the three oxidative enzymes, Mfr1, Mfr2 and Mfm1 catalyse a remarkably efficient
series of seven sequential oxidations to convert polyketide citrate 90 to the highly functionalised
squalestatin precursor 94 (Scheme 2.24).
2.7 Results – Putative SQS cluster in Dothistroma septosporum
Previous bioinformatic studies of the SQS cluster by Beate Bonsch revealed a putative squalestatin
BGC in forest pathogen Dothistroma septosporum, which showed similar composition of genes in
comparison to the other three known BGC of 1 (Section 2.1.2).53,118 As no SQS–like compound was
known to be produced by this fungus, a master’s student (under my supervision), Ole Böhl, was
aiming to isolate a new member of the SQS family. The project was carried out in collaboration with
the group of Rosie E. Bradshaw from New Zealand, who kindly provided the Dothistroma septosporum
wt strain and a PKS knockout mutant with corresponding transcriptome data.
More detailed in silico analysis of the genome and transcriptome data of the Dothistroma septosporum
wt strain and the PKS knockout mutant in comparison with the MF5453 BGC revealed that the D. sep-
tosporum is missing a gene corresponding to mfpks1 (tetraketide synthase). Further, transcriptome
data for D. septosporum showed that most of the corresponding biosynthetic genes are upregulated.
The only exceptions were found to be dsM1 (hydrolase, homologous to mfm8) and dsM2 (PAL,
homologous to mfm7), which showed up to hundred times lower expression rates.122
From the expression results (described in section 2.6) and Tang and coworkers results118, it is
known that both genes are involved in the early steps of the biosynthesis to SQS1. The PAL is
involved in benzoyl CoA precursor biosynthesis and the hydrolase Mfm8 catalyses the hydrolyses
to give the first enzyme–free intermediate 90. The in silico analysis of SQS BGC of D. septosporum
suggested production of a SQS metabolite lacking the tetraketide chain. The fact, that two crucial
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genes (encoding the PAL and hydrolase) are weakly expressed could prevent production of a SQS
intermediate. However, it might also be possible that D. septosporum has endogenous benzoyl CoA
producing genes or the precursor of the PKS is not benzoyl–CoA.
Although gene composition and transcriptome data provided evidence for SQS genes being ex-
pressed by D. septosporum, no new SQS compound could be isolated trying different production
conditions.122,177
2.8 Conclusion and Outlook
The aim of this project was to elucidate the biosynthesis of squalestatin and to delineate enzymes
involved in oxidative steps to form the complex core structure of 1. Therefore seven targeted
knockout strains were generated, disrupting single genes, or two genes simultaneously, of 1 BGC.
Production of new intermediates of 1, accumulating upon knockout experiments, revealed the
order of enzymes involved in the biosynthesis of 1 and elucidated oxidative enzymes Mfr1 and
Mfr2 (non–heme iron–dependent oxygenases), as well as copper dependent monooxygenase Mfm1
(Section 2.5). In addition, heterologous expression of SQS1–producing genes in A. oryzae NSAR1 and
re–constitution of the biosynthetic pathway revealed further detailed information about the role and
function of enzymes involved and is supported by structure elucidation of intermediates isolated
from KO experiments.
In conclusion, three previously unknown oxygenases were elucidated, which belong to the classes of
copper–dependent monooxygenases (Mfm1) and to non–heme iron–dependent oxygenases (Mfr1
and Mfr2) and catalyse a remarkably efficient series of seven sequential oxidations to convert
polyketide citrate 90 to the highly functionalised squalestatin precursor 94 in order to install the
bioactive core of 1. These results, combined with previous studies by Bonsch et al.,53 as well as those
of Tang and coworkers,118 provide a full biosynthetic pathway for the production of 1 in which the
order of enzymes encoded by the squalestatin BGC is now elucidated.
In the future, in vitro studies of the powerful non–heme iron–dependent oxygenases Mfr1 and
Mfr2 and copper dependent monooxygenase Mfm1 would shed light on their unusual chemistry
and could even provide opportunities to engineer these biocatalysts to expand nature’s catalytic
versatility and develop production of medicinally important molecules for drug discovery. Previous
extensive attempts to express copper dependent monooxygenase encoding gene mfm1 in E. coli
failed.143 Also expression of another gene from 1 BGC, CoA–ligase encoding gene mfm9, in E. coli
was unsuccessful, indicating that enzymes from 1 BGC are not easily expressed in heterologous host
E. coli. Apart from in vitro tests, ongoing investigation of the biosynthetic pathway of simple alkyl
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citrate, viridiofungin A 113, could be the starting point for a rational genetic engineering strategy
where oxidative genes of the SQS1 pathway are coexpressed with those of 113 in order to give novel,
highly oxidised, viridiofungins. Mix and match experiments with oxidative genes from SQS1 BGC
could expand the chemical diversity of simpler natural products and may lead to access of novel
bioactive compounds.
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3 Biosynthetic studies of Strobilurin A
Partial results of the presented work contributed to a publication inNature Communications, 2018, 9.175
3.1 Introduction
Strobilurin A 2 (also known as mucidin) belongs to the family of strobilurins which are produced by
basidiomycete fungi.6 Strobilruin A was first isolated in 1977 from the mycelium of Strobilurus tena-
cellus strain (No. 21602) and was shown to be highly active against yeasts and filamentous fungi.6 A
closely related compound was isolated from Oudemansiella mucida and named oudemansin A 123
(Fig. 3.1). Both compounds showed complete inhibition of respiration in fungi and investigation with
Ehrlich carcinoma ascitic (ECA) cells revealed that the location of action is exclusively the respiratory
chain.178
The common structural element, the β–methoxyacrylate, is the key toxophore which targets the
Qo site of complex III of the mitochndrial electron transport chain and subsequently prevents ATP
synthesis.15 Other effects such as complete inhibition of protein, DNA and RNA synthesis is due to
intracellular ATP deficiency.179 As a result of their simple structure and strong bioactivity against
fungi, strobilurins are used as lead compounds for a number of agricultural fungicides, such as
azoxystrobin 124 (Syngenta) and Kresoxim methyl 125 (BASF) (Fig. 3.1).179,180 Both compounds show
an increased photo–stability and selectivity compared to 2 and they are among the most widely used
agricultural fungicides worldwide. The strobilurin fungicides are estimated to have been worth
$ 3.4 billion per annum in 2015 and make up 25% of the fungicide market and 6.7% of the total crop
protection market world–wide.
Various functionalised natural strobilurins are known, including strobilurin F 126181 (hydroxylated
aromatic ring) and strobilurin B 1276 (chlorinated, Fig. 3.1). Related compounds such as bolineol182 4
have also been reported, which possesses the same carbon skeleton to strobilurin A but differs in
oxidation level (Fig. 3.1).183
Even though there is great interest in strobilurins as agricultural fungicides, very little is known
about their detailed biosynthesis and the genes and enzymes involved.
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Figure 3.1 Structures of key natural and synthetic strobilurins.
3.1.1 Biosynthesis of Strobilurin A - status quo
Feeding studies with labelled precursors and proposed biosynthesis
In the 1990s feeding experiments using isotopic labelled precursors showed that oudemansin A 123
is a polyketide using benzoate as starter unit. The benzoate itself is derived from degradation of
phenylalanine 85 via cinnamate 87. The polyketide chain is extended three times and C-methylated
once. For generation of the key β–methoxyacrylate structure an unusal oxidative rearrangement
must occur and further SAM–dependent O–methlyations led to oudemansin A 123 (Scheme 3.1
A).48
Further investigation of the biosynthetic origin of 2 was carried out by our group. Feeding singly and
doubly labelled [13C]–acetates, [methyl–13C]–methionine, [2H8]–, [3-13C]– and [2,3-13C2]–phenyl– ala-
nines to the 2 producing fungus S. tenacellus showed that incorporation of precursors was consistent
with earlier feeding studies with 123 (Fig. 3.1 B).184
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Scheme 3.1 Incorporation of biosynthetic precursors: A, incorporation of 2H-, 13C- and 14C-labelled precursors into
oudemansin A 123; B, incorporation of 2H- and 13C–labelled precursors into strobilurin A 2.
Further investigations with advanced intermediates confirmed that 2 is produced via a linear tetrake-
tide, called prestrobilurin A 128. The latter is proposed to be the substrate for an oxidative rearrange-
ment to form the core β–methoxyacrylate moiety and there is evidence for the intermediacy of an
epoxide in the key rearrangement (Scheme 3.2).184
Scheme 3.2 Proposed biosynthetic steps to strobilurin A 2.
Gene cluster of strobilurin A
In previous studies in our group the producing strain of 2, S. tenacellus, was sequenced and bioin-
formatic as well as transcriptomic analyses revealed a 50 kb BGC for strobilurin A production. The
cluster contains a gene which encodes a highly reducing PKS (stpks1), genes predicted to encode pro-
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teins involved in phenylalanine metabolism (such as a PAL) and further numerous genes encoding
tailoring proteins involved in methylation and redox reactions (Fig. 3.2 A).175,185
Figure 3.2 A, organisation of genes in 2 BGC; B detailed analysis of StPKS domain architecture; C, overview of predicted
protein functions of encoded genes in 2 BGC, yellow shaded rows indicate genes shown to be involved in the biosynthesis of
strobilurin A.
It is known that resistance to strobilurins is induced by mutations in the mitochondrial cytochrome
b, encoded by CYTB.186,187 Nevertheless no homologues of CYTB were found in the 2 BGC or
nearby, but the mitochondrial CYTB of S. tenacellus shows characteristic motifs of being strobilurin
resistant.175,185
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Closer observations of StPKS revealed an unusual domain architecture. It was shown to contain
domains usually observed in hrPKS, such as KS, AT, DH, a probably inactive C-MeT, ER, KR and
ACP, but it also possesses three unusual domains in the C–terminal part of the enzyme. The ACP
is followed by a partial αβ–hydrolase which is homologous to the mammalian FAS thiolesterase
(33%identical), an unknown domain and a second C–MeT domain (Fig. 3.2 B). In contrast to the
probably inactive C–MeT domain, located in between the DH and KR domains, the C–terminal C–
MeT domain is likely to be active, as the SAM–binding site was shown to be intact. Moreover, the ER
domain is also likely to be inactive due to mutations in the active site, compared to SQTKS.175,185
3.1.2 Prestrobilurin production and benzoyl CoA biosynthesis in S. tenacellus
Initial studies to elucidate the biosynthesis by in vivo heterologous expression experiments were
conducted by Risa Nofiani (Cox group, University of Bristol). As targeted gene knockouts in S. tena-
cellus and S. lutea were not successful, key genes from the cluster were expressed in A. oryzae. The
8.5 kb intron–free PKS was reconstructed using yeast homologous recombination and cloned into the
fungal expression vector pTAGS by Risa Nofiani.175,185 Expression of stpks1 in Aspergillus oryzae did
not lead to the production of new compounds. But when the fermentation was supplemented with
benzoyl SNAC 121, a mimic of the putative starter unit benzoyl CoA 25 (Section 1.1.1), production
of a strobilurin precursor prestrobilurin A 128 was detected.175,185 Even higher yields of 128 pro-
duction were achieved when benzoyl–CoA producing genes (str11, str8, str10) from the BGC were
coexpressed in A. oryzae. The PAL (encoded by str11) is able to convert endogenous phenylalanine 85
to cinnamate 87 which undergoes oxygenation by a non–heme iron–dependent oxygenase (encoded
by str8) and then retro–Claisen reaction to form benzoic acid 86. This is then activated to benzoyl
CoA 25 by a CoA ligase (encoded by str10). Benzoyl CoA 25 is the substrate for StPKS and yields
prestrobilurin A 128 (Scheme 3.3).175,185
Scheme 3.3 Benzoyl CoA biosynthetic pathway in S. tenacellus elucidated by heterologous expression experiments in
A. oryzae NSAR1.175,185
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In general, benzoate is a rare starter unit in fungal polyketide biosynthesis (Chapter 1.1.1). However,
recent results of our group and the Tang group have shown that benzoyl CoA 25 also forms the
starter unit for SQHKS in squalestatin biosynthesis (Section 2.1).53,118 Both fungal pathways share a
common PAL enzyme but the SQS pathway involves formation of cinnamoyl CoA 88 early in the
pathway, whereas strobilurin pathway involves direct oxidative conversation of cinnamic acid 87 to
benzoic acid 86.175,185
The expression experiments conducted by Risa Nofiani showed that the first enzyme free intermediate
of StPKS is prestrobilurin A 128.175,185 It is possible that the TE domain downstream of the ACP
domain in StPKS is involved in chain release and the C–terminal C–MeT could be responsible for
attachment of the C-4 methyl group, as the more common upstream C-MeT domain seemed to be
inactive due to mutations in the active site.175,185
The analysis of genomic and transcriptomic data of genes clustered with stpks1 revealed multi-
ple putative gene candidates involved in catalysing the oxidative step, including str4 (GMC ox-
idoreductase), str7 (aldoketoreductase), str9 (FAD dependent monooxygenase) and stl2 (alcohol
dehydrogenase). The two methlytransferase encoding genes str2 and str3 were likely involved in
O–methylation to yield strobilurin.185 As four possible candidate genes for oxidations were identi-
fied from the cluster, initially all putative genes which were predicted to be part of 2 biosynthesis
(stpks1+stl2+str2+str3+str4+str7+str8+str9+str10+str11) were coexpressed in A. oryzae (Fig. 3.3). Apart
from prestrobilurin A no new related product could be observed.185 Later genetic analysis revealed
that str4 has not been incorporated into the genome of the heterologous host. Furthermore, updated
transcriptomic data revealed a mis–prediction for the start and stop codon of str9.185 Dr Kate de
Mattos–Shipley (Cox group, Bristol University) repaired the gene str9 and cloned it together with
stl2 into expression vector pTYGSmet.
Figure 3.3 Plasmid maps of genes from 2 BGC (stpks1+stl2+str2+str3+str4+str7+str8+str9+str10+str11) coexpressed in initial
heterologous expression experiments in A. oryzae NSAR1 conducted by Dr Risa Nofiani.185
The characteristic E,Z,E triene in all strobilurins is highly unusual and the origin of this motif has
been hitherto unexplained. In polyketide biosyntesis Z–olefins are rare. Nevertheless there are
examples known, such as in borrelidin 130 PKS, where a DH domain creates a typical E–olefin,
which is later isomerised (Fig. 3.4).188 Other examples were described in bacterial trans–AT PKS
(bongkrekic acid 131), where the KR sets up a β–alcohol anti to an α–proton and subsequent syn
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dehydration catalysed by the DH domain results in the Z–olefin directly (Fig. 3.4).189 It is possible
that in strobilurin biosynthesis the KR/DH domain is also able to control different stereoselectivity
during the three iterations perhaps in response to methylation, or the unknown domain of the StPKS
has a role in formation of the Z–olefin.175
Figure 3.4 Two examples of Z–olefins in polyketide biosynthesis: borrelidin 130 and bongkrekic acid 131.
3.2 Project aims
Prestrobilurin A 128 was postulated to be the substrate which undergoes oxidative rearrangement
to form the core β–methoxyacrylate moiety, but until now there is no direct evidence for this step
(Scheme 3.2).
Earlier isotopic feeding studies proposed an oxidative rearrangement possibly involving an epoxide
intermediate and two further O–methylation steps to yield 2.48,184 Initial attempts to investigate
the biosynthetic steps from prestrobilurin A 128 to strobilurin A 2 (referred to as later steps) by
heterologous expression of genes from 2 BGC in A. oryzae NSAR1, conducted by Risa Nofiani, have
not been successful yet.185
The aim of this chapter was to explore the later steps of strobilurin A biosynthesis particularly the
unusual oxidative rearrangement to form the core β–methoxyacrylate moiety. Therefore, all putative
genes involved in 2 biosynthesis (including repaired str9) should be coexpressed with prestrobilurin
producing genes in the heterologous host A. oryzae NSAR1 in order to re–establish strobilurin A
production.
In addition the number of genes coexpressed should be narrowed down to a minimal gene cluster
for 2 biosynthetic pathway. The gene involved in the oxidative rearrangement should be identified
and investigated further by heterologous expression in E. coli and subsequent in vitro studies with
the substrate prestrobilurin 128 should be conducted to study this step in detail.
In vivo characterisation of the O–MeT–encoding genes str2 and str3 by heterologous expression in
A. oryzae NSAR1 should reveal the order of methylation steps in strobilurin and bolineol biosynthesis.
Using the same methodology should reveal the role of short–chain dehydrogenase (SDR) Stl2 and
glucose–methane–choline oxidase (GMCO) Str4 in the biosynthesis of strobilurin and bolineol.
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3.3 Results – Heterologous expression of strobilurin A BGC in
A. oryzae NSAR1
3.3.1 Vector construction and gene combinations for A. oryzae transformation
In order to investigate the later steps of strobilurin biosynthesis, the provided vectors from Bristol
(KELIV01A, KELI44, KELIV01B) were used. Together these contain all genes predicted to be essential
for strobilurin A production (Fig. 3.5). For testing different set of genes and defining a minimal
gene set for production of 2, five additional fungal expression vectors (KELIV07, KELIV04, KELIV11,
KELIV12A, KELIV12B) were constructed using yeast homologous recombination, described earlier
in section 2.6.1 (Fig. 3.5). Correct cloning was confirmed by partial sequencing (Eurofins, Ebersberg)
and details for the used cloning strategy and corresponding oligonucleotides are summarised in
chapter 6, table 6.10.
Figure 3.5 Overview of kindly provided fungal expression vectors from Bristol by Dr Risa Nofiani (*) and Dr Kate de
Mattos–Shipley (**) (both: Cox group, University of Bristol) and constructed vectors in this work used for fungal expression
(pTYGSarg, met, ade, niaD).
In order to transform A. oryzae NSAR1 with combinations of constructed vectors (Fig. 3.5) a
CaCl2/PEG mediated protoplast protocol was used, which has already been described in section 2.6.1.
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Cotransformation of two, three or four vectors were carried out in a single transformation step using
selection medium which was adapted to the vectors used in the individual transformation. Overall
10 combinations of genes from strobilurin BGC on different fungal expression vectors were used
to cotransform A. oryzae NSAR1, resulting in 10 strains occupying genes from BGC of 2 (Fig. 3.6).
Genetic analysis showed the correct insertion of desired genes into A. oryzae (Appendix, Fig. 7.4).
Figure 3.6 Overview of A. oryzae NSAR1 transformations with different combinations of genes from BGC of 2.
3.3.2 Heterologous expression of later pathway genes
From previous feeding studies, in silico analysis of the gene cluster and initial expression experiments
leading to prestrobilurin A production (Section 3.1.1), it was reasoned that the next acting gene must
be involved in the oxidative rearrangement. This may be achieved by either the GMCO encoded
by str4 or the flavin–dependent monooxygenase (FMO) encoded by str9. Further str2 and str3 (two
SAM–dependent methyltransferases) were included in the first expression experiment containing
the full complement of genes, as they are probably responsible for the addition of the two O–methyl
groups of 2. Finally, the gene stl2 encoding a SDR is also coexpressed as production of bolineol 4
requires a reduction step.
In an initial heterologous expression experiment (exp. 1) the full complement of genes, including the
benzoyl CoA–production system (str8, str10 and str11), were coexpressed in A. oryzae NSAR1 (Ta-
ble 3.6, exp. 1). LCMS analysis showed two main products. These were shown to be prestrobilurin A
128 (tR = 7.6 min) and a peak at tR = 8.4 min corresponded to strobilurin A 2 production (Fig. 3.7 a).
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Figure 3.7 LCMS evaporative light–scattering (ELS) chromatograms of organic extracts of A. oryzae NSAR1 expression
strains (arbitrary units). a, A. oryzae NSAR1 + stpks1 + str2 + str3 + str4 + str11 + str8 + str10 + str9 + stl2; b, A. oryzae NSAR1 +
stpks1 + str2 + str3 + str4 + str11 + str8 + str10 + str9; c, A. oryzae NSAR1 + stpks1 + str2 + str3 + str4 + str11 + str8 + str10; d,
A. oryzae NSAR1 + stpks1 + str2 + str3 + str4 + benzoyl SNAC 121; e untransformed A. oryzae NSAR1. *Unrelated compounds.
The mass and UV spectrum as well as the HRMS (ESI+, C16H18O3Na calc. [M+Na]
+ 281.1154,
measured 281.1157) was characteristic for 2 (Fig. 3.8). Further isolation of 2.6 mg of 2 from one litre
of culture medium and subsequent NMR analysis proved it to be 2 by comparison to literature data
(Chapter 6, Table 6.14).48
Figure 3.8 A, structure of 2; B, UV chromatogram; C, ES+ spectrum.
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The major product produced in exp. 1 was found to be a new compound (tR = 7.1 min, C13H15O2
[M+H]+ calc. 203.1072, measured 203.1071, Fig. 3.7 a). It was produced in high titres (90 mg/L cul-
ture) and was isolated, submitted to NMR analysis and shown to be the 5E,3Z carboxymethyldiene
132, according to coupling constants of J = 15.5 Hz (H-5/H-6) and J = 10.8 Hz (H-4), respectively. Com-
pound 132 has been previously synthesised during the total synthesis of strobilurin A 2 (Fig. 3.9).190
Corresponding NMR assignment is displayed in chapter 6, section 6.5.6. A second, minor com-
pound was detected to coelute with 132. It was shown to be bolineol 4, because of its distinctive
[M-H2O+H]+ (229.3) and [M+Na]+ (269.3) ions (comparison to a standard of bolineol, Fig. 3.9).
Figure 3.9 LCMS analysis of exp. 1 (Fig. 3.6): A, ES+ spectrum of exp. 1 at tR = 7.1 min corresponding to 132 and 4; B,
analytical data for standard of 132; C, analytical data for bolineol 4.
In a second experiment (Fig. 3.6, exp. 2) the SDR encoding gene stl2 was omitted from the system by
using methionine vector KELIV04 for coexpression in A. oryzae NSAR1, lacking stl2. LCMS analysis
revealed a very similar result, with production of 2 and major compound 132, but lacking bolineol
4 (Fig. 3.7 b, exp. 2). Omission of the FMO encoded by str9 (Fig. 3.6, exp. 4) led to the production
of only prestrobilurin A 128 (Fig. 3.7 c, exp. 4). The same result was achieved if the benzoate genes
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(str11, str8, str10) were neglected from expression system and the fermentation was supplemented
with benzoyl SNAC 121 (Fig. 3.6, exp. 3), although 128 is produced in much lower titre in this case
(Fig. 3.7 d, exp. 3).
3.3.3 Coexpression of stPKS, benzoyl–CoA producing genes and FAD
monooxygenase encoding gene str9
Coexpression of a minimal set of genes (stpks1+str10+str8+str11+str9) without GMCO– and O–MeT–
encoding genes (Fig. 3.6, exp. 5) led to the formation of major compound 132, and also a new
compound 133, eluting at tR = 5.9 min, 30 mg/L culture (Fig. 3.10 B, exp. 5). The new compound was
shown to have characteristic absorption maxima (229.6, 294.6 nm) compared to 2 and HRMS analysis
revealed chemical formula C14H16O3 ([M-H]
− calc. 231.1021, measured 231.1021, Fig. 3.10 C).
Figure 3.10 A, LCMS evaporative light–scattering (ELS) chromatograms of organic extracts of A. oryzae NSAR1 expression
strains (arbitrary units): exp. 5, A. oryzae NSAR1 + stpks1 + str11 + str8 + str10 + str9 + stl2 with corresponding UV spectrum
of compound 133; exp. 6, A. oryzae NSAR1 + stpks1 + str11 + str8 + str10 + str9; B, structure of compound 133 with key HMBC
correlations, corresponding NMR assignment is shown in table 3.1, and mass spectra (ES+ and ES−).
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Isolation and full structure determination by NMR confirmed the new compound 133 to be desmethyl-
bolineol (Table 3.1, Fig. 3.11).
Table 3.1 Chemical shifts of 3.8 mg 133 in CDCl3 (400 MHz)
Atom δC / ppm δH / ppm (J / Hz) COSY HMBC
1 177.9 q - 2, 12
2 49.9 4.08 (m, 1H) 12 1, 3, 4, 11, 12
3 130.9 q - 11
4 131.1 6.24 (d, J = 11.4, 1H) 5, 11 2, 6, 11
5 123.6 7.02 (dd, J = 15.3, 1H) 4, 6 4, 7
6 133.5 6.56 (d, J = 15.3, 1H) 5 4, 5, 8
7 137.3 q - 5, 6, 8
8/ 8’ 128.8 7.31 (m, 2H) 9 9, 10
9/ 9’ 126.6 7.41 (m, 2H) 8, 10 8, 10
10 127.9 7.20 (m, 1H) 9 8, 9
11 21.3 1.86 (m, 3H) 4 2, 4
12 61.9 3.71 (dd, 1H), 4.08 (m, 1H) 2 1
Desmethylbolineol 133 was smoothly converted to bolineol 4 by treatment with trimethylsilyldia-
zomethane 104 (Scheme 3.4) and the spectroscopic data were shown to be identical to literature data
of bolineol (NMR data in chapter 6, section 6.5.6).182
Scheme 3.4 Treatment of compound 133 with trimethylsilyldiazomethane 104 yielded bolineol 4.
Omission of the SDR encoding gene stl2 (Fig. 3.6, exp. 6) gave the same result, showing that formation
of 133 does not require the SDR and must represent a shunt pathway in A. oryzae in the absence
of the late–acting methyltransferases Str2 and Str3 (Fig. 3.10, exp. 6). Compound 133 showed the
rearranged structure, but in comparison to strobilurin A lacks the O–methyl groups. In addition,
NMR data showed that the C-2/C-12 olefin of 133 and the second carboxyl group are reduced
indicated by the diastereomeric protons at C-12 (3.71, 4.08 ppm) in proximity to the alcohol group at
C-12 (61.9 ppm, Table 3.1, Fig. 3.11).
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Figure 3.11 1H NMR data of compound 133 in CDCl3 (400 MHz) referenced to CDCl3; see table 3.1 for assignment.
These results show that FAD dependent oxidase Str9 is responsible for the unusual rearrangement to
form the toxophore of 2, as the second putative oxidation gene str4 (GMCO) was omitted in these
experiments.
3.3.4 Defining the minimal BGC for strobilurin A production
Adding the two SAM dependent O–methyltransferases (O–MeTs) encoding genes str2 and str3 from 2
BGC to the previous expression system in A. oryzae NSAR1 (stpks1 + str11 + str8 + str10 + str9, Fig. 3.6,
exp. 7) resulted in extremely unhealthy A. oryzae cultures, which were difficult to select and grow
(Fig. 3.13 a). Extraction of these cultures revealed the formation of bolineol 4 as the major compound,
together with lesser amounts of 132 and 133. Strobilurin A 2 was detected by its distinctive mass
spectrum, but in very low titre (Fig. 3.12 B, exp. 7).
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Figure 3.12 A, coexpression of genes from 2 BGC; B, LCMS evaporative light–scattering (ELS) chromatograms of organic
extracts of A. oryzae NSAR1 expression strains (arbitrary units): exp. 7, A. oryzae NSAR1 + stpks1 + str11 + str8 + str10 + str9
+ str2 + str3; exp. 8, A. oryzae NSAR1 stpks1 + str11 + str8 + str10 + str9 + str2 + str3 + stl2, inset traces shows extracted ion
chromatogram for m/z 259.1 corresponding to 2.
Figure 3.13 Pictures of two different A. oryzae NSAR1 expression strains (7 days in DPY medium): a, sick phenotype of
exp. 7 (Fig. 3.6, exp. 7, KELIV11A) NSAR1+stpks1+str11+str8+str10+str9+str2+str3 producing 2 and 4; in comparison with b,
healthy phenotype of exp. 4 (Fig. 3.6, exp. 4, KELIV04_4) NSAR1+stpks1+str11+str8+str10+str4+str2+str3 producing 128.
Production of strobilurin A 2 and also bolineol 4, showed that the O–MeTs Str2 and Str3 are responsi-
ble for the addition of the two O–methyl groups. Further, these result showed that expression of
stpks1 (PKS) and str11 + str8 + str10 (benzoyl–CoA production) + str9 (FMO) and str2 + str3 (O–MeTs)
is sufficient to produce strobilurin A in heterologous host A. oryzae NSAR1 and therefore demonstrate
the minimal BGC for production of 2.
Reinclusion of the SDR Stl2 (Fig. 3.6, exp. 8) produced 4 only, with no production of 2 (Fig. 3.12 B,
exp. 8). These results also showed that without coexpression of GMCO–encoding gene str4 only
trace amounts of 2 were produced and that bolineol 4 is the major product.
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3.3.5 Individual role of O–methyltransferases Str2 and Str3
In order to investigate the individual role of the two O–MeTs in strobilurin 2 and bolineol 4 biosyn-
thesis, two expression vectors pTYGS–niaD–str2 and pTYGS–niaD–str3 were constructed (Fig. 3.5)
and used together with the previous system (arg, ade, met) to cotransform A. oryzae NSAR1 yielding
in 7 transformants for exp 9 and 6 transformants for exp 10 (Fig. 3.6, exp. 9+10).
Heterologous expression of O–MeTs Str2 and Str3 individually
In order to investigate the function of Str3 in strobilurin A 2 and bolineol 4 biosynthesis, str2 was
omitted from the expression system, by expression of the minimal BGC for 2 production lacking str2
(Fig. 3.6, exp. 9). This resulted in production of 132 and 133 (Fig. 3.14, exp. 9). The same panel of
compounds was already found in previous expression experiments, where no O–MeT genes were
coexpressed (Fig. 3.10, exp. 5+6). All compounds were identified by comparing retention times
and mass fragmentation patterns to previously isolated standards. Detailed analysis of the mass
spectrum (ES+ mode) of the peak eluting at 7.23 min showed that only the unmethylated compound
132 was detected by its distinctive [M–H2O+H]
+ (185.2), [M+H]+ (203.2) and [M+Na]+ (225.1) ions
(Fig. 3.15 a).
Figure 3.14 A, coexpression of genes from 2 BGC; B, LCMS evaporative light–scattering (ELS) chromatograms of organic
extracts of A. oryzae NSAR1 expression strains (arbitrary units): exp. 9, A. oryzae NSAR1 + stpks1 + str11 + str8 + str10 + str9
str3; exp. 10, A. oryzae NSAR1 stpks1 + str11 + str8 + str10 + str9 + str2, inset trace shows DAD trace.
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Figure 3.15 Mass spectra in ES+ mode: a, exp. 9 at 7.2 min; b, exp. 10 at 7.3 min.
Bolineol 4 or strobilurin A 2 were not produced. As both 133 and 132 are lacking O–methylations, we
reasoned that either Str3 is not functional or, more likely, can only catalyse a second O–methylation
step. Interestingly, some of the transformants showed a slightly unhealthier phenotype than others
when growing on DPY agar. After LCMS analysis of the extracts, the unhealthier phenotype was
shown to correlate to a higher production of 133 (Fig. 3.16 A). Growing A. oryzae NSAR1 on DPY
agar plates containing various concentrations of 133, revealed a MIC of 0.4 mg/ml for 133 against
A. oryzae NSAR1 (Fig. 3.16 B).
In order to investigate the function of Str2 in strobilurin A 2 and bolineol 4 biosynthesis, str3 was
omitted from the expression system, by expression of the minimal BGC for 2 production lacking str3
(Fig. 3.6, exp. 10). This led to one major peak in the ELSD traces of the extracts of transformants
(Fig. 3.14, exp. 10). According to the retention time (tR = 7.3 min) and the mass spectrum, the major
compounds produced corresponded to 132 and 4. Bolineol 4 was detected to coelute with 132 by its
distinctive [M–H2O+H]
+ (229.2) and [M+Na]+ (269.3) ions (Fig. 3.15 b).
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Figure 3.16 A, phenotype and LCMS (DAD) traces of NSAR1 stPKS1 + str11+ str8 + str10 + str9 + str3 transformants 1–6; B,
toxicity test with compound 133 against A. oryzae NSAR1; DPY agar (5ml) was supplemented with various concentrations
(0.5, 1, 2, 5 mg) of compound 133 diluted in 200 µl DMSO, control only 200 µl DMSO.
A new minor compound 134 eluting at 8.9 min was also detected in the DAD trace of the pro-
ducing fungus (Fig. 3.14, exp. 10, inset trace). The amount produced was too little to purify the
compound and to elucidate the structure by NMR. Nevertheless, the mass spectrum correlates to
an O–methylated 132, matching its ions: [M+H]+ (217.2) and [M+Na]+ (239.2) ions (Fig. 3.17 A).
Further support for this structure is given by its characteristic UV spectrum (maxima at 212, 292 nm),
which matches UV spectrum for compound 132 (Fig. 3.17 B). In comparison to production of 133 in
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previous experiment (exp. 9), in this study with str2 being expressed, compound 133 could not be
detected, and neither could production of 2 be observed.
Figure 3.17 Analytical data of compound 134: A, mass spectra in ES+ mode of exp 10 at 8.9 min; B, UV spectra of compound
134 in comparison with compound 132.
Toxicity of bolineol
Overexpression of str2 in the absence of str3 resulted in extremely unhealthy A. oryzae cultures on
DPY agar. This was reasoned to be caused by bolineol 4 production. In order to test this hypothesis,
a toxicity test with 4 towards untransformed A. oryzae was conducted. Bolineol could not be isolated
from the expression host, due to coelution with 132. Therefore, desmethylbolineol 133 was isolated
from A. oryzae NSAR1 transformant of exp. 6 (30 mg/L culture) and was smoothly converted to 4 by
treatment with trimethylsilyldiazomethane (see section 6.5.6).182 The agar toxicity test revealed a
MIC of 0.1 mg/ml for 4 against A. oryzae NSAR1 (Fig. 3.18).
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Figure 3.18 Toxicity test with bolineol 4 against A. oryzae NSAR1. DPY agar (5ml) was supplemented with various
concentrations (0.1, 0.2, 0.3, 0.5, 1, 2 mg) of compound 4 diluted in 200 µl DMSO, control only 200 µl DMSO.
3.4 Results – In vitro activity tests with Str9
FAD dependent oxidase Str9 was found to catalyse the unusual rearrangement to form the toxophore
of 2 by heterologous expression experiments in A. oryzae. The rearranged product 133 was shown to
be a reduced congener of the expected aldehyde product 135 in vivo (Scheme 3.5 A). In order to verify
the in vivo results and to find the real product of the rearrangement, the sequence of Str9 should be
codon–optimised and expressed in Escherichia coli in N–terminal his–tagged form and purified as
soluble protein. Its activity should be tested in in vitro assays using purified prestrobilurin 128 as
substrate and essential cofactors FAD and NAD(P)H (Scheme 3.5 B).
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Scheme 3.5 Rearrangement catalysed by Str9: A, transformation catalysed by Str9 in vivo (heterologous expression in
A. oryzae NSAR1); B, postulated reaction catalysed by Str9 in vitro.
3.4.1 Prestrobilurin producing strain
Figure 3.19 Analysis of crude extract of A. oryaze NSAR1+stpks1+str8+str10+str11+str2+str3+str4 (KELIV04_4, Fig. 3.6, exp.
4): A, corresponding yellow crude extract; B, LCMS analysis (DAD and ELSD trace) of the crude extract; C, 1H NMR in CDCl3
showing only 128 signals.
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The appropriate substrate for in vitro assays with Str9 is prestrobilurin A 128 (Scheme 3.5).
The previously engineered heterologous expression strainA. oryazeNSAR1 containing stpks1+str8+str10+str11
+str2+str3+str4 (KELIV04_4, Fig. 3.6, exp. 4) showed production of very high titres of prestrobilurin A.
Extraction of one litre of the supernatant of fermented KELIV04_4, using the common extraction
method for A. oryzae (Section 6.5.4), yielded 150 mg of bright yellow crude extract (Fig. 3.19 A).
Prestrobilurin A was previously described to be a yellow powder.175,185 LCMS and proton NMR
analysis of the crude extract showed that the producing fungus almost exclusively produced the
substrate 128, as no contaminating peaks could be detected (Fig. 3.19 B + C). Therefore no further
purification step was required.
3.4.2 Expression and purification of recombinant Str9
The str9 gene was obtained as E. coli codon optimised N–terminal his–tagged clones, expressed in
its soluble form in E. coli BL21 (16 ◦C, 20 h, 0.1 mM IPTG, section 6.4.1) and purified by gravimetric
Ni–NTA affinity purification (Fig. 3.20 A, section 6.4.2).
Figure 3.20 A, SDS–PAGE of Ni–NTA purified His6–Str9, 12%- polyacrylamide gel, protein pre–stained marker (M), lysate
(L), cell pellet (P), Flow–through (D), Elution fractions in [mM] imidazole with combined elution fractions after Ni–NTA of
His6–Str9 showing its yellow colour; B, UV/VIS spectrum of purified His6–Str9 with FAD specific wavelength maxima at 368
and 455 nm.
The recombinant protein His6–Str9 was shown to have a bright yellow colour suggesting its holo–form
with cofactor FAD bound to the enzyme (Fig. 3.20 A). This was verified by ultraviolet spectroscopy
showing the characteristic absorption maxima for FAD at 368 and 455 nm (Fig. 3.20 B). The protein
sequence of Str9 was confirmed by mass spectrometry (Dr. Jennifer Senkler, Braun group, Leibniz
Universität Hannover), using the methods of Klodmann and coworkers (Appendix 7.2.2 Fig. 7.5).191
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3.4.3 In vitro activity test with Str9
Initial in vitro assays using purified prestrobilurin 128, recombinant, purified His6–Str9 and NAD(P)H
in various buffers in air were performed, but no oxidised and rearranged product 135 could be
observed by LCMS analysis (Fig. 3.21). The reason for this was most likely the observed insolubility
of the substrate 128 in the aqueous buffer system.
Figure 3.21 LCMS analysis of in vitro assay with substrate 128 and purified enzyme Str9 in comparison to a control without
Str9 (DAD traces).
However, usage of a system containing a high concentration of ethanol (50%) led to conversion
of trace amounts of the substrate. A product corresponding to 135 could clearly be observed by
LCMS analysis showing characteristic UV maxima for strobilurins and corresponding mass spectra
(Fig. 3.22, 3.23, 3.24).
Figure 3.22 LCMS analysis of in vitro assay with substrate 128 and purified enzyme Str9 in comparison to a control missing
Str9 with an excess of ethanol in the assay mixture (DAD traces).
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Figure 3.23 ES− and ES+ extracted ion chromatograms of in vitro assay with substrate 128 and purified enzyme Str9 in
comparison to a control missing Str9 with an excess of ethanol in the assay mixture.
Figure 3.24 Chemical analysis of product 135 of in vitro assay with Str9: A, structure of product 135; B, UV chromatogram;
C, corresponding ES− and ES+ spectra.
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3.5.1 FAD dependent oxidase Str9 accomplishes both the oxidation and the
rearrangement
Previous isotopic labelling experiments postulated that the released polyketide prestrobilurin
128 requires oxidation and rearrangement to form the key acrylate moiety of the strobilurins
(Scheme 3.6).48,184 Heterologous expression of the FAD–dependent oxidase encoded by str9 in
the presence of 128 catalysed the oxidative rearrangement in vivo involving the highly unusual mi-
gration of a carboxylate. The same reaction was also observed in in vitro assays with the recombinant,
purified His6–Str9. Based on the in vivo and in vitro results it is proposed that epoxidation of the 2,3
olefin of 128, followed by Meinwald rearrangement of 136 would give the aldehyde intermediate
135 (Scheme 3.6).
Scheme 3.6 Biosynthetic steps to strobilurin A 2.
Related oxidative rearrangements involving an epoxide intermediate are proposed for the biosynthe-
sis of aspyrone 13774 and bartanol 138192 (Scheme 3.7 A+B). Last year, Tang and coworkers found a
family of CrtC–type (carotenoid 1,2–hydratase) enzymes, which can catalyse similar rearrangements
of epoxides. For the particular CrtC–enzyme PenF this rearrangement is a Meinwald rearrangement
on the pathway to penigequinolone A 139 (Scheme 3.7 C).193
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Scheme 3.7 Proposed oxidative rearrangements similar to Str9–catalysed reaction in strobilurin biosynthesis: A, biosynthesis
of aspyrone 137; B, biosynthesis of bartanol 138; C, biosynthesis of penigequinolone A 139.
In the strobilurin rearrangement, formation of radical intermediates, as involved in similar processes
during the mechanism of methylmalonate mutase194, seems unlikely. A cationic mechanism via e.g.
140 is consistent with other Meinwald processes195 and is proposed because it shows remarkable
structural similarities to the biosynthesis of the tropane alkaloid hyoscyamine 141 from littorine
142, in which a cytochrome P450 enzyme is known to catalyse the key rearrangement of 142.196
Calculations suggest that the lowest–energy pathway for this conversion involves rearrangement
of a cationic species such as 143 obtained by facile oxidation of an intermediate radical 144, with
acceleration promoted by partial deprotonation of the alcohol and partial protonation of the carboxyl
(Scheme 3.8).196
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Scheme 3.8 Proposed mechanism of the strobilurin rearrangement (A) and comparison with a proposed cationic rearrange-
ment mechanism of 2R–littorine 142 (B).
In the in vivo expression experiments the product of the unusual rearrangement was shown to
be 133, which is probably a shunt product in A. oryzae, as in vitro studies with Str9 resulted in
aldehyde 135 and A. oryzae is known to reduce aldehydes easily.155 In addition, intermediate 135
seems to be highly reactive and in the absence of other enzymes it appears to undergo rapid retro–
Claisen reaction in A. oryzae to give the observed carboxylic acid 132 (Scheme 3.9). This step is
linked to the proposed oxidative ring contractions involved during xenovulene A 73 biosynthesis
which are likewise catalysed by FAD–dependent enzymes AsR4 and AsR6 in Sarocladium schorii.90
However, Str9 showed no significant sequence homology to AsR4, ASR6 and PenF, suggesting that
Str9 accomplishes both the oxidation of 128 and the rearrangement to form 135.
It is likely that in Strobilurus species rapid enolisation of 135 would give the β–methoxyacrylate
skeleton 129 and methylation (catalysed by Str2 and Str3) would give strobilurin A 2 directly
(Scheme 3.9).
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Scheme 3.9 Biosynthetic steps to strobilurin A 2 and bolineol 4 including shunt pathways in A. oryzae observed in expression
experiments.
3.5.2 Role of the GMC oxidase Str4 and SDR Stl2 in regulation of strobilurin
and bolineol production
Heterologous expression experiments in A. oryzae revealed the reductive pathway to 133 and bolineol
4, in which the SDR is possibly catalysing the reduction (Scheme 3.9). As mentioned before, the
reduction occurs both in the presence of SDR Stl2 (exp. 1, exp. 8) and, in absence of Stl2 in heterologous
host A. oryzae (exp. 7).
Together with oxidase Str4, Stl2 could be involved in controlling the selective production of bolineol
or strobilurin in S. tenacellus. Str4 belongs to the GMCO superfamily, which are enzymes catalysing
the oxidation of primary alcohols to aldehydes. It was shown that in the presence of Str4 and in the
absence of the reductase Stl2, the pathway produces strobilurin A 2 and the shunt 132 (exp. 2). In
the absence of Str4, and the presence of Stl2, the pathway produces bolineol 4 instead (exp. 8). This
suggests that the selective production of 2 and 4 is possibly regulated by control of the individual
promoters. In the in vivo expression experiments using A. oryzae as host the more crude control of the
promoters (e.g. exp. 1) produces both compounds.
Another possible pathway from bolineol to strobilurin would include alcohol oxidation and subse-
quent O–methylation, but there was no LCMS evidence for a mono–methyl–intermediate.
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3.5.3 Role of the O–MeTs Str2 and Str3
Expression results showed that O–methylation in strobilurin biosynthesis is regiospecific. Both
O–MeTs Str2 and Str3 catalyse unique steps in the biosynthesis to 2. Even though they share 66%
amino acid identity, these two O–MeTs showed different reactivity towards their substrates. In
strobilurin A biosynthesis the initial O–methylation is selectively catalysed by Str2 at the carboxyl
group of 129 to form 145. Further O–methylation by Str3 gives 2 (Scheme 3.10). As in A. oryzae the
aldehyde 135 is reduced to the alcohol 133, also in absence of the reductive enzyme Stl2, we could
not show existence of neither 129 nor 145 in vivo. Nevertheless, the expression experiments showed
that Str2 is the O–MeT which catalyses the transfer of the methyl group to the carboxyl group of 133
as the final step of the biosynthesis to bolineol 4 (Scheme 3.10).
Scheme 3.10 Biosynthetic steps to strobilurin A 2 and bolineol 4 including methylation steps catalysed by Str2 and Str3.
In nature, there are several examples for O–MeTs which share a very similar amino acid sequence
but show different substrate selectivity or regioselectivity. For example, two O–MeTs from Clarkia
breweri which share 83% identity: IEMT and COMT, which methylate eugenol 146/ isoeugenol 147
and caffeic acid 148/ 5-hydroxyferulic acid 149, respectively (Scheme 3.11).197
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Scheme 3.11 O–methylation of eugenol 146/ isoeugenol 147 and caffeic acid 148/ 5-hydroxyferulic acid 149.
In general, O–methyltransferases have a huge influence of diversity of natural products. Methylation
of hydroxyl groups lead to a decreased water solubility and favors excretion of a metabolite from the
cell which affecting the biological activity.198
According to plate toxicity tests with 4 and 133, O–methylation by Str2 caused four times higher
toxicity toward A. oryzae. Similar experiments testing strobilurin A fungicidal activity revealed
a MIC of 25 µg/ml against a variety of plant pathogenic fungi growing on agar.199 Therefore, a
second O–methylation leads to 16 times higher toxicity against fungi compared to the unmethylated
compound 133, and four times higher compared to the singly methylated 4. On account of these
results, it can be assumed, that the toxophore group of strobilurins is more potent in its methylated
form. This is in agreement with other natural products, like pterostilbene 150, which bears a higher
antifungal activity due to its two methoxyl groups, than its desmethylated precursor resveratrol 151
(Scheme 3.12 A).200,201
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Scheme 3.12 O–methylation secondary metabolite biosynthesis: A, O–methylation of resveratrol 151 to pterostilbene 150; B,
O–methylation in pradimicin 152 biosynthesis.
In experiment 10, a new compound 134 was detected. The amount produced was enough to detect
it, but too little to isolate it for structure elucidation. Nevertheless, it is likely that O–MeT Str2 also
transfers a methyl group to the Claisen product 132, as its structure is very similar to the natural
substrate 133 and is produced in high titres in A. oryzae. The amounts of compounds produced in the
expression host can vary significantly from the natural producer, probably due to wrong balance of
expression rate of genes, based on random choice of promotors.
When O–MeT Str3 is expressed in the absence of Str2 no methylation product was found. Therefore,
we reasoned that O–MeT Str3 requires O–methylation by Str2 prior to its own methylation step
to 2, as production of strobilurin A was detected when both O–MeTs were expressed (exp. 1+2),
but not by expressing them individually (exp. 9+10). This is in contrast to observations made in
pradimicin 152 biosynthesis, where one of the two regiospecific O–MeTs, PdmF, was shown to
catalyse O–methylation regardless of a first methylation step by PdmT (Scheme 3.12 B).202
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Overall, these results contribute to the understanding of how nature has generated the valuable
class of strobilurin agricultural used fungicides. On the basis of in vivo heterologous expression
experiments in A. oryzae a minimal gene set for the production of bolineol 4 and strobilurin 2 was
elucidated. From previous studies by Risa Nofiani it is already known, that production of PKS
precursor benzoyl CoA from phenylalanine involves expression of str11 (PAL), str8 (NHI) and str10
(CoA ligase). Coexpression with the core biosynthetic gene stpks1 (PKS) revealed production of
prestrobilurin 128.175,185
In this thesis, it was shown that addition of str9 (FMO) and str2/3 (O–MeTs) to the previous expression
system was sufficient in order to produce 2 and 4 in vivo (exp 7). The FAD dependent oxidase Str9 was
found to catalyse the key oxidative rearrangement of a polyketide backbone (128) to form the crucial
β–methoxyacrylate toxophore of the strobilruin fungicides, most likely in a Meinwald rearrangement.
This was verified in vitro by conversion of the substrate 128 to the rearranged product 135 by the
purified enzyme (His6–Str9). However, to understand the mechanism, further optimisation of the in
vitro assay and experiments with isotopic labelled prestrobilurin derivatives are required.
The expression results further revealed that regiospecific O–methylation, by two O–MeTs from 2
BGC, Str2 and Str3, contributes to a better understanding of the detailed biosynthetic steps to form
the pharmacological toxophore of the strobilurins. Str2 was shown to methylate prior to methylation
by Str3 to give 2. In the reductive pathway to bolineol, which is probably catalysed by Stl2 (SDR)
in S. tenacellus, the O–MeT Str2 is responsible for methylation as the final step of the biosynthesis.
Activty tests revealed that the rearranged, unmethylated intermediate 133, the singly methylated
bolineol and the doubly methylated 2 are toxic towards A. oryzae. With increased number of methyl
groups the toxicity towards A. oryzae was shown to be increased.
In addition to the elucidation of the biosynthetic pathway to 2 and 4, two possible shunt pathways
were discovered in A. oryzae. The product of the oxidative rearrangement was shown to be highly
active in the expression host and was rapidly shunted in a retro–Claisen reaction to the carboxylic
acid 132, missing the β–arm of the molecule. It is possible that this "shunt" pathway is a kind of self
defence mechanism in A. oryzae to protect itself from production of 2, which is highly toxic. Also the
reductive pathway to bolineol, which was catalysed by an endogenous reductase from A. oryzae in
the absence of Stl2 (SDR), could display the same kind of self defence mechanism. In activity tests it
was shown that 4 is less toxic than 2.
There are still a number of unsolved questions about the biosynthesis of strobilurins, which could be
addressed in the future. S. tenacellus produce a range of modified strobilurins, such as the chlorinated
strobilurin B 127. However, the cluster encodes no obvious halogenase gene that could be involved in
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its production. It is possible that unknown proteins encoded in, or near, the BGC (e.g. str1) may form
a new class of halogenases. It is also possible that proteins encoded by str5/str6 (hydrolases) which
appear to have no chemical role in the biosynthesis of 2 and 4, could be involved in tailoring events
in the biosynthesis of other, modified strobilurins. Furthermore, the domain organisation of StPKS
differs from other highly reducing iterative fungal PKS, as it appears to include very unusual partial
hydrolase and C–MeT domains downstream of the usually terminal ACP. It would be interesting
to study these domains on the molecular base, also in order to understand how the highly unusual
E,Z,E triene 128 is built.
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4.1 Introduction
The unusual bicyclic 10–membered macrolide, SCH–642305 (SCH 3, Fig. 4.1), was first isolated
from fermentation broth of the fungus Penicillium verrucosum (culture ILF–16214) in 2003 as a
novel bacterial DNA primase inhibitor (EC50 of 70 µM).16 SCH is structurally related to the fungal
metabolite brefeldin A 153 which has been previously investigated. It is therefore useful to begin
with a review of what is known of its biosynthesis.
4.1.1 Brefeldin A biosynthesis
Brefeldin A 153 is a bicyclic polyketide isolated from various filamentous fungi such as Eupenicillium
brefeldianum ATCC 58665.203,204,205 153 consists of a cyclopentane fused to a 13–membered macrolide
which is structurally related to SCH 3 (Fig. 4.1). Brefeldin A 153 was shown to have antiviral, antifun-
gal and antitumor properties.206 Nevertheless, 153 is mainly used to study protein transport among
eukaryotes as it is a potent inhibitor for vesicle formation and transport between the endoplasmic
reticulum and Golgi apparatus.207,208,209
Figure 4.1 Incorporation of labelled sodium [18O2, 2-3H3]–acetate and 18O2 into 153.
The biosynthetic origin of 153 was studied by labelling studies, that revealed it to be an octake-
tide.210,211,212 Feeding sodium [18O2, 2-3H3]–acetate and 18O2 revealed that oxygen atoms at C-1
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and C-15 are derived from acetate and the two hydroxyl groups at C-4 and C-7 are derived from
atmospheric oxygen (Fig. 4.1).212
Tang and collaborators found a likely bref BGC in Eupenicillium brefeldianum, which consists of a
hrPKS, a thiohydrolase and four P450 encoding genes (Fig. 4.3). Reconstitution of the hrPKS (Bref–
PKS) and the partnering thiohydrolase (Bref–TH) in yeast and in vitro led to production of a linear
triene octaketide 154, which possesses the same length (16 carbons) and expected β–reduction pattern
for formation of 153. Expression of only Bref–PKS in absence of Bref–TH yielded a linear nonaketide
155 (Scheme 4.1 A).205 These results indicated that Bref–TH has a critical role in chain release control
of the octaketide product from Bref–PKS. It is important to notice that the polyketide starter unit at
C-15 remains hydroxylated and that all products of Bref–PKS are E configured trienes.
Scheme 4.1 A, BGC for brefeldin A 153 (bref BGC) in P. Brefeldianum; B, chain–length control of the hrPKS product of 153
biosynthesis; C, initial proposal for macrolactonisation in 153 biosynthesis.205
The macrolactonisation is not yet elucidated for 153. Feeding a labelled brefeldin derivative ([4–2H]–
brefeldin C 156) to E. brefeldianum led to biotransformation of 156 to [4–2H]–brefeldin A, demonstrat-
ing the C-7 hydroxylation to be a late stage event, that does not contribute to the cyclopentane ring
closure (Scheme 4.2). This suggests that the ring formation in 153 biosynthesis does not reply on C-7
oxygenation.210
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Scheme 4.2 Conversion of [4–2H]–brefeldin C to [4–2H]–brefeldin A by E. brefeldianum.
Tang and coworkers proposed a mechanism where the Bref–TH performs off–loading and lactonisa-
tion using its catalytic His-276 to deprotonate the OH-15 of 154 yielding a suitable nucleophile for
lactonisation (Scheme 4.1 B).205 However, all observed in vitro products, 154, 155 and some minor
compounds (not shown) were linear.205 This suggests the necessity of closing the cyclopentane ring
first by bringing the nuclephile closer to favour the attack to perform lactonisation (Scheme 4.3 B).
The mechanism of the cyclopentane ring formation is not yet elucidated. Two groups have made
different proposals. Mabuni et al. suggested a mechanism which involves a C-4/C-5 epoxide
intermediate 157 and subsequent ring opening (Scheme 4.3 A). The latter requires an unnatural
Z C-9/C-10 olefin which has to be put in place by post tailoring steps.212 Tang and coworkers
suggested a radical–mediated cyclisation catalysed by one of the four P450 enzymes encoded in bref
BGC (Scheme 4.3 B).163,205 Either the PKS–bound intermediate 158 or the isolated linear acid 154 can
be the substrate for the P450–catalysed C-C coupling (Scheme 4.3 B).205
Scheme 4.3 Two proposed mechanism for macrolactonisation in 153 biosynthesis: A, mechanism proposed by Mabuni et
al.212; B, radical mechanism by Tang et al., adapted from Tang et al., 2016.163
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4.1.2 Isolation of SCH and related compounds
In 2011, the endophytic filamentous ascomycete Phomopsis sp. CMU–LMA was shown to produce 3
alongside a variety of other polyketides (Fig. 4.2).8 This strain showed a 20 times higher production
of SCH (50 mg/l) than reported in previous studies with Penicillium verrucosum.16 In addition to 3,
the other produced compounds were classified in four groups: A, substituted 10–membered lactones
SCH–642305 3, LMA–P1 159; B, 14–membered lactone benquoine 160; C, six–membered lactones
LMA–P2 161, DHTO 162; and D, linear derivatives LMA–P3 163, benquinol 164 and DHTTA 165
(Fig. 4.2).8
Figure 4.2 Compounds isolated from Phomopsis sp. CMU–LMA.8
In this study, the focus is on the major compound 3. SCH possesses not only antibacterial properties
but also antiviral features (against HIV–1 Tat protein) and a limited fungicide activity.213,214 The
structure of SCH was determined by MS/NMR analysis and absolute configuration of the asymmetric
centers was determined by X–ray crystallographic analysis of the para–bromobenzoate derivative of
3.16 Due to its possible usage as an antibiotic against multi drug resistance Staphylococcus aureus and
as a bioactive compound in AIDS therapy, a number of total syntheses were published between 2005
and 2009.213,215 SCH 3 appears to be related to brefeldin 153 because it is a bicyclic macrolactone in
which the lactone is formed to an alcohol at the penultimate chain position. However, unlike 153
(C16) the chain of 3 is shorter (C14), the carboxylic ring is 6–membered versus 5–membered and ring
junction is at C-3 rather than C-5 in brefeldin. However, it is easy to imagine how a brefeldin–like
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thiohydrolase could provide a shorter polyketide in the case of SCH, and how a similar ring–forming
process could form the 5– and 6–membered carbocycles.
4.1.3 Gene cluster and first biosynthetic studies of SCH
In silico analysis of sch BGC
In previous studies, the genome of Phomopsis CMU–LMA was sequenced (by Jamal Ouzzani and
Emilie Adelin, 2005, ICSN Gif–Sur–Yvette France) and 10 years later the raw data was assembled
by Daniel Wibberg (CeBiTec, Bielefeld). Bioinformatic studies, conducted by Francesco Trenti (Cox
group, Hannover), revealed a putative sch BGC by homology searches using brefPKS.85 The Phomopsis
sch BGC was shown to be homologous to bref BGC, and was shown to contain genes for a hrPKS
(schPKS), a hydrolase (schR1), two cytochrome P450s (schR2/R3), a serine–hydrolase (schR4), a NAD
dependent oxidoreductase (schR5), a transporter (schR6), and an FAD dependent oxidase (schR7,
Fig. 4.3). SchPKS and Bref–PKS were shown to share 56% sequence identity and the trans–partnering
hydrolases Bref–TH and SchR1 were found to share 66% sequence identity at amino acid level.85
Additional in silico analysis displayed another homologous cluster (PVSCH BGC) in a known SCH
producing strain Penicillium verrucosum, which consists of only four genes, including a hrPKS
(PVSCH–PKS), a thiohydrolase (R1), a P450 encoding gene (R3) and an FAD dependent oxidase
encoding gene (R2, Fig. 4.3).16
Figure 4.3 Comparison of homologous bref BGC from P. brefeldianum, sch BGC from Phomopsis sp. and sch BGC from
P. verruscosum. Artemis double ACT was used for the pairwise comparison at translated nucleotide level, setting a threshold
at 20. Red lines imply genes on the same DNA strand, blue lines for genes on opposite strands; done by Francesco Trenti.85
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The comparison of all three homologous clusters revealed a similar composition of genes. All BGC
contain a conserved hrPKS encoding gene and a gene encoding an α/β–hydrolase.205 An FAD
dependent oxidase encoding gene was only found in both sch BGC (schR7, R2), but not in bref BGC
(Fig. 4.3). The number of P450 genes differ in the compared clusters from one (sch BGC, P. verrucosum),
two (sch BGC, Phomopsis) to four in bref BGC. This might indicate gene duplication for the P450 genes
(Fig. 4.3). As in P. verrucosum only one copy of a P450 gene is present in the PVSCH BGC, suggesting
that one P450 would be sufficient for the biosynthesis of 3. The putative sch BGC was later linked to
production of SCH by disruption of the core hrPKS gene conducted by Francesco Trenti.85
Brefeldin 153 and SCH 3 share a common structure and highly homologous genes including the
core hrPKS and partnering hydrolase, which suggests a similar chemistry for the biosynthesis.
According to 153 biosynthesis, also biosynthetic production of 3 needs a PKS product with a terminal
hydroxyl group (O-13), an all E configured triene system and chain–length control most likely by
SchR1 (hydrolase, in accordance to Bref–TH). However, the composition of post tailoring genes in
both clusters (sch BGC + bref BGC) differs. Sch BGC occupies two genes encoding for cytochrome
P450s whereas bref BGC contains four P450 encoding genes (Fig. 4.3). Furthermore the genes schR4,
schR5 and schR7 show no homologue in the bref BGC, suggesting a distinctive pathway for SCH
biosynthesis.
Feeding studies of SCH
Feeding [1-13C]–acetate confirmed 3 to be a highly reduced heptaketide, with a consistent alternating
pattern of incorporation of the label (Fig. 4.3).85 This result excluded atom rearrangement during
the formation of the 6–membered ring and the oxidation pattern of 3 suggested post–elongation
oxidative events, especially regarding the hydroxyl group at position C-4, which is probably derived
from atmospheric oxygen.85
Proposed biosynthetic pathway for SCH
Until 2018 there was not much known about the biosynthesis of SCH. In 2006, Snider and Zhou re-
ported a total synthesis towards 3. Their strategy was based on transannular Michael cyclisation of a
hypothetical 14–membered lactone 166 which is structurally related to mutolide 167 (Scheme 4.4).215
Mutolide is a polyketide which was isolated in 2000 from fungus F–24‘707.216 The biosynthetic origin
of the carbon skeleton of 167 is derived from seven acetate/malonate units which was shown by
feeding experiments with sodium [1–13C]–acetate (Scheme 4.4). Cultivation of the producing strain
in a closed 18O2 atmosphere indicated the incorporation of both hydroxyl oxygens by monoooxyge-
nases.216 The hypothetical biosynthetic route to SCH 3 proposed by Snider and Zhou on the basis of
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the fungal metabolite mutolide 167 is supported by their synthesis. However, 167 has never been
isolated from any 3–producing strain, and it requires a 5Z–configured olefin.
Scheme 4.4 A hypothetical biosynthetic route to SCH 3 proposed by Snider and Zhou on the basis of the fungal metabolite
mutolide 167.215,216
In contrast, the isolation of the all E–configured benquoine 160 revealed a different hypothesis for the
biosynthetic pathway of SCH in which 160 would be the precursor. Adelin et al. proposed two routes
to SCH 3 starting from benquoine 160 (Scheme 4.5). Route A involves carbonyl protonation to give 168
followed by intramolecular rearrangements, whereas route B starts with a series of oxidoreductions
to yield 169 and further deprotonation and subsequent enzyme–catalysed Michael cyclisation results
in 170. Reduction of the carbonyl at C-5 would yield 3 (Scheme 4.5).8 An indication that route A is
probably wrong is given by the C-4/C-5 olefin geometry switch, where the E configuration of 168 is
transformed to the Z configuration of 171 without any reason. Furthermore, the proposed cationic
chemistry of route A is more common in terpene biosynthesis and typically not found in fungal
polyketide biosynthesis.
Scheme 4.5 Two different biosynthetic routes (route A + B) to SCH proposed by Adelin et al. starting from benquoine 160.8
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Knockout studies revealed a new biosynthetic route to SCH
Previous knockout studies conducted by Francesco Trenti (Cox group, Hannover) confirmed the sch
BGC by deletion of the core hrPKS and resulting abolition of SCH 3 production. As production of
DHTTA 165 and LMA–P1 159 were also abolished due to knockout of schPKS in the wt fungus, it
seemed that these compounds may all be produced by the same PKS, but not necessarily on the same
biosynthetic pathway. Evidence is given by occupying the same number of carbons (14 carbons) and
a similar double bond system. Further the C-13 hydroxylation involved in the macrolactonisation is
conserved among the mentioned compounds and compound LMA–P1 159 shows the same bicyclic
system as 3.85 In contrast, DHTO 162, LMA–P3 163 were still be observed from PKS KO extract
suggesting them to arise from different pathways.85
In P. verruscosum only one copy of P450 encoding gene (R3) might be sufficient to produce 3 (Fig. 4.3).
Individual gene knockout of both of the P450 encoding genes from the sch BGC of Phomopsis led to
abolition of SCH suggesting that both P450s are essential for 3 biosynthesis in Phomopsis.85 Deletion
of one of the P450s (schR3) resulted in accumulation of new compound 172 and knockout of FAD
dependent oxidase encoding gene schR7 led to observation of another new compound 173. Therefore
the SCH oxidations at C-4 and C-7 are likely inserted by the two P450s, which is in agreement with
the labelling studies for 153 biosynthesis (Section 4.1.1). Oxidation at C-4 is possibly introduced
by SchR2 and hydroxylation of C-7 is probably catalysed by SchR3.85 Disruption of the other P450
encoding gene schR2 led to abolition of 3 production but did not produce any new intermediate, as
also observed for disruption of schR5. However, the abolition of 3 production for all KO mutants
(schPKS, schR2, schR3, schR5, schR7) showed that all these genes were essential for SCH biosynthesis.
Attempts to knockout the serine hydrolase encoding gene schR4 were not successful as the gene
schR4 was not disrupted in the obtained mutants.85
In accordance to the knockout studies of SCH, the proposed biosynthesis of 3 would start with
benquoine 160 being the product of the highly reducing PKS in combination with thiohydrolase
SchR1, leaving the 2E, 4E, 8E triene system in place (Scheme 4.6). The macrolactonisation might
arise spontaneously during or after the chain release. Epoxidation by cytochrome P450 SchR2 at
the 4E olefin and opening to the observed compound 172, with subsequent double bond migration
could be followed by action of the second P450 SchR3 inserting an hydroxyl group on C-7, yielding
observed intermediate 173. Thus the knockout experiments conducted by Francesco Trenti proved
the C-5–olefin to be Z. The FAD dependent oxidase SchR7 could convert the C-7 hydroxyl group
to a keto group, suggested by in silico studies. SchR7 was found to share 28% sequence identity to
a known flavoprotein converting hydroxyl groups to ketone from ascomycete Neurospora crassa.85
Putative reduction of the C-8/ C-9 olefin by oxidoreductase SchR5 would lead to the enolate which
could perform a Michael–type cyclisation generating the 6–membered ring (Scheme 4.6).85
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Scheme 4.6 Proposed biosynthesis of SCH–642305.
Although 3 and 153 share a very similar structure, as well as homologue genes for the hrPKS and
hydrolase, the biosynthesis appears to be different. Both compounds showed similar P450–mediated
oxidation at C-7 after chain release. For 153 biosynthesis it was found that the C-7 oxidation happened
after the 5–membered ring formation (shown by feeding studies, Section 4.1.1).210 The occurrence
of 172 and 173 in knockout studies showed that hydroxylation in SCH biosynthesis occurs before
the 6–membered ring is arranged, followed by oxidation to the ketone.85 This suggests a different
mechanism of ring formation in the biosynthesis of 153 and 3.
4.2 Project aims
Although SCH has a rather simple structure, the molecular basis of its biosynthetic steps have not
been elucidated. Initial knockout studies by Francesco Trenti elucidated a gene cluster responsible
for SCH production and discovered genes essential for production of 3. The characterisation of
two metabolites 172 and 173 accumulating upon those knockouts gave initial details about the
order of steps in the biosynthesis. However, targeted gene deletion was found to be not efficient
in the producing fungus due to unreliable production of metabolites. In addition, newly produced
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intermediates were rapidly shunted or degraded by the cell and therefore making subsequent
analysis complex.
To overcome the KO difficulties, A. oryzae NSAR1 should be used as a host organism to heterologously
express genes from the sch BGC in vivo. Heterologous expression is a more reliable method to resolve
the biological mechanisms that happen in vivo during its biosynthesis, with particular interest to
answer the question about the chemistry behind the 6–membered ring formation and in–turn form a
better hypothesis about brefeldin A biosynthesis. With this knowledge new hybrid metabolites could
potentially be engineered. In order to test if SCH biosynthesis can be re–established in A. oryzae
NSAR1, 3 was fed to the host organism in initial biotransformation experiments.
4.3 Results – Re–establish SCH biosynthesis in heterologous host
A. oryzae NSAR1
4.3.1 Biotransformation of SCH in expression host A. oryzae NSAR1
For expression experiments, heterologous host A. oryzae NSAR1 was chosen. In 2011, Adelin and
coworkers reported that incubation of Sch–642305 3 with Aspergillus ochraceus ATCC 1009 resting
cells led to three new SCH derivatives through an oxidoreduction of the six-membered ring of
the molecule. Reduction of the double bond gave compound 174, which subsequently undergoes
carbonyl reduction to 175 and ring hydroxylation to 176 (Fig. 4.4).217
Figure 4.4 Structure of Sch–642305 3 and its three major derivatives (174, 175 and 176) obtained from biotransformation of 3
by Aspergillus ochraceus ATCC 1009.
In order to verify if A. oryzae also transforms SCH 3 to the previously observed derivatives, a feeding
experiment was conducted. To a growing culture (2 days) of A. oryzae in DPY medium (4 x 100 ml),
7 mg of 3 were fed (diluted in 1 ml of DMSO). Extraction of the culture on day 5 of fermentation and
subsequent submission to LCMS analysis revealed two new compounds eluting at similar retention
times (tR = 5.0 min and tR = 5.5 min) as SCH (tR = 5.3 min, Fig. 4.5 A). SCH was only observed in
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traces. The nominal mass of both detected compounds was 254, two mass units higher than the
mass of SCH (252 g/mol). Observed mass fragmentation in the positive mode showed the same
fragmentation pattern for all three compounds. The sodium adduct, the proton adduct as well as
fragments corresponding to two losses of water (for 174 and 177) and three losses of water (for
3) were observed (Fig. 4.6). This indicates that the new compounds 174 and 177 are most likely
derivatives of SCH.
Figure 4.5 LCMS analysis of feeding experiment (3 to A. oryzae NSAR1): A, ES+ traces of a control (A. oryzae NSAR1 wt), a
standard of 3 and fed 3 to NSAR1; B, ELSD trace of 3 and fed 3 to NSAR1.
Further evidence is given by a very similar UV maxima for the three compounds (UVmax = 216–219,
Fig. 4.6). Additional HRMS analysis of compound 174 revealed the chemical formula (ES− C14H21O4
calc. 253.1440, measured 253.1440). According to the ELSD trace of the feeding extract, high amounts
of 174 were produced, but neither SCH nor 177 could be observed, suggesting very low yields
(Fig. 4.5 B). Using preparative LCMS, 1.2 mg of 174 were isolated. Compound 177 could not be
purified due to very low titre. Also HRMS analysis of this compound was prevented due to the same
reason.
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Figure 4.6 Mass spectra (ES+) and UV chromatograms of 3, 174 and 177.
NMR analysis (500 MHz) of 1.2 mg of 174 in CDCl3 provided good quality data. The elucidated
structure was found to be the same reduced SCH analogue 174, previously observed in Adenlin and
coworkers experiment.217 The 13C as well as the proton signals showed to be almost identical, with
our data giving additional information (Table 4.1). The second newly observed compound 177 could
be an isomer of 174 as it showed the same mass fragmentation pattern and UV maximum, but a
slightly different retention time.
In conclusion, these results show that our heterologous expression host, A. oryzae NSAR1, also
reduces SCH to 174 and a similar compound 177 through biocatalysis. The structure of the second
observed minor compound 177 could not be elucidated due too very low titres. Also Adelin and
coworkers found a minor compound with m/z = 254 eluting prior to SCH, but were not able to
characterise its structure due to the same issue.217 In our experiment only compound 174 and
177 were observed, whereas biotransformation experiments with SCH in A. ochraceus yielded two
additional derivatives of SCH: 175 and 176 (Fig. 4.4). One explanation for the difference could be
the different species used (here we used A. oryzae instead of A. ochraceus) or compounds 175 and
176 were built after day 5 of fermentation which was suggested by kinetic monitoring studies of the
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biotransformation conducted by Adelin et al.217 They showed that only 174 was built after 5 days
and compound 175 was only started to be formed from day 5 on. Compound 176 even started to
appear at day 7 suggesting it to be a direct product of 174.217
Table 4.1 Chemical shifts of 1.2 mg 174 in CDCl3
Compound 174 (1.2 mg, CDCl3, 500 MHz) Adelin et al. (2011), CDCl3
Atom δC / ppm δH / ppm J / Hz δC / ppm δH / ppm J / Hz
1 210.5 - - 211 - -
2a 35.8 2.24 dddd (14.3, 4.8, 2.4, 0.7) 35.8 2.2 m
2b 35.8 2.6 ddt (14.3, 6.4, 0.7) 35.8 2.66 m
3a 32.5 1.85 ddd (14.1, 4.8, 2.2) 32.5 1.78 m
3b 32.5 2.15 dddd (14.0, 6.1, 3.5, 2.3) 32.5 1.94 m
4 71.0 4.13 q (2.7) 70.9 4.1 m
5 41.8 2.37 dtd (12.1, 6.6, 2.2) 41.7 2.36 q (7.3)
6 47.0 2.66 m 47.8 2.66 m
7 22.1 1.47 m 21.2 1.35 m
8 22.7 1.20, 1.76 m 22.2 1.35 m
9 25.2 1.40, 1.60 m 22.7 1.35 m
10 33.2 1.35 m 33 1.35 m
11 74.1 5.1 m 74.1 5.07 m
12 173.2 - - 173.2 - -
13 39.7 2.60, 2.76 m, d (5.4) 39.8 2.66 m
14 19.7 1.26 d (6.5) 19.7 1.23 d (6.4)
4.3.2 Yeast recombination, Gateway cloning and Transformation of A. orzyae
For successful expression of SCH genes from Phomopsis sp. CMU–LMA in the heterologous host
A. oryzea NSAR1, RNA was isolated and transcribed to cDNA in order to eliminate all intron posi-
tions. The SCH producing strain was grown for 5 days in liquid PDB medium without shaking at
30 ◦C prior to RNA isolation. The synthesised cDNA was used as a template to amplify genes for
yeast homologous recombination. As described previously for cloning of mfpks2 (Section 2.6.1), the
vector pE–YA was used to assemble the schPKS gene (8 kb), in four DNA fragments of around 2 kb
each. Synthesised cDNA was used as a template for amplification of four parts of schPKS, resulting
in faint bands on the gel (Scheme 4.7 A). Sequencing results of the constructed pE–YA–schPKS
(KELIII02A(No2_3)) indicated that four predicted introns were still in place probably due to contami-
nated cDNA with gDNA. As RNA isolation was difficult and cDNA synthesis not very efficient for
the large PKS transcript, the remaining introns were removed by a manual yeast recombination based
strategy. The gene was amplified in 7 parts from vector KELIII02A(No2_3), in order to eliminate the
introns by using oligonucleotides with a 30 bp overlap to the next exon positions (Scheme 4.7 B).
Sequencing results of the constructed vector (KELIII07) revealed a point mutation ("A" insertion at
position 2490 of schPKS) in the N–terminal part of schPKS (Fig. 4.7 C). An insertion would cause a
frame shift and has to be repaired for successful expression. Again yeast homologous expression
was used to eliminate the extra base by cutting plasmid KELIII07 with KpnI and repairing the vector
with a patch amplified from KELIII02A(No2_3) (Scheme 4.7 C).
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Scheme 4.7 Cloning strategy of schPKS using three rounds of yeast recombination: A, first cloning round, amplifying four
parts of schPKS from cDNA; B, second cloning round, manually removing 4 remaining introns by amplifying seven DNA
fragments from template KELIII02A(No2_3) using yeast recombination; C, final cloning round, repairing of "A" insertion
using KpnI digest and amplifying a patch from KELIII02A(No2_3), resulting in KELIII08.
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Scheme 4.8 Constructed expression vectors containing schPKS and tailoring genes from sch BGC: A, Gateway cloning
resulting in pTYGSarg–schPKS (KELIII08); B, constructed plasmids containing sch tailoring genes; C, vector KELIII08C
occupying point mutations in schR3.
The repaired pE–YA vector containing schPKS (KELIII08) was checked by sequencing and used
for in vitro recombination (Gateway cloning) with an expression vector for fungal transformation
(pTYGSarg), resulting in pTYGSarg–schPKS (Scheme 4.8 A, KELIII08A). All tailoring genes (schR1,
schR2, schR3, schR4, schR5, schr7) could be amplified from cDNA and after purification using a kit
a suitable amount of DNA (40 ng/ml) was achieved for each gene in order to perform the yeast
recombination. Constructed expression vectors for expression in A. oryzae NSAR1 are displayed in
scheme 4.8 B and oligonucleotides and templates used for vector construction are summarised in
chapter 6, table 6.11. Vectors which were constructed in this work, but not used in this study are
displayed in figure 7.6 (Appendix).
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Expression vector KELIII08C containing schPKS, schR1, schR2 and schR3 was found to possess two
point mutations ("T", "G" deletion) in schR3 (Scheme 4.8 C). These mutations would cause a frame
shift and therefore leading to an inactive schR3 gene in expression experiments. Nevertheless, the
constructed vector was used for experiments lacking schR3.
In order to transform A. oryzae NSAR1 with combinations of constructed vectors (Fig. 4.8) a
CaCl2/PEG mediated protoplast protocol was used, which has already been described in section 2.6.1.
Cotransformation of one, two or three vectors were carried out in a single transformation step using
selection medium which was adapted to the vectors used in the individual transformation. Overall 8
combinations of genes from sch BGC on different fungal expression vectors were used to cotransform
A. oryzae NSAR1, resulting in 8 strains occupying genes from sch BGC (Table 4.2). Genetic analysis
showed the correct insertion of desired genes into A. oryzae (Appendix, Fig. 7.7).
Table 4.2 Overview of A. oryzae NSAR1 transformations with different combinations of genes from sch BGC; TH: thioesterase,
Hyd: Hydrolase, Oxi: Oxidase
Exp. No Exp. ID Selection marker Transformed expression vector(s)
Genes sch
pks r1 r2 r3 r4 r5 r7
PKS TH P450 P450 Hyd Oxi FMO
1 KELIII12 arg, ade, met KELIII08A,
KELIII10A,
KELIII02D
X X X X X X X
2 KELIII08A arg KELIII08A X - - - - - -
3 KELIII08B arg KELIII08B X X - - - - -
4 KELIII08C arg KELIII08C X X X - - - -
5 KELIII13 arg, ade KELIII08A, KELIII10A X X X X - - -
6 KELIII14 arg, ade, met KELIII08A, KELIII10A, KELIII11A X X X X - - X
7 KELIII16 arg, ade, met KELIII08A, KELIII15, KELIII02D X - X X X X X
4.3.3 Expression of whole SCH cluster in A. oryzae
In an initial experiment (exp. 1, table 4.2), all genes from the sch BGC were coexpressed in A. oryzae
NSAR1. Gene schR6 was not included, as it was predicted to encode a transporter. Cotransformation
of three expression vectors, containing 7 genes (schPKS, schR1, schR2, schR3, schR4, schR5, schR7),
resulted in 16 transformants. For analysis of their secondary metabolite profile 11 of the transformants
were sub–cultured in PamyB induction medium (DPY). The obtained extracts were submitted to LCMS
and the chromatograms were analysed. From previous biotransformation experiments it is known,
that the expected product would not be 3, but its reduced analogue 174, eluting at tR = 5.5 min
(Section 4.3.1).
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Figure 4.7 Chemical analysis of transformant containing whole sch BGC (exp. 1, table 4.2): A, Coexpression of 7 genes
(schPKS, schR1, schR2, schR3, schR4, schR5, schR7); B, LCMS trace of exp. 1 compared to NSAR1 wt control, DAD chromatogram
with UV spectrum of 178 eluting tR = 4.9 min and 179 eluting at tR = 5.1 min.
In the extract of the transformant containing the whole sch BGC, a new major peak eluting at
tR = 4.9 min and a minor compound eluting at tR = 5.1 min were observed compared to a wt control
(Fig. 4.7). Both compounds 178 and 179 were shown to possess a similar UV spectrum as reduced
SCH 174 with a maximum absorption at 210 nm (Fig. 4.7).
Further HRMS analysis showed that major compound 178 has the identical mass and thus molecular
formula as 174 (ES− C14H21O4 calc. 253.1440, measured 253.1440). Minor compound 179 showed the
same HRMS as SCH, accordingly two hydrogen atoms less than 174 (ES− C14H19O4 calc. 251.1283,
measured 251.1286, Fig. 4.8). More sophisticated analysis of the mass fragmentation pattern revealed
loss of three water molecules for compound 178 (Fig 4.8). A similar pattern was also observed for 179,
showing significant fragments for losses of two water molecules (Fig 4.8). LCMS analysis indicated
that the new compounds are both analogues of 174, but not identical, as the retention times vary
between 0.4 to 0.6 min.
158
4.3 Results – Re–establish SCH biosynthesis in heterologous host A. oryzae NSAR1
Figure 4.8 LCMS (ES+ and ES−) and HRMS analysis of new compounds obtained from extractes of transformant containing
whole sch BGC (exp. 1, table 4.2).
Structure elucidation of compound 178 and 179
For structure elucidation of major compound 178, combined analytical extracts of producing transfor-
mants were submitted to preparative LCMS analysis and 1 mg of pure 178 was isolated. Subsequent
NMR analysis in deuterated DMSO yielded 1H and 13C chemical shifts for C-1 to C-11 corresponding
to compound 172 (Fig. 4.9 A). Compound 172 has previously been isolated from ∆schR3 strain
by Francesco Trenti.85 However, compound 172 (m/z = 236.3 g/mol) has a lower mass than 178
(m/z = 254.3 g/mol), corresponding to loss of one molecule of water (Fig. 4.9 B).
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Figure 4.9 Structure elucidation of 178: A, structure of 178 (1 mg, DMSO, 500 MHz) with key HMBC correlations and
assigned NMR signals in comparison with 172 (1 mg, CDCl3, 400 MHz), isolated from ∆schR3 strain (data provided by
Francesco Trenti)85; B, structure of 172 with corresponding ES+ and UV spectrum.
Chemical shifts were assigned according to previously isolated 172. However, comparison of the
1H NMR signals identified changes in chemical shifts of the protons at C-13 and C-14. The chemical
shift of methyl group protons at C-14 showed an upfield shift of 0.25 ppm. Furthermore, a larger
shift was identified for protons at C-13, which shifted around 1.3 ppm upfield compared to 172. This
could indicate that the lactone is not closed in this analogue of SCH, but opened to the corresponding
free acid.
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Figure 4.10 1H NMR of compound 178 in DMSO–d6 (500 MHz) referenced to DMSO–d6.
The olefin at C-2/C-3 was shown to be trans, as the corresponding doublets of doublets at 5.86 and
6.67 ppm appeared to have the same coupling constant of 15.4 Hz (Fig. 4.9 A + 4.10). Corresponding
signals of H-5, H-6, H-8 and H-9 were superimposed in the region between 5.29 and 5.42 ppm. In
order to determine the stereoisomery of the two olefins C-5/C-6 and C-8/C-9 of 178, 1H–decoupling
experiments were performed. H-7 decoupling allowed the determination of the coupling constant
between H-5 and H-6, which was found to be 10.8 Hz, suggesting a cis olefin (Fig. 4.11). This is in
agreement to the J5−6 (11.3 Hz) of 172 (2E,5Z,8Z, Fig. 4.9 A).85
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Figure 4.11 Decoupling of H-4 in 178 1H–NMR (500 MHz).
In order to determine the stereoisomery of the C-8/C-9 olefin, H-7 and H-10 decoupling was
performed in two separate experiments. NMR decoupling measurements on a Bruker DRX 600 MHz
allowed the determination of the coupling constant between H-8 and H-9, which was found to
be 15.4 Hz, suggesting a trans olefin (Fig. 4.12), which is in agreement to the J8−9 (15.1 Hz) of 172
(2E,5Z,8Z, Fig. 4.9 A).85
162
4.3 Results – Re–establish SCH biosynthesis in heterologous host A. oryzae NSAR1
Figure 4.12 Decoupling of H-7 (red) and H-10 (green) in 178 1H–NMR (600 MHz)
Further evidence that 178 is the free acid and not the lactone were given by using pH indicator
Bromcresol green. While 172 spotted on a TLC plate was not turning yellow upon exposure of pH
indicator Bromocresol green, 178 showed a yellow spot indicating an acid (Fig. 4.13).
Figure 4.13 TLC plate with one drop of each 178 and 172, stained with pH indicator Bromocresol green - a colour change to
yellow indicating an acid.
Together with the NMR data, these results strongly proposed structure 178, which is in accordance
with the HRMS result. Nevertheless, expected reduced analogue of SCH 174 was not observed in the
DAD trace, as no peak was detected around 5.5 min.
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Figure 4.14 Structure elucidation of 179 (1.9 mg, DMSO, 500 MHz) with key HMBC correlations and assigned NMR signals.
For structure elucidation of minor compound 179, possessing the same nominal mass as SCH (m/z
252), the producing transformant was re–grown in 10 x 100 ml DPY medium and extracted after 7
days. The crude extract was submitted to preparative LCMS analysis and 1.9 mg of pure 179 was
isolated. Subsequent NMR analysis in deuterated DMSO (500 MHz) revealed almost identical shifts
compared to those of 178 (Fig. 4.14) suggesting a similar structure and configuration pattern of the
olefins. However, position C-13 was identified as quaternary C-atom and the corresponding chemical
shift of C-13 (δ 208.3) indicated a carbonyl group. This assumption would also correspond to HRMS
analysis of 179 (C14H19O4 calc. 251.1283, measured 251.1286).
The DAD chromatogram of A. oryzae NSAR1 transformant containing genes for the whole sch BGC,
revealed two new compounds. Major compound 178, as well as minor compound 179, are congeners
of expected reduced form of SCH 174. Nevertheless, the characteristic lactone structure element was
not observed for either compound.
Detailed analysis of mass traces
More detailed analysis showed a minor compound with the nominal mass of 254 eluting at tR = 5.5
min in the ES+ BPI chromatograms of three transformants containing all genes of sch BGC, which
corresponds to 174 (Fig. 4.15). Also the minor reduced SCH compound 177 previously detected in
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the biotransformation experiment with SCH, was produced in traces (tR = 5.0 min) (Fig. 4.15). Both
peaks were shown to have the characteristic mass fragmentation pattern (namely loss of one and two
H2O), strongly suggesting them to be expected reduced congeners of SCH, 174 and 177 (Fig. 4.16).
Structure elucidation of compound 177 by NMR was not possible due two very low titres. Further
HRMS analysis was also prevented for the same reason. Nevertheless, these results indicated that the
7 genes (schPKS, schR1, schR2, schR3, schR4, schR5, schR7), defined as the whole sch BGC, expressed in
heterologous host A. oryzae, led to trace amounts of reduced forms of SCH. This confirms the cluster
to be responsible for production of 3 and showed that no other genes are essential to produce SCH.
Figure 4.15 Chemical analysis of A. oryzae NSAR1 + 7 genes, exp. 1 (Table 4.2), transformant 3, 4, 5, in comparison to
A. oryzae NSAR1 wt and biotransformation experiment feeding SCH to A. oryzae NSAR1 wt, ES+ traces.
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Figure 4.16 MS analysis of 174 and 177 produced by A. oryzae NSAR1 + 7 genes (transformant 4).
However, just trace amounts of SCH analogue 174 were observed from expression transformants.
The major compound 178 was shown to be an acyclic derivative of 172. As both intermediates
accumulated upon disruption of schR3 and schR7 were found to be lactones suggesting that 178 and
minor compound 179 were shunt products. It is possible that endogenous genes in A. oryzae led to
hydrolysis of an early pathway product in SCH biosynthesis, probably 172 or a related compound,
yielding 178. The shunt product would then stop the pathway to SCH and adventitious oxidation of
the hydroxyl group at C-13 to the ketone can occur, probably catalysed by a monooxygenase from
the host organism.
Another possibility is that the programming of SchPKS resulted in no ketoreduction (by KR domain)
in the first cycle of β–processing yielding a ketone function at C-13. Tang and coworkers also found
that Bref–PKS revealed products with different reduction pattern in vitro due too limiting amounts
of NADPH.205 A minor PKS product unlactonised 7–dehydrobrefeldin A acid 180 was shown to
possess a keto group instead of an alcohol group at C–15 (analogue to C–13 in 3, Scheme 4.17).205
7–dehydrobrefeldin A acid 180 was earlier isolated from the endophytic fungal strain Cylindrocarpon
obtusisporum together with brefeldin A 153.218
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Figure 4.17 Comparison of 179 observed from in vivo expression experiments with A. oryzae NSAR1 and 7–dehydrobrefeldin
A acid 180 produced by Bref–PKS.
Oikawa and coworkers previously reported unexpected side reactions by the heterologous host
A. oryzae NSAR1 in studies on fungal polyketide cytochalasin K 181.219 They were able to isolate a
linear intermediate analog 182 from the A. oryzae transformant harboring polyketide PKS–NRPS
and trans–acting ER genes ccsA and ccsC, which is most likely derived by a two–step reduction of
183 by reductases in A. oryzae (Scheme 4.9).220 Moreover determination of a second by–product 184
suggesting oxidation of 182 by an unknown monooxygenase in A. oryzae (Scheme 4.9).219
Scheme 4.9 Proposed biosynthetic pathway of cytochalasin and undesired reduction and random oxidation by heterologous
host A. oryzae NSAR1 while expression of PKS–NRPS encoding gene ccsA and trans–acting ER encoding gene ccsC.219
Similar oxidation products have been reported in heterologous production of desmethylbassianin221
and in heterologous expression of the avirulence gene ACE1 from the fungal rice pathogen Mag-
naporthe oryzae in A. oryzae.222 All observed oxidations, probably caused by endogenous enzymes
in A. oryzae, occurred at the terminal end of linear polyketide precursors, as also shown in our
experiments, where 178 was oxidised to 179.
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4.3.4 Expression of early genes in A. oryzae
The results of coexpression of 7 genes from the cluster showed that schPK was cloned correctly.
Previous knockout studies could not reveal the PKS product, which was predicted to be benquoine
160 or a related species.85
Figure 4.18 Chemical analysis of extract of expression exp. 2 (table 4.2, schPKS) and exp. 3 (table 4.2, schPKS + schR1)
compared to A. oryzae NSAR1 wt control: A, coexpression of schPKS and schR1; B, DAD analysis; C, ES+ traces.
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Expression of schPKS alone (Table 4.2, exp. 2) and coexpression with hydrolase encoding gene schR1
in analogy to brefeldin 153 biosynthesis205 (Table 4.2, exp. 3) in heterologous host A. oryzae NSAR1
should provide the first intermediate of the pathway to SCH 3.
In total, 7 transformants containing schPKS in their genome and 9 transformants containing schPKS
and schR1 in their genome were grown, extracted and submitted to LCMS analysis. Neither the DAD
chromatograms nor the ES+ traces showed new peaks compared to NSAR1 wt control (Fig. 4.18).
This indicates that no PKS product could be detected using standard LCMS methods. Previous
results showed that SCH analogues can be produced by expression experiments, neglecting the
possibility of an error in the PKS sequence. The PKS product is possibly degraded in the heterologous
host.
4.3.5 Re–constructing the biosynthesis of SCH in A. orzyae
Cotransformation of cytochrome P450 encoding gene schR2 with schPKS and schR1 resulted in
10 transformants. Vector KELIII08C (exp. 4, table 4.2) was used to transform A. oryzae NSAR1,
containing a mutated schR3 gene. As the mutations lead to a frame shift, expression of schR3 cannot
result in an active protein. All 10 transformants were grown in DPY and extracted after 7 days and
submitted to LCMS analysis. The chemical analysis revealed a similar metabolic profile as observed
for the whole cluster expression. Compound 178 was again found to be the major compound
(tR = 4.9 min) and 179 the minor compound (Fig. 4.19, exp. 4). Traces of reduced SCH 174 were not
observed in the extract of this transformants. Adding the second P450 encoding gene schR3 to the
expression system showed no production of any SCH metabolite (Fig.4.19, exp. 5). In total, 6 extracts
of transformants containing schPKS, schR1, schR2, schR3 were analysed. Upon addition of oxidase
encoding gene schR7 compounds 178 and 179 were detected again, but in lower titres (Fig. 4.19, exp.
6).
Together these results show that SchPKS, the partnering hydrolase SchR1 and one of the two P450s
SchR2 are sufficient to produce 172 analogue 178, which is probably a shunt product in A. oryzae.
Previous knockout studies led to the disruption of schR3 and subsequent accumulation of compound
172, indicating hydroxylation at C-4 by SchR2.85 In these expression experiments in A. oryzae, 178 is
produced in high amounts no matter how many tailoring genes were added to the expression system
(e.g. schR3, schR7), indicating a pathway interruption by A. oryzae endogenous enzymes, which
possibly hydrolyse 172 to give the observed acid 178. Further adventitious oxidation catalysed by an
enzyme in A. oryzae would yield 179.
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Figure 4.19 Chemical analysis of extract of expression exp. 4, exp. 5, exp. 6 (table 4.2, compared to A. oryzae NSAR1 wt
control: A, expressed genes in exp. 4, 5 and 6; B, DAD analysis; * marked peaks correspond to unrelated compounds.
4.3.6 Expression of whole SCH cluster without hydrolase SchR1
It is also possible that over–expressed gene schR1 encoding for the partnering hydrolase led to
unwanted over–hydrolysis of SCH pathway intermediate 172. In order to overcome this possibility
schR1 was removed from the expression system and in the same way assuming that off-loading of the
PKS product would be catalysed from an A. oryzae hydrolase. Co–expression of schPKS, schR2, schR3,
schR4, schR5 and schR7 (exp. 7, table 4.2) in A. oryzae resulted in no SCH intermediate produced
(Fig. 4.20). This experiment showed that hydrolase SchR1 is essential for production of SCH or
intermediates from the pathway.
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Figure 4.20 A, coexpression of schPKS, schR2, schR3, schR4, schR5 and schR7; B, chemical analysis of extract of A. oryzae
NSAR1 sch BGC missing schR1 (exp. 7, table 4.2, compared to A. oryzae NSAR1 wt control, DAD chromatograms and ES+
traces.
4.4 Conclusion and Outlook
Biotransformation experiments showed that our heterologous expression host, A. oryzae NSAR1,
reduced fed SCH 3 to 174 and a minor compound 177 through biocatalysis, as previously observed
in A. ochraceus by Adelin and coworkers (Scheme 4.10).217 Due to very low titres of 177 its structure
could not be elucidated. Nevertheless these results indicated that heterologous expression of genes
from sch BGC would lead to 174 instead of 3 in our host A. orzyae NSAR1.
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Scheme 4.10 Schematic overview of biotransformation of SCH in Aspergillus species: A. ochraceus217 and A. oryzae NSAR1,
yielding reduced congener 174.
For successful expression of SCH genes from 3 producing fungus Phomopsis sp. CMU–LMA in
the heterologous host A. oryzea NSAR1, RNA was isolated and transcribed into cDNA in order to
eliminate all intron positions. Yeast recombination based cloning was used to assemble the 8 kb
schPKS gene. Corresponding tailoring genes of the cluster were cloned into fungal expression
plasmids in different set of genes using the same method (Fig. 4.8). Overall 8 combinations of genes
from sch BGC on various fungal expression vectors were used to transform A. oryzae NSAR1, applying
a CaCl2/PEG mediated protoplast protocol (Table 6.11). Genetic analysis via PCR of resulting strains
showed the desired set of genes integrated into the genome of the heterologous host (Fig. 7.7).
Coexpression of all predicted biosynthetic genes from sch BGC (schPKS, schR1, schR2, schR3, schR4,
schR5, schR7) in A. oryzae NSAR1 (exp. 4, table 4.2), resulted in production of trace amounts of
biotransformed SCH 174, as well as the minor compound 177 (Scheme 4.11, exp. 1). This was
shown by the same UV, mass fragmentation pattern and retention time compared to a standard of
174. Further evidence by isolation of 177 and NMR analysis was not possible due to tiny amounts
produced. Nevertheless desired compound 174 was only observed in traces, whereas two new
compounds were produced in higher titres: major compound 178 and a minor compound 179. Both
compounds were isolated and subsequent NMR analysis resulted in two new structures which
showed similarities to previously observed 172 from knockout studies of schR3. Compound 178 was
shown to be an acyclic derivative of 172 and 179 appeared to be an oxidised congener of 178, as the
hydroxyl group at C-13 is oxidised to the ketone.
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Scheme 4.11 Overview of compounds produced by heterologous expression experiments with different sets of genes from 3
BGC in A. oryzae NSAR1.
Previous knockout studies suggested a biosynthetic pathway, in which benquoine 160 is the first
enzyme free intermediate and 172 the product of an oxidation step catalysed by cytochrome P450
SchR2. A second oxidation by P450 SchR3 is proposed to yield compound 173, which was isolated
from a schR7 knockout experiment (Scheme 4.12).
As disruption of schR3 and schR7 led to lactone intermediates, it was suggested that the acyclic
intermediates 178 and 179 observed in heterologous expression experiments are shunt products.
Observation of very low titres of 174, but high amounts of hydrolysed intermediates 178 and 179 in
coexpression experiments with all pathway genes is consistent with a shunt pathway in A. oryzae
(Scheme 4.12). Endogenous genes in A. oryzae possibly lead to hydrolysis of an early pathway
product in SCH biosynthesis (possibly 172), as the minimal gene set for production of 178 and 179
included only three genes: schPKS; the partnering hydrolase encoding gene schR1; and one of the
two P450 encoding genes schR2 (exp. 4, table 4.2, Scheme 4.11). The real product of the reaction
catalysed by SchR2 is probably 172, which is hydrolysed to 178. The shunt product 178 would then
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accumulate and block the pathway to SCH. Further random oxidation of the hydroxyl group at C-13
of 178 would yield in 179, probably catalysed by an oxidative enzyme from A. oryzae metabolism
(Scheme 4.12).
Scheme 4.12 Proposed biosynthesis of SCH 3 with elucidated steps and involved enzymes from knockout studies conducted
by Francesco Trenti85 and putative shunt products derived from expression experiments in A. oryzae NSAR1.
Attempts to identify a product of SchPKS was not possible using heterologous expression in A. oryzae,
probably due to analytical issues detecting a very non–polar compound such as the proposed
benquoine 160 (Scheme 4.11, exp. 2+3). Benquoine was also never observed in Phomopsis wt
fermentations and therefore prevented feeding of 160 to A. oryzae. Previous experiments in which
linear fatty acid–like compounds were expressed in A. oryzae resulted in very rapid degradation.123
Re–construction of the pathway in A. oryzae was not efficient, because of the putative shunt products
which occur early during biosynthesis of SCH in the heterologous host. Nevertheless, it was shown
that in principal all genes from sch BGC were cloned correctly and expressed in A. oryzae NSAR1, as
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trace amounts of the expected reduced form of SCH 174 and 177 could be detected (Scheme 4.11,
exp. 1).
Overall, these experiments show that A. oryzae NSAR1 is probably not a suitable host for recon-
struction of SCH biosynthesis. Compound 178 was found to represent a "bottleneck" in expression
experiments, by stopping the biosynthetic pathway to SCH possibly due to hydrolysis of an early
intermediate 172 (Scheme 4.12). It was shown previously that A. oryzae endogenous enzymes can
lead to shunt products or by–products of a biosynthetic pathway expressed heterologously.219,222
In order to avoid the undesired reaction in the host strain, Oikawa and coworkers introduced the
downstream gene in the heterologous production of solanapyrone C, which abolished undesired
products.219 In our re–constitution experiments with genes from sch BGC this strategy was shown to
be unsuccessful. The biosynthesis was still observed to be halted with production of 178 although
downstream genes as second P450 SchR3 and also oxidase SchR7 were introduced to the expression
system. Sequencing results showed that SchR3 and SchR7 were correctly cloned, ruling out inactivity
of these proteins.
To overcome the putative shunt problem in A. oryzae NSAR1, another fungal host, such as Tricho-
derma reesei, could be chosen for heterologous expression of genes from the sch BGC. The filamentous
ascomycete T. reesei is highly relevant for industry due to its outstanding secretory capacities and
therefore also an attractive host for expression of homologous and heterologous proteins.223,224 In
order to use T. reesei as recombinant production host, it was rationally engineered and optimised for
fermentation processes and a broad selection of promoters and expression systems is provided.225
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5 Overall Conclusion and Future
Experiments
Overall, the combination of gene deletion experiments, fungal heterologous expression, and in vitro
enzymatic reactions was demonstrated to be a powerful tool to elucidate the fungal polyketide
pathways to squalestatin S1 1, strobilurin A 2, and to SCH–642305 3, as well as to identify key
enzymes for their biosynthesis.
Using a combination of seven targeted gene knockouts and heterologous expression of squalestatin
genes in host A. oryzae revealed the order of enzymes involved in the biosynthesis of 1 and uncov-
ered three previously unknown oxidative enzymes involved in the pathway to 1. Two non–heme
iron–dependent oxygenases Mfr1 and Mfr2 were shown to catalyse an impressive series of six consec-
utive oxidation steps from alkylcitrate 90 to form the core structure of 1. Additional hydroxylation on
the hexaketide chain catalysed by an unknown copper dependent monooxygenase Mfm1 revealed
94, which is the substrate for acyltransferase Mfr4 yielding 92. These results, together with earlier
studies of the biosynthesis of 1 by Bonsch et al.53 and Tang and coworkers118, contribute to the
elucidation of the full biosynthetic pathway. Future experiments with purified oxygenases (Mfr1 and
Mfr2) of the pathway could reveal more information about the detailed function of these unusual
tailoring enzymes (detailed conclusion in section 2.8).
The previously unknown enzyme involved in the oxidative rearrangement to form the toxophore
of strobilurins was uncovered in this thesis using heterologous expression of various gene sets
for production of 2. By narrowing down the number of coexpressed genes, the FAD dependent
monooxygenase Str9 was identified to catalyse the oxidative rearrangement. In vitro studies with
the purified enzyme confirmed the in vivo expression results and elucidated the rearranged product
135, which was shown to undergo two O–methylation steps by O–MeTs Str2 and Str3 to yield 2. The
formally reduced congener bolineol 4 was shown to be produced by the same BGC as 2. Product 135
was shown to be reduced in A. oryzae (propably catalysed by SDR Stl2 in S. tenacellus) to 133, which
forms the substrate for O–MeTs Str2 to yield 4. Further expression results suggested that the SDR
Stl2 together with oxidase Str4 could be involved in controlling the selective production of 2 or 4 in
S. tenacellus, possibly regulated by control of the individual promoters. These results contribute to
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the understanding of how nature has generated this valuable class of agricultural used fungicides.
Future experiments could regard the investigation of the unusual domains within StPKS to uncover
the origin of the E,Z,E motif of prestrobilurin 128 (detailed conclusion in section 3.6).
The usage of fungal heterologous expression for the elucidation of biosynthetic pathways was shown
to be successful for 1 and 2. Investigation of the SCH biosynthetic pathway were shown to be difficult
using heterologous expression in A. orzyae due to shunt pathways in A. oryzae. Individual expression
of schPKS or coexpression experiments with schPKS and schR1 (in analogy to brefeldin biosynthesis),
showed no intermediate in vivo, possibly due to rapid degradation of the PKS product. Feeding 3 to
the fungal host A. orzyae led to conversion to a reduced congener 174. Nevertheless, re–constitution
of the biosynthetic pathway of 3 was shown to be successful by expression of the full sch BGC in
A. oryzae yielding traces of biotransformed SCH 174. However, the major products of this experiment
were the acyclic derivative 178 and its oxidised congener 179. It was suggested that both are shunt
products originating from 172 (∆schR3 product),85 which are hydrolysed by A. oryzae and therefore
blocking the pathway to SCH. Coexpression experiments with schPKS, schR1 (hydrolase), and schR2
(P450) revealed the same panel of putative shunt products 178 and 179. To overcome the putative
shunt problem in A. oryzae NSAR1, another fungal host, such as Trichoderma reesei, could be chosen
for heterologous expression of genes from the sch BGC (detailed conclusion in section 4.4).
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6 Experimental
All chemicals and media ingredients used in this work were purchased from Sigma Aldrich, Thermo
Fisher Scientific, Carl Roth, VWR, Acros and Duchefa Biochemie.
6.1 Antibiotics, media, buffer and solutions
Buffers and media used in this work were sterilised for 15 min at 120 ◦C (Autoclave 2100 Classic,
Prestige Medical) or by disposable sterile filter (0.45 µm pore size, Roth). To prepare all media, buffers
and antibiotic stocks, deionised water was further purified by a GenPure Pro UV/UF milipore device
from Thermo Scientific.
6.1.1 Media
Table 6.1 Media used in this work for experiments with E. coli, S. cerevisiae and MF5453
Media Composition [% (w/v)] Ingredients
LB 0.50 yeast extract
1.00 tryptone
0.50 NaCl
Super optimal broth (SOB) 0.50 yeast extract
2.00 tryptone
0.06 NaCl
0.02 KCl
SOC 93.75 (v/v) SOB
1.25 (v/v) MgCl2 x 6 H2O
5.00 (v/v) D(+)-glucose 20 %
YPAD 1.00 yeast extract
2.00 tryptone
2.00 D(+)-glucose monohydrate
0.03 adenine
CM2 (pH 6.8) 2.00 cotton seed flour
10.00 lactose monohydrate
2.00 (v/v) trace element solution
YMG (+TES) 0.40 D(+)-glucose monohydrate
0.40 yeast extract
1.00 malt extract
optional 2.00 (v/v) trace element solution
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Table 6.2 Media used in this work for experiments with A. oryzae
Media Composition [% (w/v)] Ingredients
GNB 2.00 D(+)-glucose Monohydrate
3.00 Nutrient broth Nr. 2 from Oxoid
CMP 3.50 Czapek Dox broth
2.00 D(+)–maltose monohydrate
1.00 polypeptone
Starch M 2.00 starch from potato
1.00 polypeptone
5.00 (v/v) solution A
5.00 (v/v) solution B
DPY 2.00 dextrin from potato starch
1.00 polypeptone
0.50 yeast extract
0.50 monopotassium phosphate
0.05 MgSO4 x H2O
Table 6.3 Agar used in this work for experiments with E. coli, S. cerevisiae and MF5453
Agar Composition [% (w/v)] Ingredients
LB agar 0.50 yeast extract
1.00 tryptone
0.50 NaCl
1.50 agar
ME agar 1.28 malt extract
0.08 peptone ex Soya
0.24 glycerol
0.28 dextrin from potato starch
1.50 agar
Softagar 0.50 NaCl
1.00 agar
YPAD agar 1.00 yeast extract
2.00 tryptone
2.00 D(+)-glucose monohydrate
0.03 adenine
1.50 agar
SM–URA agar 0.17 yeast nitrogen base
0.50 ammonium sulfate
2.00 D(+)-glucose monohydrate
0.077 complete supplement mixture minus uracil
1.50 agar
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Table 6.4 Agar used in this work for experiments with A. oryzae
Agar Composition [% (w/v)] Ingredients
CZD/S agar 3.50 Czapek Dox broth
18.22 D-sorbitol (1 M)
0.10 ammonium sulfate
0.05 adenine
0.15 L–methionine
1.50 agar
CZD/S1 agar (-Met) 3.50 Czapek Dox broth
18.22 D-sorbitol (1 M)
0.10 ammonium sulfate
optional 0.15 L–methionine
1.50 agar
CZD/S Softagar 3.50 Czapek Dox broth
18.22 D-sorbitol (1 M)
0.10 ammonium sulfate
0.05 adenine
0.15 L–methionine
0.80 agar
CZD/S1 (-Met) Softagar 3.50 Czapek Dox broth
18.22 D-aorbitol (1 M)
0.10 ammonium sulfate
optional 0.15 L–methionine
0.80 agar
CD1 agar 3.50 Czapek Dox broth
4.68 NaCl (0.8 M)
0.10 ammonium sulfate
0.05 adenine
0.15 L–methionine
1.50 agar
CD2 agar (-Met) 3.50 Czapek Dox broth
4.68 NaCl (0.8 M)
0.10 ammonium sulfate
optional 0.15 L–methionine
1.50 agar
DPY agar 2.00 dextrin from potato starch
1.00 polypeptone
0.50 monopotassium phosphate
0.50 yeast extract
0.05 MgSO4 x H2O
2.50 agar
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6.1.2 Buffers and solutions
Table 6.5 Buffers and solutions used in this work with their composition
Solutions Composition [% (w/v)] Ingredients
Solution A 4.00 NaNO3
4.00 KCl
1.00 MgSO4
0.02 FeSO4 x 7 H2O
Solution B 2.00 K2HPO4
Trace elements solution 0.1000 FeSO4 x 7 H2O
0.0758 MnSO4 x 4 H2O
0.0025 CuCl2 x 2 H2O
0.0100 CaCl2 x 2 H2O
0.0056 boric acid
0.0019 ammonium molybdate tetrahydrate
0.0200 ZnSO4 x 2 H2O (dissolved in 0.6 M HCl)
Composition [mM]
TAE buffer 40 Tris–HCl
20 acetic acid
1 EDTA
MF5453 protoplasting
solution
10 sodium phosphate buffer pH 6
800 NaCl
10 CaCl2
20 mg/ml lysing enzyme from Trichoderma hazianum (Sigma–Aldrich)
10 mg/ml Driselase from Basidiomycetes sp. (Sigma–Aldrich)
A. oryzae NSAR1
protoplasting solution
800 NaCl
10 mg/ml lysing enzyme from Trichoderma hazianum (Sigma–Aldrich)
Fungal transformation
solution 1 (Trafo)
50 Tris–HCl pH 7.5
800 NaCl
10 CaCl2
Fungal transformation
solution 2 (Trafo)
60 % (w/v) PEG 3350
50 Tris–HCl pH 7.5
800 NaCl
10 CaCl2
6.1.3 Antibiotics
Antibiotics stock solutions were prepared in millipore water or ethanol. They were filter sterilised
through 0.45 µm syringe filter and stored at −20 ◦C. Stock and working concentrations are listed in
table 6.6. Carbenicillin was used for ampicillin selection.
Table 6.6 Antibiotics used in this work
Antibiotic Solvent Stock concentration Working concentration
[ mg/ml] [µg/ml]
Carbenicillin (Carb) H2O 50 50
Chloramphenicol (Cm) Ethanol 30 30
Hygromycin (Hyg) H2O 50 150
Kanamycin (Kan) H2O 50 50
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6.2 Microbiology methods
6.2.1 Strains
Table 6.7 Strains and origin used in this work
Strain Genotype Phylum Origin
E. coli OneShot TOP10 F-mcrA ∆(mrr-hsdRMS-mcrBC)
Φ80lacZ∆M15 ∆lacX74 recA1
araD139 ∆(araleu)7697 galU galK rpsL
(StrR) endA1 nupG
Proteobacteria Thermo Fisher
Scientific
E. coli OneShot ccdB
survival 2T1R
F-mcrA Δ(mrr-hsdRMS-mcrBC)
Φ80lacZΔM15 ΔlacX74 recA1
araΔ139 Δ(ara-leu)7697 galU galK
rpsL (StrR) endA1 nupG fhuA::IS2
Proteobacteria Thermo Fisher
Scientific
E. coli BL21 (DE3) F˘ompT hsdSB (r˘B m
˘
B) gal dcm (DE3) Proteobacteria Thermo Fisher
Scientific
Saccharomyces cerevisiae
CEN.PK
MATa/α ura3-52/ura3-52
trp1-289/trp1-289
leu2-3_112/leu2-3_112 his3 Δ1/his3
Δ1MAL2-8C/MAL2-8C
SUC2/SUC2
Ascomycetes Hahn group,
Hannover
Aspergillus oryzae NSAR1 ∆argB sC˘ adeA niaD˘ Ascomycetes Lazarus group,
Bristol
Unidentified strain MF5453 wildtype Ascomycetes
6.2.2 E. coli
Growth and maintenance
All E. coli strains were grown on solid or liquid LB medium with appropriate antibiotics. Cultures
were incubated at 37 ◦C and 200 rpm for 12 to 18 h. For long term storage glycerol stocks (25 %
glycerol) were stored at −80 ◦C.
Transformation of chemically competent E. coli cells
An aliquot of 50 µl chemically competent cellsc was defrosted on ice. After addition of either 1 µl
of purified plasmid or 10 µl for a ligation mixture, the cells were left on ice for 10 to 30 min. The
heat shock was carried out at 42 ◦C for 30 to 45 s before the cells were immediately put on ice for
2 min, following addition of 250 µl of SOC medium and 1 h incubation at 37 ◦C, 350 rpm. The cells
were spinned down for 15 s, most of the supernatant was discarded and around 200 µl were streaked
onto LB agar plates with appropriate antibiotic(s). The plates were left to grow overnight in a 37 ◦C
incubator.
ckindly provided by technical staff
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6.2.3 S. cerevisiae
Growth and maintenance
A stock of S. cerevisiae CEN.PK2 was spread onto YPAD agar medium and incubated at 30 ◦C for 48 h.
A single colony was used to inoculate 10 ml liquid YPAD, grown overnight at 30 ◦C and 200 rpm.
S. cerevisiae CEN.PK2 transformed with ura3 containing plasmids was grown on solid or liquid
SM–URA, incubated at 30 ◦C for up to 3 days.
Preparation and transformation of competent S. cerevisiae cells
Preparation of S. cerevisiae competent cells was done using the LiOAc/SS carrier DNA/PEG protocol
developed by Gietz and Woods.226 For each transformation competent yeast cells were prepared
freshly. A single colony was inoculated into 10 ml of YPAD medium and grown overnight at 30 ◦C,
200 rpm. The seed culture was added to 40 ml of YPAD in a 250 ml flask and incubated at 30 ◦C, 200
rpm, for 4–5 h. Cells were harvested by centrifugation for 5 min at 3000 x g. After washing with
25 ml water the cell pellet was resuspended in 1 ml water and transferred to a 1.5 ml tube. The cells
were pelleted at 20000 x g for 15 s, the supernatant discarded and cells resuspended in 400 µl water.
Afterwards the suspension was aliquoted (100 µl into 1.5 mL tubes each). For yeast recombination
based cloning using S. cerevisiae, competent cell aliquots were pelleted 20000 x g for 15 s and the
supernatant discarded, following addition of 250 µl PEG solution, 36 µl 1 M LiOAc, 50 µl ssDNA (2
mg/mL) and up to 34 µl of DNA was added to the pelleted cells. Cells were resuspended in the
transformation mixture by careful pipetting. The mixture was incubated at 30°C for 50 min and
afterwards cells were pelleted at 3000 x g for 15 s. The cell pellet was gently resuspended in 1 ml
water before 200 µl of the mixture was spread over SM–URA plates and incubated at 30°C for 3 to 4
days.
6.2.4 A. oryzae NSAR1
Growth and maintenance
Aspergillus oryzae NSARI was grown on ME or DPY agar plates at 28 ◦C or in DPY medium at 28 ◦C
and 120 rpm. For long term storage glycerol stocks (25 % glycerol) were prepared from spores
collected from plates and stored at −80 ◦C.
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PEG–mediated transformation of A. oryzae NSAR1
A. oryzae conidia from a sporulating plate were inoculated into 100 ml GN medium in a 250 ml flask,
which was incubated overnight at 30 ◦C, 180 rpm. The grown mycelia was collected by filtration
through sterile Miracloth and was incubated in 10 ml protoplasting solution containing 20 mg/mL
Lysing Enzyme, which was sterilized through a 0.45 µm syringe filter, to build protoplasts (lying
falcon, 30 ◦C, 70 rpm, 3 h). The protoplasts were released from hyphal strands by gentle pipetting
with wide–bore pipette. Afterwards the mycelia was collected by filtration through sterile miracloth
and washed with NaCl (0.8 M). The supernatant was centrifuged (10 min, 3000 x g) for collecting
protoplasts. Resulting supernatant was discarded and collected protoplasts were resuspended
in solution 1 (100 µl per transformation) and 10 µl of purified plasmid DNA was added. The
transformation mixture was incubated on ice for 2 min before adding 1 ml solution 2 and incubating
again for 20 min at room temperature. Afterwards pre–warmed 5 ml CZD/S(1) softagar (-methionine)
(50 ◦C) was added to the mixture and overlaid onto prepared CZD/S(1) plates (-methionine). Plates
were incubated at 28 ◦C for 3–5 days until colonies appeared.
For selection on arginine–(adenine or methionine) deficient media, the selection has to be repeated
twice in order to prevent false positives due to consuming arginine from dead cell material. A few
spores of the grown colony were picked with a tooth pick and transferred to a CD1 plate, without
sorbitol. The plates were incubated at 28 °C for 3–4 days and the step was repeated by streaking
out single colonies. In preparation for fermentation, a single colony was grown on DPY agar for 1
week.
6.2.5 Unidentified strain MF5453
Growth and maintenance
Unidentified fungus MF5453 was grown on solid ME agar or in different liquid media (CM2, YMG,
YMG+TES) at 25 ◦C for production of SQS1 (200 rpm if liquid culture). For long term storage glycerol
stocks (50 % glycerol) were prepared from mycelium of liquid cultures and stored at −80 ◦C.
Transformation
The fungus MF5453 was grown in CM medium for 48 h at 25 ◦C, 200 rpm. The mycelium was
washed three times by filtration through a coarse sieve (0.8 M NaCl) in order to remove particles of
cotton seed flour. Around 1 g of fine mycelia was collected in a sterile falcon tube and 10 ml of filter–
sterilized protoplasting solution (20 mg/ml) lysing enzyme, Sigma L1412, 20 mg/ml of driselase
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in 0.8 M sodium chloride, 10 mM sodium phosphate buffer pH 6) was added. The protoplasting
mixture was incubated at 30 ◦C for 3 hours with gentle shaking (lying falcon, 70 rpm). The suspension
was filtered through a wide–bore and cotton–filled autoclaved pipette tip (5 ml) and washed with
0.9 M NaCl. Resulting protoplast solution was pelleted at 3000 x g for 10 min. Protoplasts were
resuspended in 160 µl solution 1 and 40 µl solution 2. Non–purified DNA fragments (part1 and
part2) of bipartite PCR were also added (10 µl each) and the suspension was incubated on ice for
30 min. After adding 1 ml of solution 2 the mixture was incubated for another 20 min at room
temperature. Pre–warmed 10 ml soft agar (45 ◦C, 1 % agar containing 5 % NaCl) were poured to each
transformation mixture and mixed gently before distributing on to two thin MEA pates containing
150 µg/ml hygromycin B (37 ◦C pre–warmed plates). After incubation at 25 ◦C for 24 h the plates
were overlaid with 10 ml MEA agar containing 150 µg/ml hygromycin B. After incubation at 25 ◦C
for 8–10 days, growing colonies were selected and cultivated on secondary plates with 150 µg/ml
hygromycin B. Growing colonies were picked to MEA plate without antibiotic before transferring to
liquid medium for subsequent fermentation and analysis.
6.3 Molecular biology methods
All enzymes were purchased from New England Biolabs (NEB) and used according to manufacturer’s
instructions with appropriate supplied buffers.
6.3.1 Polymerase Chain Reaction (PCR)
Polymerase chain reaction (PCR) was used to amplify DNA fragments. OneTaq® 2X Master Mix
(NEB) with standard buffer was used for screening purposes. For cloning tasks the proofreading
Q5® High–Fidelity 2X Master Mix (NEB) was used. For both enzymes manufacturer’s instructions
were followed. In case of E. coli colony screening a single colony was picked with a toothpick and
directly transferred to the reaction tube as template for the PCR reaction.
6.3.2 Oligonucleotides
All oligonucleotides used in this work were designed using the software Geneious (7.1.9) and
purchased from Sigma Aldrich.
Table 6.8 Oligonucleotides used in this work
Cox ID number 5’-3’ sequence
22 CGTCAGGACATTGTTGGAG
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Table 6.8 Oligonucleotides used in this work
Cox ID number 5’-3’ sequence
23 CTGTCGAGAAGTTTCTGATCG
57 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGGACGTTTCCAAGGAAGA
60 TCCTCGCCATGCCTGTTATC
61 CCGCGGAATGGCTTGATAAC
62 TGCCAACTTTGTACAAGAAAGCTGGGTCGGCTAAGAACCAGAGTTCTTCA
64 ATGCCAAGTTGCCAACAGGT
87 CTTCTTAAATATCGTTGTAACTGTTCCTGA
88 CGAAGTATATTGGGAGACTATAGCTACTAG
89 ATTCACCACTATTATTCCCACCCTATAATA
90 GAGACGAAACAGACTTTTTCATCGCTAAAA
91 CTTTTCTTTTCTCTTTCTTTTCCCATCTTC
92 TGACCTCCTAAAACCCCAGTG
306 TTTAAGAAGGAGCCCTTCACCAAGGGTGGGCCCGGGGAAACCTTGACTCACTGCGG
307 ACTAGAGGATCCCCATCATGGGCATATCTCGCACTTTGGT
308 ACCAAAGTGCGAGATATGCCCATGATGGGGATCCTCTAGT
310 AGGTCACGGTATAGCGCAGGCAGGTCGAGTGGAGATGTGG
313 TACGACAATCTCTCTCCACCCATGATGGGGATCCTCTAGT
314 ACTAGAGGATCCCCATCATGGGTGGAGAGAGATTGTCGTA
315 CCACATCTCCACTCGACCTGGGATCGTTGCGGAAATACAC
316 GTGTATTTCCGCAACGATCCCAGGTCGAGTGGAGATGTGG
411 AGCGAATGGATATGGTCGGG
461 ACTAGAGGATCCCCATCATGTGCATCGGGGCCGCTCCATG
462 CATGGAGCGGCCCCGATGCACATGATGGGGATCCTCTAGT
463 CCACATCTCCACTCGACCTGGGGATCGAGTCATCTCTTCG
464 CGAAGAGATGACTCGATCCCCAGGTCGAGTGGAGATGTGG
567 ACTAGAGGATCCCCATCATGCGACCACAGCTTGCAACATC
568 GATGTTGCAAGCTGTGGTCGCATGATGGGGATCCTCTAGT
569 AAGATGGCATTGTTCGTGGCCAGGTCGAGTGGAGATGTGG
570 CCACATCTCCACTCGACCTGGCCACGAACAATGCCATCTT
573 ACTAGAGGATCCCCATCATGCACTACCAAGAAGCTCGGCA
574 TGCCGAGCTTCTTGGTAGTGCATGATGGGGATCCTCTAGT
575 CCTACTTTGCCGTCTGTGGTCAGGTCGAGTGGAGATGTGG
576 CCACATCTCCACTCGACCTGACCACAGACGGCAAAGTAGG
578 CTATATGGGAGAGGGATCAG
579 TGCCATCTCATGATTATCAGAC
580 TTTATATCTCACGACGTGCA
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Table 6.8 Oligonucleotides used in this work
Cox ID number 5’-3’ sequence
581 ATTGGCTCTTGTATGTTCAC
582 GAAACCTTGACTCACTGCGG
583 TAAAAATTTGAACTTTCGCGAG
584 TGCATTTCTCACCATCGCAC
585 TCGTCTCGAGAGCCATTTCG
586 AGAACACCAAGGAGCGAACC
587 GGTCTACGAGCATCAGAGGC
589 GCCAACTTTGTACAAAAAAGCAGGCTCCGCTGCATTTCTCACCATCGCAC
590 TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCGTCTCGAGAGCCATTTCG
591 GCCAACTTTGTACAAAAAAGCAGGCTCCGCAGAACACCAAGGAGCGAACC
592 TGCCAACTTTGTACAAGAAAGCTGGGTCGGGGTCTACGAGCATCAGAGGC
593 GCCAACTTTGTACAAAAAAGCAGGCTCCGCTTTATATCTCACGACGTGCA
594 TGCCAACTTTGTACAAGAAAGCTGGGTCGGATTGGCTCTTGTATGTTCAC
597 GCCAACTTTGTACAAAAAAGCAGGCTCCGCCTATATGGGAGAGGGATCAG
598 TGCCAACTTTGTACAAGAAAGCTGGGTCGGTGCCATCTCATGATTATCAG
605 CCACATCTCCACTCGACCTGAGATGCACCTCCTGTAACTA
606 TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCACATCCTTAGACCTTCTTC
607 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCGATTTACTAGTACCAT
608 ACGACAATGTCCATATCATCAATCATGACCTTATCCTGCTAACACTTCTT
609 GTCGACTGACCAATTCCGCAGCTCGTCAAAATGGCTATCGTCAACGGCGC
610 GGTTGGCTGGTAGACGTCATATAATCATACCTACAACTTGAACTTCTGCA
611 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCTCAGAATGAAGAAGAT
612 TTCATTCTATGCGTTATGAACATGTTCCCTCTAGCGAGCTAAGAATGCTT
613 TAACAGCTACCCCGCTTGAGCAGACATCACCATGGCGACAGCTATCCTTCC
614 ACGACAATGTCCATATCATCAATCATGACCCTAAAAGAACACCAAGGAGC
615 GTCGACTGACCAATTCCGCAGCTCGTCAAAATGGCGACTGCAACAACAAC
616 GGTTGGCTGGTAGACGTCATATAATCATACCTAGTCAAAGAAAACCCAGA
746 GATGTCTACTTCGCGGAGTGCAGGTCGAGTGGAGATGTGG
747 CCACATCTCCACTCGACCTGCACTCCGCGAAGTAGACATC
748 AACTTTGTACAAGAAAGCTGGGTCGGCGCGCCCGGGCAAGAGCAGCAATTGACCAT
751 AAGCCGACATGCTATTGAGCCATGATGGGGATCCTCTAGT
752 CCACACATTGATCGATCCGTCAGGTCGAGTGGAGATGTGG
753 CCACATCTCCACTCGACCTGACGGATCGATCAATGTGTGG
754 AACTTTGTACAAGAAAGCTGGGTCGGCGCGCCCGGGTCCATTGTATGTCCATGCCT
765 GCCAACTTTGTACAAAAAAGCAGGCTCCGCGACTGCAACAACAACTCTAC
766 ACTAGAGGATCCCCATCATGTTGGGGTGCAGTGACATCGT
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Table 6.8 Oligonucleotides used in this work
Cox ID number 5’-3’ sequence
767 CAAGAGCAGCAATTGACCAT
768 AGAACACCAAGGAGCGAACC
769 GACTGCAACAACAACTCTAC
770 TCCATTGTATGTCCATGCCT
822 ATGGCGGCTACGAATGATCCC
823 GAAACCTTGACTCACTGCGGC
841 GTCGACTGACCAATTCCGCAGCTCGTCAAAATGGACTTCCCCGGGAATTC
842 GGTTGGCTGGTAGACGTCATATAATCATACTCACCAATGTGTCGAAAGGA
861 CCAATGTATACTGGTCTCACCCCATCCGCGAAACAATTGGCCACTGCCTC
862 GAGGCAGTGGCCAATTGTTTCGCGGATGGGGTGAGACCAGTATACATTGG
863 TGTAGAGGTCTGCCACGGTTGCCATATGATGAGAATGATAGCCCATTGGT
864 ACCAATGGGCTATCATTCTCATCATATGGCAACCGTGGCAGACCTCTACA
867 GCCAACTTTGTACAAAAAAGCAGGCTCCGCAATCCTCACATCCTTAGACC
868 ACTAGAGGATCCCCATCATGGCGAGATATGCCGAATAGTA
869 TACTATTCGGCATATCTCGCCATGATGGGGATCCTCTAGT
870 GCTGCTCCACATAACTTGCTCAGGTCGAGTGGAGATGTGG
871 CCACATCTCCACTCGACCTGAGCAAGTTATGTGGAGCAGC
872 TGCCAACTTTGTACAAGAAAGCTGGGTCGGCGATATGTGGTTCAATCATT
886 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGGACTTCCCCGGGAATTC
887 ACGACAATGTCCATATCATCAATCATGACCTCACCAATGTGTCGAAAGGA
988 ATGCCATACCCGTCTGACTTG
989 CAAGCAAATAGTCCAACGACA
966 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGCCTTCGTCATACATACA
967 AGAAGTGGGTAGCACGTTCC
968 AGCCTCTCGTGACTGCATTG
969 TGCTGTAGTTGTGCTTGGAG
970 CCTCTCCAACGCCACGGTCT
971 CGTGAGCTGAAGATATTGGC
972 CACATTGGCGCCGAGATATT
973 TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCACGTAACAACCATCTTGG
975 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGGCGCCAACAGTCGAACC
976 GGTTGGCTGGTAGACGTCATATAATCATACCTAATTCCTTAATAAATGCT
977 TTCATTCTATGCGTTATGAACATGTTCCCTCTAATTCCTTAATAAATGCT
978 TAACAGCTACCCCGCTTGAGCAGACATCACATGGCATTACACGATATTTT
979 ACGACAATGTCCATATCATCAATCATGACCCTACTTGACGTGGAAGCGAA
980 GTCGACTGACCAATTCCGCAGCTCGTCAAAATGCTGAGCATTACAATATT
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Table 6.8 Oligonucleotides used in this work
Cox ID number 5’-3’ sequence
981 GGTTGGCTGGTAGACGTCATATAATCATACCTAGTCAGTGGTGAGCTTTT
982 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGGTCCGAATTCTGTGTCT
983 TTCATTCTATGCGTTATGAACATGTTCCCTTCAGTCATAGTTTGCCATTG
984 AACAGCTACCCCGCTTGAGCAGACATCACCATGGAGCAACAAACCATTCT
985 ACGACAATGTCCATATCATCAATCATGACCTCATACAGCAAAAGATTGCC
986 GTCGACTGACCAATTCCGCAGCTCGTCAAAATGAACCCTTACTTTCAAAG
987 GGTTGGCTGGTAGACGTCATATAATCATACTTACAGCACTGCAGAGCTGA
990 ATGATCGTGATGTCTCGCCTG
991 CTATCGCAGCATCCTCCCTCT
992 ATGACCATCCTCCGTTCTCGC
993 ATTGTCTACGATCGGTCGCGC
1011 ATGGCCGTTGATCGCAAGA
1012 CTAGACAAGGCGTTCCTCA
1013 ATGCCTGAAGGAACCATGA
1014 TTAGGGCTTGATCGCAATT
1015 ATGTCACCTACTGCTGAAAT
1016 GAATACGAATGGACCATCAG
1036 TCCTTTCCCTCTCTCCGGTGACTCGTTTTC
1037 GCAGTTCCCTACTCTCGCGT
1038 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGGCCGTTGATCGCAAGAT
1039 GGTTGGCTGGTAGACGTCATATAATCATACCTAGACAAGGCGTTCCTCAA
1079 CAGGGACAATGCCCATGGTTACAGCAACGTCCTTGAAGTTCACACCCGCC
1080 AGCTGTACGCGGCGGGTGTGAACTTCAAGGACGTTGCTGTAACCATGGGC
1081 TCAAGAACACACTCGCAAGCGTCGATGCCTCCTCAAATGACATTGAGTCA
1082 ACCATATTCCTGACTCAATGTCATTTGAGGAGGCATCGACGCTTGCGAGT
1083 CCCTCCCGTGGCGGAATGAATCAAGACTCGATGACCCTTTTGGGTGTTTG
1084 TACGACCTGGCAAACACCCAAAAGGGTCATCGAGTCTTGATTCATTCCGC
1085 CTTCTCATCATTTCCGACGGTGGCGAATATCTCGGCGCCAATGTGCTGGC
1086 ATCCAGATTTGCCAGCACATTGGCGCCGAGATATTCGCCACCGTCGGAAA
1103 TGTAACCATCTGCTTTCTTATCAAAAGTGTTGTCCATATTATGCTCAGGG
1104 TGTACCTCAGCCCTGAGCATAATATGGACAACACTTTTGATAAGAAAGCA
1105 ATGTCTTCTCCTGCTGCTCA
1106 TTAGACACGCTTCTGCGACC
1107 ATGGCCGCCGAATCTGCTAA
1108 TTAGGCACTCTTCTTCACCG
1109 GTCGGGCTGGGTCACATCCAT
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Table 6.8 Oligonucleotides used in this work
Cox ID number 5’-3’ sequence
1110 GGGAGTCTCTCAAGGCCCTCC
1116 CGACCATGATGATACCACGGC
1134 ATGGGAGCCTCGCACTCGACA
1135 TTATGCGACGCCCTTGATGAG
1251 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGTCTTCTCCTGCTGCTCA
1252 TTCATTCTATGCGTTATGAACATGTTCCCTTTAGACACGCTTCTGCGACC
1253 TAACAGCTACCCCGCTTGAGCAGACATCACATGGCCGCCGAATCTGCTAA
1254 ACGACAATGTCCATATCATCAATCATGACCTTAGGCACTCTTCTTCACCG
6.3.3 Details for constructed vectors in this thesis
Combination of oligonucleotides used for amplification of squalestatin KO fragments and construc-
tion details for fungal transformation plasmids used for heterologous expression of strobilurin A
genes and SCH genes in A. oryzae NSAR1 are displayed in tables 6.9, 6.10 and 6.11.
Table 6.9 Combination of oligonucleotides used for amplification of squalestatin KO fragments
Construct ID Target Oligonucleotides for amplification
of KO fragments
Oligonucleotides for construction
in S. cerevisiae
KELI30 mfr4
Pg : P578 + P22 Pa+b : P597+314
P23 + Ph : P579 Pc+d : P598+315
Pe+ f : P313+316
KELI27 mfm1
Pg : P584 + P22 Pa+b : P589+567
P23 + Ph : P585 Pc+d : P570+590
Pe+ f : P568+569
KELI28 mfr1+2
Pg : P586 + P22 Pa+b : P591+573
P23 + Ph : P587 Pc+d : P576+592
Pe+ f : P574+575
KELI38 mfr1
Pg : P767 + P22 Pa+b : P591+573
P23 + Ph : P768 Pc+d : P747+748
Pe+ f : P574+746
KELI39 mfr2
Pg : P769 + P22 Pa+b : P765+766
P23 + Ph : P770 Pc+d : P753+754
Pe+ f : P571+752
KELI29 mfr3
Pg : P580 + P22 Pa+b : P593+461
P23 + Ph : P581 Pc+d : P594+463
Pe+ f : P462+464
KELI48 mfm3
Pg : P822 + P22 Pa+b : P867+868
P23 + Ph : P823 Pc+d : P869+870
Pe+ f : P871+872
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Table 6.10 Construction details for fungal transformation plasmids used for heterologous expression of strobilurin A genes
in A. oryzae NSAR1
Construct ID Vector backbone Template Oligonucleotides for construction in S. cerevisiae
KELIV01A pTYGSarg cDNA stPKS, str2, str3, str4; kindly provided by Dr Risa Nofiani
KELI44 pTYGSade cDNA str8, str10, str11; kindly provided by Dr Risa Nofiani
KELIV01B pTYGSmet cDNA str9, stl2; kindly provided by Dr Kate de Mattos–Shipley
KELIV07 pTYGSarg KELIV01A template cut with NdeI and repaired with patch amplified
from pTYGSarg: P1136+1137 to remove all genes but stPKS
KELIV04 pTYGSmet KELIV01B str9: P1038+1039
KELIV11 pTYGSniaD KELIV01A str2: P1251+1252; str3: P1253+1254; Patch_Peno: P87+88
KELIV12A pTYGSniaD KELIV11 str2: P1251+1252; Patch_PgdpA: P91+92; Patch_Peno:
P87+88
KELIV12B pTYGSniaD KELIV11 Patch_PadH: P89+90; str3: P1253+1254; Patch_Peno: P87+88
Table 6.11 Construction details for fungal transformation plasmids used for heterologous expression of SCH genes in A.
oryzae NSAR1
Construct ID Vector
backbone
Template Oligonucleotides for construction in S.
cerevisiae
KELIII02A(No2_3)* pE–YA cDNA schPKS 4 fragments: P966-P973
KELIII07* pE–YA KELIII02A(No2_3) schPKS 7 fragments: P966+1103; P1104+1109,
P1110+1079, P1080+1081, P1082+1083,
P1084+1085, P1086+973
KELIII08 pE–YA KELIII02A(No2_3) Patch: P1104+1116; KELIII07 cut with KpnI
KELIII02B pTYGSarg cDNA schR1: P975+976
KELIII02C* pTYGSmet cDNA schR1: P975+977, schR2: P978+979, schR3*:
P980+981
KELIII02D pTYGSmet cDNA schR4: P982+983, schR5: P984+985, schR7:
P986+987
KELIII08A pTYGSarg - LR with KELIII08 and KELIII02A
KELIII08B pTYGSarg - LR with KELIII08 and KELIII02B
KELIII08C* pTYGSarg - LR with KELIII08 and KELIII02C
KELIII10A pTYGSade KELIII08C, gDNA
(schR3)
schR1: P975+977, schR2: P978+979, schR3:
P980+981
KELIII10B pTYGSade KELIII08C schR1: P975+977, schR2: P978+979,
Patch_Peno: P87+88
KELIII10C pTYGSade KELIII08C schR1: P975+977, Patch_PgdpA: P91+92, schR3:
P980+981
KELIII11A pTYGSmet KELIII02D Patch_PadH: P89+90, Patch_PgdpA: P91+92,
schR7: P986+987
KELIII11B pTYGSmet KELIII02D Patch_PadH: P89+90, schR5: P984+985, schR7:
P986+987
KELIII11C pTYGSmet KELIII02D schR4: P982+983, Patch_PgdpA: P91+92, schR7:
P986+987
KELIII15 pTYGSade KELIII10A Patch_PadH: P89+90, schR2: P978+979, schR3:
P980+981
*point mutations in gene
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6.3.4 cDNA preparation
cDNA was prepared from total RNA using oligo(dT) nucleotides and the RevertAid Premium Tran-
scriptase kit purchased from Thermo Fisher Scientific. Manufacturer’s instructions were followed. In
case of SCH cDNA preparation for amplification of schPKS Maxima Reverse Transcriptase (NEB)
was used in combination with specific primer P973.
6.3.5 Agarose gel electrophoresis
Agarose gel electrophoresis was used to purify and analyse double stranded DNA fragments and
was performed using horizontal gel tanks (BioRad) with 0.5 x TAE buffer. DNA samples were mixed
with 6X DNA Loading Dye and loaded on 1% (w/v) agarose gels (electrophoresis grade agarose
dissolved in 40 ml TAE buffer for two gels) which contained RedSafe DNA Stain (1 µl in 40 ml). 1
kb DNA Ladder (NEB) was used as a molecular DNA size marker. Electrophoresis was carried out
at 80–120 V for 20 min to 45 min using 0.5xTAE as running buffer. DNA was visualised under a
UV–trans–illuminator (254 nm) and photographed using a UVP camera (Gel Doc XR+, Bio-Rad).
NucleoSpin® Gel and PCR Clean–up kit purchased from Macherey–Nagel was used to purify and
extract PCR amplified DNA after agarose gel purification. Manufacturer’s protocol was followed as
recommended.
6.3.6 DNA purification from gel or from PCR
Amplified DNA was purified for sequencing or cloning using NucleoSpin® Gel and PCR Clean–up
kit purchased from Macherey–Nagel. Manufacturer’s protocol was followed as recommended. Prior
to elution with ddH2O the column was heated to 70
◦C for 5 min.
6.3.7 Isolation of plasmid DNA from E. coli
Isolation of plasmid DNA from an overnight culture of E. coli was performed using the NucleoSpin®
Plasmid kit (Machery–Nagel), according to the manufacturer’s protocol. For larger plasmids (> 15 kb)
PureLink® Quick Plasmid Miniprep Kit (Invitrogen) was used to obtain high concentrated plasmid.
192
6.3 Molecular biology methods
6.3.8 Isolation of plasmid DNA from S. cerevisiae
Zymoprep Yeast Plasmid Miniprep II kit purchased from Zymo Research was used to isolate plasmid
DNA from yeast cells. The whole amount of colonies of half a SM–URA transformation plate
generated by yeast recombination were collected with a tooth pick into the first solution of the yeast
miniprep kit. Yeast DNA was isolated according to manufacturer’s instructions. For final elution
10 µL ddH2O was used.
6.3.9 Isolation of genomic DNA from fungus
Approximately 100 mg of filtered mycelium from a liquid culture was used to extract genomic DNA,
following the the manufacturer’s instructions of the GeneElute™ Plant Genomic DNA Miniprep Kit
(SIGMA Life Science).
6.3.10 Cloning procedure
Restriction digest
Restriction enzyme digestions (single or double) were carried out according to the manufacturer’s
guidelines. Reaction mixtures were incubated at 37 ◦C in a incubator for 0.5 to 5 h and afterwards
subsequently inactivated for 20 min at 65 ◦C or 80 ◦C. The resulting fragments were then separated
by agarose gel electrophoresis or used directly for yeast recombination.
Dephosphorylation of linear DNA and ligation
In order to prevent self–ligation of linearised plasmids, they were treated with shrimp alkaline
phosphatase (SAP). After digestion, 1 µl of enzyme was added to the reaction mixture for 1 h at
37 ◦C. Ligation reactions were performed using T4 DNA ligase. The reaction typically contained 5X
molar excess of DNA insert. Reaction mixtures were incubated in the fridge overnight followed by
inactivation at 65 ◦C for 20 min.
Gateway Cloning
For in vitro recombination from pE-YA entry clones into pTYGS family destination vectors, the
Invitrogen Gateway LR Clonase II enzyme mix was used according to manufacturer’s protocol with
a reduced reaction scale (reduced by half).
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DNA sequencing
DNA samples were sequenced by Eurofins Genomics (Ebersberg).
6.4 Biochemistry methods
A codon optimised sequence for str9 was purchased from Invitrogen (Darmstadt, Germany). The
sequence was constructed with a N-terminal 6xhis tag in the expression vector pET100.
6.4.1 Recombinant protein expression and cell lysis
Recombinant N–terminal hexa–histidine tagged Str9 was produced by overexpression in BL21 (DE3)
E. coli cells using the plasmid pET100–His6–Str9, which contains a codon optimised sequence for
Str9. For overproduction single colonies were used to inoculate LB medium. Cultures were grown to
an OD600 of 0.4 to 0.6 at 37 °C, induced with 0.1 mM isopropyl–β–D–thiogalactopyranoside (IPTG)
and shaken at 16 °C for 20 h. Cells were harvested by centrifugation (4000 g, 4 °C, 15 min). For
purification, 2 g cells were resuspended in 20 mL lysing buffer (50 mM Phosphate buffer, pH 8.0) and
cell disruption was done by sonification (pulse program, 30 sec on/off, 15 min). After centrifugation
(20000 g, 4 °C, 40 min) the obtained crude lysate was passed through a gravimetric Ni-NTA column
(2 mL bed volume).
6.4.2 Protein purification by nickel affinity chromatography
The loaded Ni–NTA column was washed with 5 mL of lysing buffer containing 20 mM imidazole.
Elution of the target protein was achieved with 3 mL of lysing buffer containing 250 to 500 mM
imidazole. The elution fractions were combined and concentrated (Satorius Vivaspin 20–10000 MW
cut-off) and imidazole was removed from the buffer. The purified enzyme was immediately used for
activity assays or analysed using polyacrylamide gel electrophoresis (SDS–PAGE).
6.4.3 SDS–PAGE
Separation and analysis of proteins was carried out using 12 % polyacrylamide gels (Table 6.12).
Protein samples were prepared with SDS loading buffer and boiled at 95 ◦C for 10 min before 15 µl of
the samples and 5 µl of Color Prestained Protein Standard (Broad Range, 11—245 kDa, NEB) were
loaded onto the gel. The gels were run for 60 min at 40 mA. Afterwards gels were incubated in 30 mL
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Coomassie staining solution for 1 h before destaining in Coomassie bleach solution for another hour.
Destained gels were scanned using the Molecular Imager Gel doc XR+ (Bio–Rad) system.
Table 6.12 Composition of a 12 % polyacrylamide gel
12 % separating gel [ml] 5 % stacking gel [ml]
30 % Acrylamide/bisacrylamide®
(Rotiphorese Gel 30 (37.5:1)) 3.00 0.535
ddH2O 2.45 1.70
1.5 M Tris–HCl, pH 8.8 1.90 -
0.5 M Tris–HCl, pH 6.8 - 0.25
10 % (w/v) SDS 0.075 0.02
10 % (w/v) APS 0.075 0.02
TEMED 0.003 0.002
Table 6.13 Buffer and solution used for protein purification and analysis
Solutions Composition [% (w/v)] Ingredients
Coomassie Dye 25 acetic acid
10 isopropanol
0.1 coomassie
Coomassie Bleach 25 acetic acid
10 Isopropanol
4 x Lämmli buffer 250 mM Tris–HCl, pH 6.8
8 SDS
40 glycerine
10 β–Mercaptoethanol
2.5 mg/l bromophenol blue
Composition [mM]
10 x SDS Running buffer 25 Tris
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6.4.4 Enzyme activity assay with Str9
Activity assays were carried out in a total volume of 400 µL containing 2 mM of prestrobilurin in
200 µl ethanol and 5 mg/mL of Str9 in 200 µl phosphate buffer (pH 8.0, 50 mM phosphate buffer
plus 1.25 mM NADH/NADPH mixture and 0.3 mM FAD, 2.5 mM FMN mixture). Reactions were
incubated at 30 °C for 30 min at 400 rpm and then for 60 h at room temperature without shaking.
Prior to extraction with 400 µl ethyl acetate, reactions were acidified with 2 M HCl to pH 4. After
evaporation of the solvent, the product was resolved in 150 µl DMSO and analysed by HPLC-MS.
Reactions without enzyme served as controls.
6.4.5 Bolineol and 133 toxicity test against A. oryzae
Toxicity test were carried out on small agar plates filled with 5 ml DPY agar supplemented with
different concentrations of bolineol 4 (0.1, 0.2, 0.3, 0.5, 1, 2 mg) or 133 (0.5, 1, 2, 5 mg). Both
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compounds were diluted in 200 µl DMSO prior to addition to the liquid DPY agar. Control plates
were supplemented with 200 µl DMSO only. A. oryzae NSAR1 spores were streaked on the plates on
day 1.
6.5 Chemical analysis
6.5.1 Liquid Chromatography Mass Spectrometry (LCMS)
Analytical LCMS
Analytical LCMS data was obtained using a Waters LCMS system comprising of a Waters 2767
autosampler, Waters 2545 pump system, a Phenomenex Kinetex column (2.6 µm, C18, 100 Å, 4.6 x
100 mm) equipped with a Phenomenex Security Guard precolumn (Luna, C5, 300 Å) and a flow rate
of 1 ml/min. Detection was carried out by a diode array detector (Waters 2998) in the range 210
to 600 nm and an ELSD detector (Waters 2424) together with a mass spectrometry, Waters SQD-2
mass detector, operating simultaneously in ES+ and ES− modes between 150 and 1000 m/z. Gradient
was run over 15 min starting at 10 % acetonitrile/ 90 % HPLC grade water (0.05 % fromic acid) and
ramping to 90 % acetonitrile.
Preparative LCMS
In order to purify compounds from a raw extract or from a reaction mixture a Waters mass–directed
autopurification system comprising of a Waters 2767 autosampler, Waters 2545 pump system, a
Phenomenex Kinetex Axia column (5 µm, C18, 100 Å, 21.2 x 250 mm) equipped with a Phenomenex
Security Guard precolumn (Luna, C5, 300 Å) . Gradient was run over 10 min or 15 min starting at
10 % acetonitrile/ 90 % HPLC grade water (0.05 % fromic acid) and ramping to 90 % acetonitrile.
The flow was set to 20 ml/min and the post–column flow was split (100:1) and the minority flow
was made up with HPLC grade MeOH + 0.045 % formic acid to 1 ml/min for simultaneous analysis
by diode array detector (Waters 2998) in the range 210 to 600 nm and an ELSD detector (Waters
2424) together with a mass spectrometry, Waters SQD-2 mass detector, operating simultaneously in
ES+ and ES- modes between 150 and 1000 m/z. Detected peaks were collected into glass test tubes.
Combined tubes were evaporated (vacuum centrifuge).
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High Resolution Mass Spectrometry (HRMS)
High Resolution Mass Spectrometry (HRMS) was performed on a Q–Tof Premier mass spectrometer
(Waters). It was coupled to an Acquity UPLC–domain. The ESI mass spectroscopy was measured in
positive and negative modes.
6.5.2 Nuclear magnetic resonance (NMR) analysis
NMR measurements were acquired on a Bruker DRX 400, 500 MHz or 600 MHz and were done by the
NMR department of Organic Chemistry Department, Leibniz Universität Hannover. Chemical shifts
are shown in parts per million (ppm) in comparison to the TMS (Tetramethylsilane) standard. The
coupling constants J were quoted in Hz throughout. Complete structural elucidation of synthesised
compounds as well as purified/ isolated compounds were obtained with 2D experiments: Correlation
Spectroscopy (COSY), Heteronuclear Single Quantum Coherence (HSQC), Heteronuclear Multiple
Bond Correlation (HMBC) as required.
6.5.3 Extraction of MF5453 cultures
MF5453 cultures were clarified by Büchner filtration (sometimes after homogenising the cultures
with a blender), the supernatant was acidified to pH 2-4 with concentrated H2SO4 and extracted
twice with ethyl acetate. Combined organic layers were dried over MgSO4 and solvent removed
under reduced pressure. Extracts were dissolved in acetonitrile/H2O (1:1) to a concentration of
10 mg/ml, filtered over glass wool and analysed or purified by LCMS.
Small scale extraction (1 ml)
For screening of multiple putative KO transformants, a small scale extraction method was used.
Therefore, 1 ml of 10 ml of MF5453 liquid culture (CM2 medium, grown for 7 days) was spinned
down (5 min, maximum speed). The obtained supernatant was acidified with 2 M H2SO4 and
transferred to a 2 ml centrifuge tube and extracted twice with 1 ml ethyl acetate (1:1). Solvents were
removed in a vacuum centrifuge, samples were dissolved in 0.2 ml in acetonitrile/H2O and analysed
by LCMS.
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6.5.4 Extraction of A. oryzae cultures
A. oryzae cultures were clarified by Büchner filtration, cells were stirred in 100 ml acetone for 1 h, the
solvent was removed under reduced pressure and to the remaining water fraction 100 ml H2O was
added and like the supernatant acidified to pH 2 with 2 M HCl and extracted twice with an equal
amount of ethyl acetate. Combined organic layers were dried over MgSO4 and solvent removed
under vacuum. Extracts were dissolved in acetonitrile/H2O (1:1) for squalestatin intermediates and
in methanol for SCH and strobilurin intermediates to a concentration of 10 mg/ml, filtered over
glass wool and analysed or purified by LCMS.
6.5.5 Chemical synthesis
The numeration of the molecules in this thesis was defined pragmatically.
Synthesis of N–acetylcysteamine174 (HSNAC, 15)
Cysteamine hydrochloride (9.01 g, 79.28 mmol, 1.0 eq.) was dissolved in water (360 ml). Sodium
bicarbonate (20.00 g, 238.08 mmol, 3.0 eq.) and potassium hydroxide (4.51 g, 80.44 mmol, 1.02 eq.)
were added to the stirred solution. Acetic anhydride (8.09 g, 7.49 ml, 79.26 mmol, 1.0 eq.) was added
drop wise over 5 min and the reaction mixture was stirred for another 10 min. The aqueous layer was
extracted with ethyl acetate (3 x 300 ml). The organic phases were combined, washed with saturated
NaCl solution (100 ml), dried over MgSO4 and concentrated in vacuo to yield SNAC 15 (colourless
oil, 3.278 g, 27.50 mmol, 34%).
1H NMR (400 MHz, CDCl3) δ ppm: 1.34–1.38 (t, J = 8.5 Hz, 1H, S–H), 2.00 (d, J = 1.1 Hz, 3H, H–1),
2.66–2.69 (m, 2H, H–4), 3.39–3.44 (qd, J = 6.3, 1.6 Hz, 2H, H–3); 6.12 (brs, 1H, N–H). 13C NMR (101
MHz, CDCl3) δ ppm: 170.4 (C–2), 42.6 (C–3), 24.7 (C–4), 23.4 (C–1); R f = 0.2, 1:1 (v/v) CH2Cl2:ethyl
acetate.
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Synthesis of benzoyl–SNAC27 (121)
EDC x HCl (1.39 g, 0.0073 mol, 1.1 equiv.) and a catalytic amount of 4–DMAP (0.18 g, 0.0014 mol,
0.22 equiv.) were added to a stirred solution of benzoic acid (800 mg, 0.007 mol, 1.0 equiv.) and
N–acetylcysteamine (0.86 g, 0.007 mol, 1.1 equiv.) in anhydrous CH2Cl2 (15 ml) at 0
◦C. After stirring
at room temperature overnight the reaction was quenched with HCl (1 M, 20 ml). The aqueous layer
was extracted with CH2Cl2. The combined organic layers were washed with saturated NaHCO3 and
NaCl–solution, dried over MgSO4 and concentrated under reduced pressure. Purification by flash
chromatography on silica gel (CH2Cl2:EtOAc / 1:1) yielded benzoyl–SNAC 121 (1.27 g, 87%) as a
white powder.
1H NMR (400 MHz, CDCl3) δ ppm: 1.98 (s, 3H, H–1), 3.22–3.25 (t, J=6.8 Hz, 2H, H–4), 3.52-3.56 (m,
2H, H–3), 5.91 (s, 1H, N–H), 7.45–7.48 (m, 2H, H–8/8’), 7.57-7.62 (m, 1H, H–9), 7.96–7.98 (m, 2H,
H–7/7’). HRMS (ESI+) m/z calc. for C11H13NO2SNa [M+Na]
+ 246.0565, found 246.0562, R f = 0.3
(1:1 (v/v) CH2Cl2:ethyl acetate).
Synthesis of 105
Isolated, impure 90 (5.8 mg, 0.01 mmol, 1 equiv.) was dissolved in 1 ml MeOH and TMS (Trimethylsi-
lyl)diazomethane solution (2.0 M in diethyl ether) (45 µl, 0.09 mmol, 9 equiv.) was added to the
stirred solution. The mixture was stirred overnight at room temperature and quenched the next day
by removing solvent under reduced pressure. The remaining product was purified by preparative
LCMS as described in section 6.5.1 but a gradient from 70 % to 90 % acetonitrile was used which
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yielded 1 mg of product 105. For NMR assignment see section 2.5.3, figure 2.16. HRMS (ESI+) m/z
calc. for C26H38O7Na [M+Na]
+ 485.2515, found 485.2513.
Synthesis of 111
Isolated 101 (4.8 mg, 0.01 mmol, 1 equiv.) was dissolved in 1 ml MeOH and TMS diazomethane
solution (2.0 M in diethyl ether) (45 µl, 0.09 mmol, 9 equiv.) was added to the stirred solution. The
mixture was stirred overnight at room temperature and quenched the next day by removing solvent
under reduced pressure. The remaining product was purified by preparative LCMS as described
in section 6.5.1 which yielded 1.1 mg of product 111. HRMS (ESI+) m/z calc. for C26H34O11Na
[M+Na]+ 522.1999, found 522.1998. For NMR assignment see section 2.5.4, figure 2.29.
6.5.6 Isolation of strobilurin expression intermediates
Compounds were isolated from raw extract of fungal cultures using preparative LCMS (15 min
gradient: 10 to 90% water–acetonitrile).
Strobilurin A 2
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Table 6.14 NMR data of 2 compared to literature48
LK122 Literature
Atom δC / ppm δH / ppm (J/Hz) Atom δC / ppm δH / ppm (J/Hz)
1 168 q 1 167.3 q
2 111 q 2 110.3 q
3 131.5 q 3 131 q
4 129.9 6.27 m (1H) 4 129.4 6.23 dqd (J = 9.4 Hz, 1.2 Hz, 0.8 Hz)
5 126.7 6.62 dd (J = 15.6, 10.7) 5 126.2 6.67 dd (J = 15.0 Hz, 9.4 Hz)
6 131.3 6.49 dd (J = 15.8, 0.8 Hz) 6 130.7 6.44 dd (J = 15.0 Hz, 0.8 Hz)
7 159 7.43 s (1H) 7 158.5 7.40 s (1H)
8 23.8 1.98 m (3H) 8 23.3 1.97 d (J = 1.2 Hz, 3H)
9 51.8 3.74 s (3H) 9 51.1 3.69 s (3H)
10 62.1 3.85 s (3H) 10 61.4 3.74 s (3H)
11 138 q 11 137.4 q
12, 16 126.5 7.34 m (2H) 12, 16 125.9
7.10-7.36 m (5H, phenyl)13, 15 128.6 7.28 m (2H) 13, 15 128.1
14 127.3 7.19 m (1H) 14 126.8
Compound 132
Isolation of 132 from raw extract (1 l fermentation) of A. oryzae expression strain containing stPKS,
str2, str3, str4 str11, str8, str10, str9 and stl2 yielded in 90 mg of compound 132. Structure elucidation
revealed two isomers 132a and 132b in the ratio 3:1. HRMS (ESI−) m/z calc. for C13H15O2 [M+H]
203.1072, found 203.1071.
NMR data of 132a is identical to literature known data.190 1H NMR (400 MHz, CDCl3) of 132a δ
ppm 1.96 (s, 3 H, H-11), 3.32, (s, 2 H, H-2), 6.22 (d, J = 10.8 Hz, 1 H, H-4), 6.53 (d, J = 15.4 Hz, 1 H,
H-6), 6.96 (dd, J1 = 10.9 Hz, J2 = 15.5 Hz, 1 H, H-5), 7.22 (m, 1H, H-10), 7.31 (m, 2 H, H-8/8’), 7.40 (m,
2H, H-9/9’); 13C NMR (101 MHz, CDCl3) δ ppm 24.7 (C-11), 38.0 (C-2), 124.4 (C-5), 126.5 (C-9/9’),
127.6 (C-10), 128.7 (C-8/8’), 129.6 (C-4), 130.7 (C-3), 132.5 (C-6), 137.6 (C-7), 177.2 (C-1).
1H NMR (400 MHz, CDCl3) of 132b δ ppm 1.96 (s, 3 H, H-11), 3.16 (s, 2 H, H-2), 6.16 (m, Hz, 1 H,
H-4), 6.53 (d, J = 15.4 Hz, 1 H, H-6), 6.96 (dd, J = 10.9 Hz, 15.5 Hz, 1 H, H-5), 7.22 (m, 1H, H-10), 7.31
(m, 2 H, H-8/8’), 7.40 (m, 2H, H-9/9’); 13C NMR (101 MHz, CDCl3) δ ppm 17.3 (C-11), 45.0 (C-2),
124.8 (C-5), 126.5 (C-9/9’), 127.6 (C-10), 128.7 (C-8/8’), 129.8 (C-4), 131.0 (C-3), 132.6 (C-6), 137.7 (C-7),
177.7 (C-1).
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Methylation of 133 to bolineol 4
To confirm the structure of compound 133 (0.011 g, 0.048 mmol, 1.0 eq.), it was methylated using
TMS–CHN2 (0.016 g, 0.14 mmol, 3.0 eq.) in MeOH at RT overnight in order to obtain bolineol 4
(2.1 mg) after purification using preparative LCMS. Comparison of the obtained 1H NMR data (see
below) to literature data182 confirmed the structure.
1H NMR (400 MHz, CDCl3) δ ppm 1.81 (m, 3H, H-11), 3.74 (3H, s, H-13), 3.68 (1H, dd, J= 11.1, 5.5,
H-2), 3.99 (1H, dd, J = 8.7, 5.5, H-12), 4.10 (1H, dd, J = 11.1, 8.7, H-12), 6.22 (1H, dq, J = 11.1, 1.3, 4-H),
6.55 (1H, d, J = 15.4, H-6), 7.00 (1H, dd, J = 15.3, 11.0, H-5), 7.23 (1H, m, H-10), 7.32 (m, 2H, H-8/8’),
7.41 (2H, m, H-9/9’).
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7 Appendix
7.1 SQS1 – additional data
7.1.1 Genetic analysis of expression transformants
Figure 7.1 Genetic analysis of A. oryzae NSAR1 transformants of experiments 1 to 4.
211
Figure 7.2 PCR analysis of A. oryzae NSAR1 transformants of experiments 5 to 10; oligonucleotides: mfpks2 (P862+863), mfm8
(P886+887), mfr3 (P609+610), str10 (P992+993), str11 (P988+989), str8 (P990+991), mfr1 (P613+614), mfr2 (P615+616), mfm1
(P611+612).
212
7.1.2 Expression of early genes
Figure 7.3 Chemical analysis of transformants of experiment 1 to 4 in comparison to A. oryzae NSAR1 wt control, DAD (top)
and ES- traces (bottom), *unrelated compound (tR = 5.57 min), m/z 163 (ES-), bottom: peak (tR = 8.98 min) also in wt control
(tR = 9.03 min).
213
7.2 Strobilurin – additional data
7.2.1 Genetic analysis of heterologous expression transformants
Figure 7.4 Genetic analysis of A. oryzae NSAR1 transformants of experiments 1 to 10 from strobilurin heterologous expression
experiments.
214
7.2.2 ESI—MS/MS analysis of Str9
Figure 7.5 ESI—MS/MS analysis of His6-–Str9. The expressed protein band was cut from the SDS PAGE and confirmed by
mass spectrometry using the methods of Klodmann and coworkers.191 Blue bars indicate detected peptide fragments.
215
7.3 SCH – additional data
7.3.1 Expression vectors not used in this thesis
Figure 7.6 Constructed fungal expression vectors for expression of genes from sch BGC, which were not used in this study.
216
7.3.2 Genetic analysis of expression transformants
Figure 7.7 PCR analysis of A. oryzae NSAR1 transformants of experiments 1 to 7 with indicated gene fragment sizes;
oligonucleotides: schPKS (P966+1103), schR1 (P975+976), schR2 (P978+979, schR3 (P980+981), schR4 (P982+983), schR5
(P984+985), schR7 (P986+987), schR3*: intact gene with point mutations.
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